Low molecular weight inhibitors of complement proteases

ABSTRACT

Peptide substances, their preparation and their use as complement inhibitors are described. These are in particular substances having a guanidine or amidine radical as a terminal group. In particular, inhibitors of the complement proteases C1s and C1r are described.

The present invention relates to peptide substances, their preparation and their use as complement inhibitors. In particular, these are substances having a guanidine or amidine radical as terminal group. In particular, the present invention relates to inhibitors of the complement proteases C1s and C1r.

The activation of the complement system leads, via a cascade of about 30 proteins, finally to, inter alia, the lysis of cells. At the same time, molecules which, like, for example, C5a, can lead to an inflammatory reaction are liberated. Under physiological conditions, the complement system provides defense against foreign bodies, e.g. viruses, fungi, bacteria and cancer cells. The activation by the various routes takes place initially via proteases. Activation enables these proteases to activate other molecules of the complement system, which in turn may be inactive proteases. Under physiological conditions, this system—similarly to blood coagulation—is under the control of regulator proteins which counteract excessive activation of the complement system. In these cases, intervention to inhibit the complement system is not advantageous.

In some cases, however, the complement system overreacts and this contributes to the pathophysiology of disorders. In these cases, therapeutic intervention in the complement system by inhibition or modulation of the overshooting reaction is desirable. Inhibition of the complement system is possible at various levels in the complement system and by inhibition of various effectors. The literature contains examples of the inhibition of the serine proteases at the C1 level with the aid of the C1-esterase inhibitor as well as inhibition at the level of the C3- and C5-convertases with the aid of soluble complement receptor CR1 (sCR1), inhibition at the C5 level with the aid of antibodies and inhibition at the C5a level with the aid of antibodies or antagonists. The tools used for achieving the inhibition in the abovementioned examples are proteins. The present invention describes low molecular weight substances which are used for inhibiting the complement system.

In general activation of the complement system is to be expected in every inflammatory disorder which is associated with intrusion of neutrophilic blood cells. It is therefore expected that an improvement in pathophysiological status will be achieved in all these disorders by inhibiting parts of the complement system.

The activation of the complement is associated with the following disorders or pathophysiological conditions (Liszewski, M. K.; Atkinson, J. P.: Exp. Opin. Invest. Drugs 7(3) (1998): 324-332; Morgan, B. P.: Biochemical Society Transactions 24; (1996), 224-9; Morgan, B. P.: Critical Review in Clinical Laboratory Sciences 32 (3); (1995), 265-298; Hagmann, W. K.; Sindelar, R. D.: Annual reports in medicinal chemistry 27, (1992), 199 et seq.; Lucchesi, B. R.; Kilgore, K. S.: Immunopharmacology 38 (1997), 27-42; Makrides, S. C.: Pharmacological Reviews 50(1)(1998), 59-85)

Reperfusion injuries after ischemias; ischemic conditions, during, for example, operations with the aid of heart-lung machines; operations in which blood vessels are clamped off generally for avoiding major hemorrhages; myocardial infarction; thromboembolic cerebral infarction; pulmonary thrombosis, etc.;

Hyperacute organ rejection; especially in xenotransplantations;

Organ failure, e.g. multiple organ failure or ARDS (adult respiratory distress syndrome);

Disorders due to trauma (cranial trauma) or multiple injury, e.g. thermal injury (burns);

Anaphylactic shock;

Sepsis; “vascular leak syndrome”: in the case of sepsis and after treatment with biological agents, such as interleukin-2 or after transplantation;

Alzheimer's disease and other inflammatory neurological disorders, such as myastenia graevis, multiple sclerosis, cerebral lupus, Guillain-Barre syndrome; meningitis; encephalitis;

Systemic lupus erythematosus (SLE);

Rheumatoid arthritis and other inflammatory disorders of the rheumatoid disorder group, e.g. Behcet's Syndrome; Juvenile rheumatoid arthritis;

Renal inflammations of various origin, e.g. Glomerulonephritis, Lupus nephriti;

Pancreatitis;

Asthma; chronic bronchitis;

Complications during dialysis in the case of kidney failure;

Vasculitis; thyroiditis;

Ulcerative colitis and other inflammatory disorders of the gastrointestinal tract;

Autoimmune diseases.

It is possible that complement plays a role in spontaneous abortions, based on immunological rejection reactions (Giacomucci E., Bulletti C., Polli V., Prefetto R A., Flamigni C., Immunologically mediated abortion (IMA). Journal of Steroid Biochemistry & Molecular Biology, 49(2-3) (1994), 107-21). Here, it is possible that modulation of the immunological rejection reaction is achieved by inhibition of the complement system and hence the rate of abortions is correspondingly reduced.

Complement activation plays a role in the case of side effects of drugs. Liposome-based therapies which are used, for example, in cancer treatment may be mentioned as an example here. Hypersensitive reactions have been observed in patients who have been treated with drug formulations based on liposomes (Transfusion 37 (1997) 150). Activation of the complement system has also been demonstrated for other excipients used in drug formulations, e.g. Cremophor EL (Szebeni, J. et al. Journal of the National Cancer Institute 90 (4); 1998). The complement activation may therefore be responsible for the anaphylactoid reactions observed in some cases. Inhibition of the complement system, for example by the C1s inhibitors mentioned here, should therefore alleviate the side effects of medicaments based on activation of the complement system and reduce resulting hypersensitivity reactions.

In the abovementioned disorders, activation of the complement system has been demonstrated.

The synthesis of complement proteins in special diseased tissues or organs indicates participation of the complement system in the pathophysiology of these disorders. Thus, in the case of myocardial infarction, vigorous further synthesis of many complement proteins in the myocardium was detected (Yasojima, K.; Schwab, C.; McGeer, E. G.; McGeer, P. L.; Circulation Research 83 (1998), 860-869). This was also detected in inflammatory disorders of the brain, e.g. multiple sclerosis and bacterial meningitis, and in colitis.

Evidence that complement activation has taken place can be provided by detecting the cell lysis complex in the tissue and by detecting soluble SC5b-9 or other activation products of complement, e.g. factor Bb, C3a; C4a, C5a; C3b, C3d; etc., in the plasma. By corresponding tests, it was possible to demonstrate, inter alia, participation of the complement system in the atherosclerosis as well as to show a relationship with myocardial infarction, unstable angina pectoris and organ transplantations, to mention but a few examples.

Raised blood levels of complement proteins, such as C3 or C4, are correlated with various cardiovascular disorders, e.g. heart failure, as well as diabetes. A similar relationship has imposulated for an increase in TNF in the case of heart failure. Initial studies on the treatment of heart failure with TNF inhibitors (soluble TNF receptor, antibodies) were rated positively. TNF is secreted, for example, after stimulation by complement factor C5a. It has been possible to show that inhibition of the C5a action prevents release of TNF (XVII International Complement Workshop, P. Ward, Abstract 324 in Molecular Immunology 35 (411 6-7), 1998). Accordingly, a treatment of disorders, in which raised levels of complement proteins are present, with the inhibitors described in this publication is possible, as the treatment of disorders in which raised levels of TNF are present.

Furthermore, the participation of complement has been demonstrated in the case of (Atherosclerosis 132 (1997); 131-138. Particular complications due to rapid atherosclerotic processes occur, for example, in organs after transplantations. These processes are the most frequent reason for the chronic failure of the transplanted organs in clinical medicine. In future, apart from transplantations of human organs (allotransplantations) uses of transplants from other species (xenotransplants) has also been considered.

Accordingly, the treatment of the abovementioned disorders or pathophysiological conditions with complement inhibitors is desirable, in particular the treatment with low molecular weight inhibitors.

FUT and FUT derivatives are amidinophenolic esters and amidinonaphthol esters and are described as complement inhibitors (e.g. Immunology 49(4) (1983), 685-91).

Serine proteases are present in the complement system in the three different activation routes: the traditional, alternative and MBL route (Arlaud, G. J. et al. Advances in Immunology 69; (1998) 249 et seq.). In their respective routes, they play a decisive role at the beginning of the cascade.

Inhibitors of the corresponding serine proteases can intervene here both in a completely inhibitory manner and in a modulating manner (partial inhibition) if the complement has been pathophysiologically activated.

Some proteases of the various activation routes are particularly suitable for inhibiting the complement system. From the class of the thrombin-like serine proteases these are the complement proteases C1r and C1s in the traditional route, factor D and factor B in the alternative route and MASP I and MASP II in the MBL route. Inhibition of these proteases then leads to restoration of physiological control of the complement system in the abovementioned disorders or pathophysiological conditions.

The traditional route of the complement system is usually activated by means of antibodies which have bound to an antigen. In physiological conditions this route of the complement system helps in the defense against foreign bodies which are recognized by antibodies. However, an overreaction leads to injuries in the tissue and the body. These injuries can be prevented by inhibiting of the traditional route. According to present knowledge, activation of the complement system via antibodies is experienced during hyperacute organ rejection and especially in the case of xenotransplantations; in the case of reperfusion injuries after ischemias (possibly via IgM antibodies and a neoepitope; Literature: Journal of Exp. Med. 183, (1996), 2343-8; Carroll, XVII International Complement Workshop, Rhodes 1998), for example in the case of myocardial infarction, other thrombotic disorders or long-term vascular occlusions, as are usual, for example, during operations; in the case of anaphylactic shock; in the case of sepsis; in the case of SLE; in the case of disorders in the area of rheumatoid arthritis, renal inflammations of various origins; vasculitis, all autoimmune diseases and allergies. In general, injuries in various organs due to activation of the complement system are to be expected in the case of every disorder in which circulating immune complexes are present. A part of the invention is to prevent these injuries by the C1-inhibitors described.

Activation of the complement system by the traditional route takes place under pathophysiological conditions partly with circumvention of antibodies. Examples of this are Alzheimer's disease, and the unspecified activation of this route by other proteases, as occur, for example, in the lysis therapy following myocardial infarction. In these cases, too, limitation of the injury to be achieved with the C1 inhibitors described.

The activation of the classical route has been demonstrated, for example, by the detection of the activated proteins, for example C1q in the affected tissue (e.g. Circulation Research 83; (1998) 860). However, the pathophysiological participation of the complement system is more substantial if inhibitors which inhibit only the traditional route in the complement system are used. A physiological inhibitor for this purpose is the C1-esterase inhibitor (protein is described in The Complement System, Rother, Till, Hänsch eds.; Springer; 1998; pages 353 et seq.). With the aid of this inhibitor, participation of the traditional route and the possibility of therapeutic intervention have been demonstrated in experiments. Some references are given in more detail below:

1. Bauernschmitt R. Bohrer H. Hagl S. Rescue therapy with C1-esterase inhibitor concentrate after emergency coronary surgery for failed PTCA. Intensive Care Medicine. 24(6): (1998), 635-8.

2. Khorram-Sefat R. Goldmann C. Radke A. Lennartz A. Mottaghy K. Afify M. Kupper W. Klosterhalfen B. The therapeutic effect of C1-inhibitor on gut-derived bacterial translocation after thermal injury. Shock. 9(2): (1998) 101-8.

3. Niederau C. Brinsa R. Niederau M. Luthen R. Strohmeyer G. Ferrell L D. Effects of C1-esterase inhibitor in three models of acute pancreatitis. International Journal of Pancreatology. 17(2): (1995) 189-96.

4. Hack C E. Ogilvie A C. Eisele B. Jansen P M. Wagstaff J. Thijs L G. Initial studies on the administration of C1-esterase inhibitor to patients with septic shock or with a vascular leak syndrome induced by interleukin-2 therapy. Progress in Clinical & Biological Research. 388: (1994), 335-57.

5. Dalmasso A P. Platt J L. Prevention of complement-mediated activation of xenogeneic endothelial cells in an in vitro model of xenograft hyperacute rejection by C1 inhibitor. Transplantation. 56(5): (1993), 1171-6.

6. Nurnberger W. Michelmann I. Petrik K. Holthausen S. Willers R. Lauermann G. Eisele B. Delvos U. Burdach S. Gobel U. Activity of C1 esterase inhibitor in patients with vascular leak syndrome after bone marrow transplantation. Annals of Hematology. 67(1): (1993), 17-21.

7. Buerke M. Prufer D. Dahm M. Oelert H. Meyer J. Darius H. Blocking of classical complement pathway inhibits endothelial adhesion molecule expression and preserves ischemic myocardium from reperfusion injury. Journal of Pharmacology & Experimental Therapeutics. 286(1): (1998), 429-38.

8. Nissen M H. Bregenholt S. Nording J A. Claesson M H. C1-esterase inhibitor blocks T lymphocyte proliferation and cytotoxic T lymphocyte generation in vitro. International Immunology. 10(2): (1998), 167-73.

9. Salvatierra A. Velasco F. Rodriguez M. Alvarez A. Lopez-Pedrera R. Ramirez R. Carracedo J. Lopez-Rubio F. Lopez-Pujol A. Guerrero R. C1-esterase inhibitor prevents early pulmonary dysfunction after lung transplantation in the dog. American Journal of Respiratory & Critical Care Medicine. 155(3): (1997), 1147-54.

10. Horstick G. Heimann A. Gotze O. Hafner G. Berg O. Boehmer P. Becker P. Darius H. Rupprecht H J. Loos M. Bhakdi S. Meyer J. Kempski O. Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation. 95(3): (1997), 701-8.

11. Heckl-Ostreicher B. Wosnik A. Kirschfink M. Protection of porcine endothelial cells from complement-mediated cytotoxicity by the human complement regulators CD59, C1 inhibitor, and soluble complement receptor type 1. Analysis in a pig-to-human in vitro model relevant to hyperacute xenograft rejection. Transplantation. 62(11): (1996), 1693-6.

12. Niederau C. Brinsa R. Niederau M. Luthen R. Strohmeyer G. Ferrell L D. Effects of C1-esterase inhibitor in three models of acute pancreatitis. International Journal of Pancreatology. 17(2): (1995), 189-96.

13. Buerke M. Murohara T. Lefer A M. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion circulation. 91(2): (1995), 393-402.

14. Hack C E. Ogilvie A C. Eisele B. Jansen P M. Wagstaff J. Thijs L G. Initial studies on the administration of C1-esterase inhibitor to patients with septic shock or with a vascular leak syndrome induced by interleukin-2 therapy. Progress in Clinical & Biological Research. 388: (1994), 335-57.

15. Dalmasso A P. Platt J L. Prevention of complement-mediated activation of xenogeneic endothelial cells in an in vitro model of xenograft hyperacute rejection by C1 inhibitor. Transplantation. 56(5): (1993), 1171-6.

16. Guerrero R. Velasco F. Rodriguez M. Lopez A. Rojas R. Alvarez M A. Villalba R. Rubio V. Torres A. del Castillo D. Endotoxin-induced pulmonary dysfunction is prevented by C1-esterase inhibitor. Journal of Clinical Investigation. 91(6): (June 1993), 2754-60.

Inhibitors which inhibit C1s and/or C1r but not factor D are desirable. Preferably, MASP-I and lysis enzymes, such as t-PA and plasmin, should not be inhibited.

A hereditary disease, hereditary angioneurotic edema, which is due to a deficiency of C1-esterase inhibitor is usually treated by administering C1-esterase inhibitor. Treatment with the C1 inhibitors described here, under certain circumstances as additional medication, is likewise an application of this invention.

Substances which effectively inhibit C_(1s) and C_(1r) are particularly preferred.

PHARMACOLOGICAL EXAMPLES Example A

Color Substrate Test for C1r Inhibition

Reagents: Clr from human plasma, activated, two-chain form (purity: about. 95% according to SDS gel). No foreign protease activity detectable. Substrate: Cbz-Gly-Arg-S-Bzl, product No.: WBASO12, (from PolyPeptide, D-38304 Wolfenbüttel, Germany) Color reagent: DTNB (5,5′dinitro- bis-2-nitrobenzoic acid) (NO. 43760, Fluka, CH-9470 Buchs, Switzerland) Buffer: 150 mM Tris/HCl pH = 7.50 Color substrate test for Clr inhibition Test The color substrate test for determining the Cls procedure: activity is carried out in 96-well microtiter plates. 10 μl of the inhibitor solution in 20% strength DMSO (DMSO diluted with 15 millimolar Tris/HCl pH = 7.50) are added to 140 μl of test buffer, which contains Cls in a final concentration of 0.013 U/ml and DTNB with a final concentration of 0.27 mM/l. Incubation is carried out for 10 minutes at 20 to 25° C. The test is started by adding 50 μl of 1.5 millimolar substrate solution in 30% strength DMSO (final concentration 0.375 mmol/l). After an incubation time of 30 minutes at from 20 to 25° C., the absorbance of each well at 405 nm is measured in a two-beam microtiter plate photometer against a blank value (without enzyme). Measurement IC₅₀: required inhibitor concentration to reduce criteria: the amidolytic Clr activity to 50%. Statistical The dependence of absorbance on the inhibitor evaluation: concentration serves as a basis for the calcula- tion.

Example B

Material and Methods: Color Subrate Test for C1s Inhibition

Reagents: Cls from human plasma, activated, two-chain form (purity: about 95% according to SDS gel). No foreign protease activity detectable. Substrate: Cbz-Gly-Arg-S-Bzl, product No.: WBASO12, (from PolyPeptide, D-38304 Wolfenbüttel, Germany) Color reagent: DTNB (5,5′dinitro- bis-2-nitrobenzoic acid) (No. 43760, Fluka, CH-9470 Buchs, Switzerland) Buffer: 150 mM Tris/HCl pH = 7.50 Test The color substrate test for determining the Cls- procedure: activity is carried out in 96-well microtiter plates. 10 μl of the inhibitor solution in 20% strength DMSO (DMSO diluted with 15 millimolar Tris/HCl pH = 7.50) are added to 140 μl of test buffer, which contains Cls in a final concentration of 0.013 U/ml and DTNB with a final concentration of 0.27 mM/l. Incubation is carried out for 10 minutes at from 20 to 25° C. The test is started by adding 50 μl of 1.5 millimolar substrate solution in 30% strength DMSO (final concentration 0.375 mmol/l). After an incubation time of 30 minutes at from 20 to 25° C., the absorbence of each well at 405 nm is measured in a two-beam microtiter plate photometer against a blank value (without enzyme). Measurement IC₅₀: required inhibitor concentration to reduce criterion: the amidolytic Cls activity to 50%. Statistical The dependence of the absorbance on the inhibitor evaluation: concentration serves as a basis for calculation.

Example C

Detection of Inhibition of Complement in the Traditional Route by the Hemolytic Test

The measurement of potential complement inhibitors is carried out, on the basis of diagnostic tests, using a test for measuring the traditional route (literature: Complement, A practical Approach; Oxford University Press; 1997; page 20 et seq.). For this purpose, human serum is used as a source of complement. However, a test of the same type is also carried out using various sera of other species in analogous manner. Erythrocytes from sheep are used as an indicator system. The antibody-dependent lysis of these cells and the hemoglobin which consequently emerges are a measurement of the complement activity.

Reagents, Biochemicals:

Veronal from Merck #2760500 Na Veronal from Merck #500538 NaCl from Merck #1.06404 MgCl₂ × 6H₂O from Baker #0162 CaCl₂ × 6H₂O from Riedel de Haen #31307 Gelatin from Merck #1.04078.0500 EDTA from Roth #8043.2 Alsever's solution from Gibco #15190-044 Penicillin from Grünenthal #P1507 10 Mega Amboceptor from Behring #ORLC Stock solutions: VBS stock solution: 2.875 g/l of Veronal; 1.875 g/l Na Veronal; 42.5 g/l NaCl Ca/Mg stock solution: 0.15 M Ca++, 1 M Mg++ EDTA stock solution: 0.1 M pH 7.5 Buffer: GVBS buffer: dilute VBS stock solution 1:5 with Fin Aqua; dissolve 1 g/L of gelatin with a little buffer at elevated temperatures GVBS++ buffer: dilute Ca/Mg stock solution 1:1000 in GVBS buffer GVBS/EDTA buffer: dilute EDTA stock solution 1:10 in GVBS buffer

Biogenic Components:

Sheeps' erythrocytes (SRBC): sheep's blood was mixed 1+1 (v/v) with an Alsevers solution and filtered through glass wool and {fraction (1/10)} of the volume of EDTA stock solution +1 pinch of penicillin were added. Human serum: after removal of the coagulated fractions by centrifuging at 4° C., the supernatant was stored in aliquots at −70° C. All measurements were carried out with one batch. No substantial deviations compared with serum of other test subjects were found.

Procedure:

1. Sensitization of the Erythrocytes

SRBC were washed three times with GVBS buffer. The cell count was then set at 5.00E+08 cells/ml in GVBS/EDTA buffer. Amboceptor was added in a dilution of 1:600, and the SRBC was sensitized with antibodies by incubation for 30 minutes at 37° C. with agitation. The cells were then washed three times with GVBS buffer at 4° C., then taken up in GVBS++ buffer and adjusted to a cell count of 5×10⁸.

2. Lysis Experiment:

Inhibitors were preincubated in various concentrations with human serum or serum of other species in suitable dilution (e.g. 1:80 for human serum; a suitable dilution is one at which about 80% maximum lysis which can be achieved by serum is achieved) in GVBS++ for 10 minutes at 37° C. in a volume of 100 μl. 50 μl of sensitized SRBC in GVBS++ were then added. After incubation for 1 hour at 37° C. with agitation, the SRBC were separated off by centrifuging (5 minutes; 2500 rpm 4° C.). 130 μl of the cell-free supernatant were transferred to a 96-well plate. The evaluation was carried out by measurement at 540 nm against GVBS++ buffer.

The absorbencies at 540 nm are used for the evaluation. (1):  Background; cells  without  serum(3):  100%  Lysis, cells  with  serum(x):  measured  values  with  test  substance ${{Calculation}\text{:}\quad \% {Lysis}} = \frac{(x) - {(1) \times 100\%}}{(3) - (1)}$

Example D

Testing of Inhibitors for Inhibition of the Protease Factor D

In the alternative route of the complement system, factor D performs a central function. Owing to the low plasma concentration of factor D, the enzymatic step involving the cleavage of factor B by factor D constitutes the rate-determining step in the alternative route of complement activation. Owing to the limiting role which this enzyme plays in the alternative route, factor D is a target for the inhibition of the complement system.

The commercial substrate Z-Lys-SBzl*HCl is converted by the enzyme factor D (literature: Kam, C. M. et al., J. Biol. Chem. 262, 1987, 3444-3451). The detection of the cleaved substrate is effected by reaction with Ellmann's reagent. The product formed is detected spectrophotometrically. The reaction can be monitored online. This permits measurements of enzyme kinetics.

Material:

Chemicals: Factor D Calbiochem 341273 Ellmann's reagent SIGMA D 8130 Z-Lys-SBz1*HCl (= substrate) Bachem M 1300 50 mg/ml (MeOH) NaCl Riedel-De-Häen 13423 Triton-X-100 Aldrich 23,472-9 Tris (hydroxymethyl)-aminomethane MERCK Dimethylformamide (DMF) Buffer: 50 mM Tris 150 mM NaCl 0.01% Triton-X-100 pH 7.6 Stock solutions: Substrate 20 mM (8.46 mg/ml = 16.92 μl (50 mg/ml) + 83.1 μl H₂O) Ellmann's reagent 10 mM (3.963 mg/ml) in DMF Factor D 0.1 mg/ml Samples (inhibitors) 10⁻² M in DMSO Procedure: Batches: Blank value: 140 μl of buffer + 4.5 μl of substrate (0.6 mM) + 4.5 μl of Ellmann's reagent (0.3 mM) Positive control: 140 μl of buffer + 4.5 μl of substrate (0.6 mM) + 4.5 μl of Ellmann's reagent (0.3 mM) + 5 μl of Factor D Sample measurement: 140 μl of buffer + 4.5 μl of substrate (0.6 mM) + 4.5 μl of Ellmann's reagent (0.3 mM) + 1.5 μl of samples (10⁻⁴ M) + 5 μl of Factor D

The batches are pipetted together into microtiter plates. After mixing of buffer, substrate and Ellmann's reagent (possibly inhibitors), the enzyme reaction is started by adding in each case 5 μl of factor D. Incubation takes place at room temperature for 60 minutes.

Measurement:

Measurement at 405 nm for 1 hour at 3 minute intervals

Evaluation:

The result is plotted graphically. The change in the absorbence per minute (delta OD per minute; slope) is relevant for the comparison of inhibitors so it is possible to determine K_(i) values of inhibitors therefrom. In this test the serine protease inhibitor FUT-175; Futhan; from Torii; Japan, was also run as an effective inhibitor.

Example E

Detection of the inhibition of complement in the alternative route by the hemolytic test (Literature: Complement, A practical Approach; Oxford University Press; 1997, page 20 et seq.)

The test is carried out similarly to clinical tests. The test can be modified by additional activation by means of, for example, Zymosan or Cobra Venom Factor.

Material:

EGTA (ethylenebis Boehringer Mannheim 1093053 (oxyethylenenitrilo)-tetracetic acid MgCl₂ * 6 H₂O MERCK 5833.0250 NaCl MERCK 1.06404.1000 D-Glucose Cerestar Veronal MERCK 2760500 Na Veronal MERCK 500538 VBS stock solution (5×) Gelatin Veronal buffer PD Dr. Kirschfink; University of Heidelberg, Inst. for Immunoloqy; Gelatin MERCK 1.04078.0500 Tris (hydroxymethyl) amino- MERCK 1.08382.0100 methane CaCl₂ MERCK Art. 2382

Human serum was either bought from various suppliers (e.g. Sigma) or obtained from test subjects in the BASF Sud casualty department.

Guinea pigs' blood was obtained and diluted 2:8 in citrate solution. Several batches without obvious differences were used.

Stock Solutions:

VBS stock solution: 2.875 g/l of Veronal 1.875 g/l of Na Veronal 42.5 g/l of NaCl GVBS: dilute VBS stock solution 1:5 with water (Finn Aqua) + 0.1% of gelatin heat till gelatin has dissolved and cool 100 mM EGTA: slowly bring 38.04 mg of EGTA in 500 ml of Finn Aqua to pH 7.5 with 10 M NaOH till dissolved and then make up to 11 Mg-EGTA: 5 ml or 100 mM EGTA 3.5 ml or 100 mM MgCl₂ 10.4 ml of GVBS 31.1 ml of 5% glucose solution Saline: 0.9% of NaCl in water (Finn Aqua) GTB: 0.15 mM CaCl₂ 141 mM NaCl 0.5 mM MgCl₂ * 6 H₂O 10 mM Tris 0.1% of gelatin pH 7.2-7.3

Procedure:

1. Cell Preparation:

The erythrocytes from the guinea pig blood washed several times by centrifuging (5 minutes; 1000 rpm) with GTB until the supernatant was clear. The cell count was adjusted to 2*10⁹ cells/ml.

2. Procedure: the individual batches were incubated for 30 minutes at 37° C. with agitation. The incubation was then stopped for 480 μl of ice-cold physiological saline solution and the cells were separated off by centrifuging for 5 minutes at 5000 rpm. 200 μl of supernatant were measured at 405 nm by transfer to a microtiter plate and evaluation in a microtiter plate photometer.

Pipetting Scheme (Stated Amounts in μl)

Back- 100% Background + Max. ground 100% Lysis + Factor D lysis (− serum) Lysis factor D (− serum) (water) Cells 20 20 20 20 20 Serum 1:4 20 20 Mg-EGTA 480 480 480 480 Factor D 0.5 μg 0.5 μg Saline (for 480 480 480 480 stopping) H₂O 980

Evaluation:

The OD—values are used for the evaluation. (1):  Background; cells  without  serum(3):  100%  lysis + Factor  D; cells  with  serum(x):  measured  values  with  test  substances ${{Calculation}\text{:}\quad \% {Lysis}} = \frac{(X) - {(1)*100\%}}{(3) - (1)}$

The present invention relates to peptide and peptidomimetic substances, their preparation and their use as complement inhibitors. In particular, these are substances having an amidine or guanidine radical as a terminal group.

The present invention also relates to the use of known amidine-containing substances for the preparation of complement inhibitors, specifically of inhibitors of C1s and C1r.

The present invention relates to the use of known and novel substances having an amidine or guanidine terminal group for the preparation of complement inhibitors, specially of inhibitors of C1s and C1r.

The present invention relates in particular to the use of chemically stable substances of the formula I, their tautomers, pharmacologically tolerated salts and prodrugs for the preparation of drugs for the treatment and prophylaxis of disorders which are alleviated or cured by partial or complete inhibition, in particular selective inhibition, of C1s and/or C1r. Formula I has the structure

A—B—D—E—G—K—L  (I)

where

A is

H, C₁₋₆-alkyl, C₁₋₆-alkyl-SO₂, R^(A1)OCO (where R^(A1) is H, C₁₋₁₂-alkyl, C₃₋₈-cycloalkyl, C₁₋₃-alkyl-C₃₋₈-cycloalkyl or C₁₋₃-alkylaryl), R^(A2)R^(A3)NCO (where R^(A2) is H—, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl; R^(A3) is H, C₁₋₆-alkyl or C₀₋₃-alkylaryl; R^(A2)-R^(A3) together may also form a ring of 3 to 7 carbon atoms), R^(A4)OCO₂ (where R^(A4) is C₁₋₆-alkyl or C₁₋₃-alkylaryl), R^(A4)OCONR^(A2), NO₂, R^(A4)CONR^(A2), R^(A1)O, R^(A2)R^(A3)N, R^(A1)S, HO—SO₂, R^(A2)R^(A3)N—SO₂, Cl, phenoxy, Br, F, tetrazolyl, H₂O₃P, R^(A1)—N(OH)—CO, R^(A1)R^(A2)NCONR^(A3), where aryl in each case may be substituted by up to 2 identical or different radicals from the group consisting of F, Cl, Br, OCH₃, CF₃, CH₃ and NO₂;

B is

—(CH₂)_(l) _(^(B)) —L^(B)—(CH₂)_(m) _(^(B)) — where

l^(B) is 0, 1, 2 or 3;

m^(B) is 0, 1, 2, 3, 4 or 5;

L^(B) is

where, in each of the abovementioned ring systems, a phenyl ring may be fused on, which phenyl ring may be substituted by up to 2 identical or different radicals from the group consisting of CH₃, CF₃, Br, Cl and F or may be substituted by R⁸OOC— (where R⁸ is H or C₁₋₃-alkyl);

 where

n^(B) is 0, 1 or 2,

p^(B) is 0, 1 or 2,

q^(B) is 1, 2 or 3,

R^(B1) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl, C₀₋₃-alkylheteroaryl, C₀₋₃-alkyl-C₃₋₈-cycloalkyl, OH or OCH₃;

R^(B2) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl;

R^(B3) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl, C₀₋₃-alkylheteroaryl, R^(B5)OCO (where R^(B5) is H, C₁₋₆-alkyl or C₁₋₃-alkylaryl), R^(B6)—O (where R^(B6) is H or C₁₋₆-alkyl), F, Cl, Br, NO₂ or CF₃;

R^(B4) is H, C₁₋₆-alkyl, R^(B6)—O, Cl, Br, F or CF₃;

R^(B1) and R^(B2) may also be bonded together;

T^(B) is CH₂, O, S, NH or N—C₁₋₆-alkyl;

X^(B) is O, S, NH or N—C₁₋₆-alkyl;

B is furthermore

—(CH₂)₁ _(^(B)) —L^(B)—M^(B)—L^(B)—(CH₂)_(m) _(^(B)) , where

l^(B) and m^(B) have the abovementioned meanings and the two groups L^(B), independently of one another, are identical or different radicals from among the stated radicals;

M^(B) is a single bond, O, S, CH₂, CH₂—CH₂, CH₂—O, O—CH₂, CH₂—S, S—CH₂, CO, SO₂, CH═CH or C≡C;

may furthermore be

-1-adamantyl-, -2-adamantyl-, -1-adamantyl-CH₂—,

-2-adamantyl-CH₂—,

A—B may furthermore be

D is a single bond or

CO, OCO, NR^(D1)—CO (where R^(D1) is H, C₁₋₄-alkyl or

C₀₋₃-alkylaryl), SO₂ or NR^(D1)SO₂;

E is a single bond or

 where

k^(E) is 0, 1 or 2;

l^(E) is 0, 1 or 2;

m^(E) is 0, 1, 2 or 3;

n^(E) is 0, 1 or 2;

p^(E) is 0, 1 or 2;

R^(E1) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, aryl (in particular phenyl or naphthyl), heteroaryl (in particular pyridyl, thienyl, imidazolyl or indolyl) or C₃₋₈-cycloalkyl having a fused-on phenyl ring, it being possible for the abovementioned radicals to carry up to three identical or different substituents from the group consisting of C₁₋₆-alkyl, OH, O—C₁₋₆-alkyl, F, Cl and Br;

R^(E1) is furthermore R^(E4)OCO—CH₂— (where R^(E4) is H, C₁₋₁₂-alkyl or C₁₋₃-alkylaryl);

R^(E2) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, aryl (in particular phenyl or naphthyl), heteroaryl (in particular pyridyl, furyl, thienyl, imidazolyl or indolyl), tetrahydropyranyl, tetrahydrothiopyranyl, C₃₋₈-cycloalkyl having a fused-on phenyl ring, it being possible for the abovementioned radicals to carry up to three identical or different substituents from the group consisting of C₁₋₆-alkyl, OH, O—C₁₋₆-alkyl, F, Cl and Br, or is CH(CH₃)OH, CH(CF₃)₂;

R^(E3) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, aryl (in particular phenyl or naphthyl), heteroaryl (in particular pyridyl, thienyl, imidazolyl or indolyl) or C₃₋₈-cycloalkyl having a fused-on phenyl ring, it being possible for the abovementioned radicals to carry up to three identical or different substituents from the group consisting of C₁₋₆-alkyl, OH, O—C₁₋₆-alkyl, F, Cl and Br;

R^(E2) and R^(B1) may together furthermore form a bridge having (CH₂)₀₋₄, CH═CH, CH₂—CH═CH or CH═CH—CH₂ groups; the groups stated under R^(E1) and R^(E3) may be linked to one another via a bond; the groups stated under R^(E2) and R^(E3) may also be linked to one another via a bond;

R^(E2) is furthermore COR^(E5) (where R^(E5) is OH, O—C₁₋₆-alkyl or OC₁₋₃-alkylaryl), CONR^(E6)R^(E7) (where R^(E6) and R^(E7) are H, C₁₋₆-alkyl or C₀₋₃-alkylaryl);

E may also be D-Asp, D-Glu, D-Lys, D-Orn, D-His, D-Dab, D-Dap or D-Arg;

G is

where l^(G) is 2, 3, 4 and 5, where a CH₂ group of the ring may be replaced by O, S, NH, NC₁₋₃-alkyl, CHOH, CHOC₁₋₃-alkyl, C(C₁₋₃-alkyl)₂, CH(C₁₋₃-alkyl), CHF, CHCl or CF₂;

 where

m^(G) is 0, 1 or 2;

n^(G) is 0, 1 or 2;

p^(G) is 1, 2, 3 or 4;

R^(G1) is H, C₁-C₆-alkyl or aryl;

R^(G2) is H, C₁-C₆-alkyl or aryl;

R^(G1) and R^(G2) together may furthermore form a —CH═CH—CH═CH chain;

G is furthermore

 where

q^(G) is 0, 1 or 2;

r^(G) is 0, 1 or 2;

R^(G3) is H, C₁-C₆-alkyl, C₃₋₈-cycloalkyl or aryl;

R^(G4) is H, C₁-C₆-alkyl, C₃₋₈-cycloalkyl or aryl (in particular phenyl or naphthyl);

K is

NH—(CH₂)_(n) _(^(K)) —Q^(K) where

n^(K) is 0, 1, 2 or 3;

Q^(K) is C₂₋₆-alkyl, it being possible for the chain to be straight-chain or branched and up to two CH₂ groups can be replaced by O or S;

Q^(K) is

 where

R^(K1) is H, C₁₋₃-alkyl, OH, O—C₁₋₃-alkyl, F, Cl or Br;

R^(K2) is H, C₁₋₃-alkyl, O—C₁₋₃-alkyl, F, Cl or Br;

X^(K) is O, S, NH or N—C₁₋₆-alkyl;

W^(K) is

 where, in the latter case, L may not be a guanidine group;

n^(K) is 0, 1 or 2;

p^(K) is 0, 1 or 2;

q^(K) is 1 or 2;

 where

R^(L1) is H, OH, O—C₁₋₆-alkyl, O—(CH₂)₀₋₃-phenyl, CO—C₁₋₆-alkyl, CO₂—C₁₋₆-alkyl or CO₂—C₁₋₃-alkylaryl.

The term C_(1-x)-alkyl includes all straight-chain and branched alkyl chain of up to x-carbon atoms.

The term C₃₋₈-cycloalkyl refers to carbocyclic saturated radicals of 3 to 8 carbon atoms.

The term aryl refers to carbocyclic aromatics of 6 to 14 carbon atoms, in particular phenyl, 1-naphthyl or 2-naphthyl.

The term heteroaryl refers to aromatics having a five- or six-membered ring and at least one heteroatom N, O or S, in particular pyridyl, thienyl, furyl, thiazolyl or imidazolyl; furthermore, two aromatic rings may be fused, e.g. indole, N—C₁₋₃-alkylindole, benzothiophene, benzothiazole, benzimidazole, quinoline or isoquinoline.

The term C_(x-y)-alkylaryl refers to carbocyclic aromatics which are linked to the skeleton via an alkyl group of x, x+1, . . . y−1 or y carbon atoms.

The present invention furthermore relates to compounds which contain the structural element

—G—K—L

where G, K and L have the abovementioned meanings. Preferably, G—K—L has the meaning of the novel compounds stated below. The structural fragment is valuable as part of complement inhibitors and in particular C_(1s)- and/or C_(1r)-inhibitors.

The present invention furthermore relates to the intermediates of the following formulae

where A, B, D, E, G and K have the meanings of the following novel compounds of the formula I.

The novel intermediates are used for the preparation of the compounds I and are valuable building blocks for the synthesis of serine protease inhibitors.

The compounds of the formula I may be present as such or in the form of their salts with physiologically tolerated acids. Examples of such acids are: hydrochloric acid, citric acid, tartaric acid, lactic acid, phosphoric acid, methanesulfonic acid, acetic acid, formic acid, maleic acid, fumaric acid, succinic acid, hydroxysuccinic acid, sulfuric acid, glutaric acid, aspartic acid, pyruvic acid, benzoic acid, glucuronic acid, oxalic acid, ascorbic acid and acetylglycine.

The novel compounds of the formula I are competitive inhibitors of the complement system, in particular of C_(1s), and furthermore C_(1r).

The novel compounds can be administered orally or parentally (subcutaneously, intravenously, intramuscularly, intraperitonially or rectally) in the usual manner. The application can also be effected by means of vapors or sprays through the nasopharyngeal space.

The dosage depends on the age, condition and weight of the patient and on the method of application. As a rule, the daily dose of active compound per person is from about 10 to 2000 mg in the case of oral administration and from about 1 to 200 mg in the case of parental administration. This dose can be given in from 2 to 4 single doses once a day as a sustained-release form.

The compounds can be used in the conventional solid or liquid pharmaceutical application forms, for example as tablets, film-coated tablets, capsules, powders, granules, coated tablets, suppositories, solutions, ointments, creams or sprays. These are prepared in a conventional manner. The active compounds can be processed with the conventional pharmaceutical excipients, such as tablet binders, fillers, preservatives, tablet disintegrants, flow regulators, plasticizers, wetting agents, dispersants, emulsifiers, solvents, diffusion coatings, antioxidants and/or propellants (cf. H. Sucker et al.: Pharmazeutische Technologie, Thieme-Verlag, Stuttgart, 1978). The application forms thus obtained usually contain the active compound in an amount of 0.1 to 99% by weight.

Prodrugs are understood as meaning compounds which are converted in vivo (e.g. first pass metabolism) into the pharmacologically active compounds of the formula I.

The present invention also relates to the following novel compounds A—B—D—E—G—K—L and drugs which contain these compounds. Furthermore, these compounds are suitable as particularly good complement inhibitors.

Here:

A is

H, C₁₋₆-alkyl, C₁₋₆-alkyl-SO₂, R^(A1)OCO (where R^(A1) is H, C₁₋₁₂-alkyl, C₃₋₈-cycloalkyl, C₃₋₈-cycloalkyl-C₁₋₃-alkyl or C₁₋₃-alkylaryl), R^(A2)R^(A3)NCO (where R^(A2) is H—, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl; R^(A3) is H, C₁₋₆-alkyl or C₀₋₃-alkylaryl); R^(A4)OCONR^(A2) (where R^(A4) is C₁₋₆-alkyl or C₁₋₃-alkylaryl), R^(A4)CONR^(A2), R^(A1)O, R^(A2)R^(A3)N, HO—SO₂—, phenoxy, R^(A2)R^(A3)N—SO₂, Cl, Br, F, tetrazolyl, H₂O₃P—, NO₂, R^(A1)—N(OH)—CO— or R^(A1)R^(A2)NCONR^(A3), where aryl in each case may be substituted by up to 2 identical or different radicals from the group consisting of F, Cl, Br, CF₃, CH₃, OCH₃ and NO₂;

B is

—(CH₂)_(l) _(^(B)) —L^(B)—(CH₂)_(m) _(^(B)) — where

l^(B) is 0, 1, 2 or 3;

m^(B) is 0, 1 or 2;

L^(B) is

where, in each of the abovementioned ring systems, a phenyl ring can be fused on, which phenyl ring may be substituted by up to 2 identical or different radicals from the group consisting of CH₃, CF₃, Br, Cl and F or may be substituted by R⁸OOC— (where R⁸ is H or C₁₋₃-alkyl);

 where

n^(B) is 0, 1 or 2;

p^(B) is 0, 1 or 2;

q^(B) is 1, 2 or 3;

R^(B1) is C₀₋₃-alkylaryl, C₀₋₃-alkylheteroaryl, C₀₋₃-alkyl-C₃₋₈-cycloalkyl, OH or OCH₃;

R^(B2) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl;

R^(B3) is H, C₁₋₆alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl; R^(B5)OCO (where R^(B5) is H, C₁₋₆-alkyl or C₁₋₃-alkylaryl), R^(B6)—O (where R^(B6) is H or C₁₋₆-alkyl), F, Cl, Br, NO₂ or CF₃;

R^(B4) is H, C₁₋₆-alkyl, R^(B6)—O, Cl, Br, F or CF₃;

R^(B5) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl;

T^(B) is CH₂, O, S, NH or N—C₁₋₆-alkyl;

R^(B1′) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl, C₀₋₃-alkylheteroaryl or C₀₋₃-alkyl-C₃₋₈-cycloalkyl;

R^(B1) and R^(B2) may also be bonded together;

X^(B) is O, S, NH or N—C₁₋₆-alkyl;

U^(B) is ═CH— or ═N—;

V^(B) is ═CH— or ═N—;

B is furthermore

—(CH₂)_(l) _(^(B)) —L^(B)—M^(B)—L^(B)—(CH₂)_(m) _(^(B)) , where

l^(B) and m^(B) have the abovementioned meanings and the two groups L^(B), independently of one another, are the radicals stated under L^(B);

M^(B) is a single bond, O, S, CH₂, CH₂—CH₂, CH₂—O, O—CH₂, CH₂—S, S—CH₂, CO, SO₂, CH═CH or C≡C;

B is furthermore

-1-adamantyl-CH₂—, -2-adamantyl-CH₂—, -1-adamantyl-,

-2-adamantyl-,

B may furthermore be

where h^(B) is 1, 2, 3 or 4

(R^(B7) is C₁₋₆-alkyl or C₃₋₈-cycloalkyl)

B may furthermore be

where X^(B1) is a bond, O, S, or

where r^(B) is 0, 1, 2 or 3;

and R^(B9) is H or C₁₋₃-alkyl;

A—B may be

D is a single bond or CO, OCO, NR^(D1)—CO (where R^(D1) is H, C₁₋₄-alkyl or C₀₋₃-alkylaryl), SO₂ or NR^(D1)SO₂;

E is a single bond or

 where

k^(E) is 0, 1 or 2;

l^(E) is 0, 1 or 2;

m^(E) is 0, 1, 2 or 3;

n^(E) is 0, 1 or 2;

p^(E) is 0, 1 or 2;

R^(E1) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, aryl (in particular phenyl or naphthyl), pyridyl, thienyl or C₃₋₈-cycloalkyl having a fused-on phenyl ring, it being possible for the abovementioned radicals to carry up to three identical or different substituents from the group consisting of C₁₋₆-alkyl, O—C₁₋₆-alkyl, F, Cl and Br;

R^(E1) is furthermore R^(E4)OCO—CH₂ (where R^(E4) is H, C₁₋₁₂-alkyl or C₁₋₃-alkylaryl);

R^(E2) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, phenyl, pyridyl, furyl, thienyl, imidazolyl, tetrahydropyranyl or tetrahydrothiopyranyl, it being possible for the abovementioned radicals to carry up to three identical or different substituents from the group consisting of C₁₋₆-alkyl, O—C₁₋₆-alkyl, F, Cl and Br, or is CH(CH₃)OH or CH(CF₃)₂;

R^(E3) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl or phenyl, it being possible for the abovementioned radicals to carry up to three identical or different substituents from the group consisting of C₁₋₆-alkyl, O—C₁₋₆-alkyl, F, Cl and Br;

R^(E2) and R^(B1) may together furthermore form a bridge having (CH₂)₀₋₄, CH═CH, CH₂—CH═CH or CH═CH—CH₂ groups;

the groups stated under R^(E1) and R^(E3) may be linked to one another via a bond; the groups stated under R^(E2) and R^(E3) may also be linked to one another via a bond;

R^(E2) is furthermore COR^(E5) (where R^(E5) is OH, O—C₁₋₆-alkyl or O—C₁₋₃-alkylaryl);

if it is asymmetrically substituted, the building block E is preferably present in the R configuration;

E may also be D-Asp, D-Glu, D-Lys, D-Orn, D-His, D-Dab, D-Dap, D-Arg;

G is

where l^(G) is 2, 3, 4 and 5, where a CH₂ group of the ring may be replaced by O, S, NH, CF₂, CHF or CH(C₁₋₃-alkyl);

 where

m^(G) is 0, 1 or 2;

n^(G) is 0, 1 or 2;

p^(G) is 1 or 3;

R^(G1) and R^(G2) are each H;

R^(G1) and R^(G2) together may furthermore form a CH═CH—CH═CH chain;

G is furthermore

 where

q^(G) is 0, 1 or 2;

r^(G) is 0, 1 or 2;

R^(G3) is H, C₁-C₆-alkyl or C₃₋₈-cycloalkyl;

R^(G4) is H, C₁-C₆-alkyl, C₃₋₈-cycloalkyl or phenyl;

K is

NH—(CH₂ )_(n) _(^(K)) —Q^(K) where

n^(K) is 1 or 2;

Q^(K) is

X^(K) is O, S, NH or N—C₁₋₆-alkyl;

 where

 R^(L1) is H, OH, O—C₁₋₆-alkyl, O—(CH₂)₀₋₃-phenyl, CO—C₁₋₆-alkyl, CO₂—C₁₋₆-alkyl or CO₂—C₁₋₃-alkylaryl.

The present invention also relates to the following novel compounds, their tautomers, physiologically tolerable salts and prodrugs of the formula A—B—D—E—G—K—L and drugs which contain these compounds. These compounds are furthermore suitable as particularly good complement inhibitors.

Here:

A is

H, C₁₋₆-alkyl, C₁₋₆-alkyl-SO₂, R^(A1)OCO (where R^(A1) is H, C₁₋₁₂-alkyl, C₃₋₈-cycloalkyl, C₁₋₃-alkyl-C₃₋₈-cycloalkyl or C₁₋₃-alkylaryl), R^(A2)R^(A3)NCO (where R^(A2) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl; R^(A3) is H, C₁₋₆-alkyl or C₀₋₃-alkylaryl), R^(A4)OCONR^(A2), R^(A4)CONR^(A2) (where R^(A4) is C₁₋₆-alkyl or C₁₋₃-alkylaryl), R^(A1)O, phenoxy, R^(A2)R^(A3)N, HO—SO₂, R^(A2)R^(A3)N—SO₂, Cl, Br, F, tetrazolyl, H₂O₃P, NO₂, R^(A1)—N(OH)—CO or R^(A1)R^(A2)NCONR^(A3), where aryl in each case may be substituted by up to 2 identical or different radicals from the group consisting of F, Cl, Br, OCH₃, CH₃, CF₃ and NO₂;

B is

—(CH₂)_(l) _(^(B)) —L^(B)—(CH₂)_(m) _(^(B)) — where

l^(B) is 0, 1, 2 or 3;

m^(B) is 0, 1, 2 or 3;

L^(B) is

where, in each of the abovementioned ring systems, a phenyl ring may be fused on, which phenyl ring may be substituted by up to 2 identical or different radicals from the group consisting of CH₃, CF₃, Br, Cl and F or may be substituted by R⁸OOC— (where R⁸ is H or C₁₋₃-alkyl);

where

n^(B) is 0, 1 or 2;

p^(B) is 0, 1 or 2;

q^(B) is 1, 2 or 3;

R^(B1) is C₀₋₃-alkylaryl, C₀₋₃-alkylheteroaryl, C₀₋₃-alkyl-C₃₋₈-cycloalkyl, OH or OCH₃;

R^(B2) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl;

R^(B1) and RB² may also be bonded together;

RB^(2′) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl, C₀₋₃-alkylheteroaryl or C₀₋₃-alkyl-C₃₋₈-cycloalkyl;

B is furthermore -1-adamantyl-, -1-adamantyl-CH₂—,

-2-adamantyl- or -2-adamantyl-CH₂—,

B is furthermore —(CH₂)_(l) _(^(B)) —L^(B1)—M^(B)—LB²—(CH₂)_(m) _(^(B)) —, where l^(B) and m^(B) have the abovementioned meanings and the two groups L^(B1) and L^(B2), independently of one another, are the following radical:

where, in each of the abovementioned ring systems, a phenyl ring may be fused on;

where

n^(B) is 0, 1 or 2;

p^(B) is 0, 1 or 2;

q^(B) is 1, 2 or 3;

R^(B1) is H (only for L^(B2)), C₁₋₆-alkyl (only for L^(B2)), C₀₋₃-alkylaryl, C₀₋₃-alkylheteroaryl, C₀₋₃-alkyl-C₃₋₈-cycloalkyl, OH or OCH₃;

R^(B2) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl;

R^(B2′) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl, C₀₋₃-alkylheteroaryl or C₀₋₃-alkyl-C₃₋₈-cycloalkyl;

R^(B3) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl, C₀₋₃-alkylheteroaryl, R^(B5)OCO (where R^(B5) is H, C₁₋₆-alkyl or C₁₋₃-alkylaryl), R^(B6)—O (where R^(B6) is H or C₁₋₆-alkyl), F, Cl, Br, NO₂ or CF₃;

R^(B4) is H, C₁₋₆-alkyl, R^(B6)—O, Cl, Br, F or CF₃;

T^(B) is CH₂, O, S, NH or N—C₁₋₆-alkyl;

X^(B) is O, S, NH or N—C₁₋₆-alkyl;

R^(B1) and RB² may also be bonded together;

M^(B) is a single bond, O, S, CH₂, CH₂—CH₂, CH₂—O, O—CH₂, CH₂—S, S—CH₂, CO, SO₂, CH═CH or C≡C;

B may furthermore be

where X^(B1) is a bond, O, S or

r^(B) is 0, 1, 2 or 3;

R^(B9) is H or C₁₋₃-alkyl;

A—B may be

D is a single bond or CO, OCO, NR^(D1)—CO (where R^(D1) is H, C₁₋₄-alkyl or C₀₋₃-alkylaryl), SO₂ or NR^(D1)SO₂;

B—D may be

E is a single bond or

k^(E) is 0, 1 or 2;

l^(E) is 0, 1 or 2;

m^(E) is 0, 1, 2 or 3;

n^(E) is 0, 1 or 2;

p^(E) is 0, 1 or 2;

R^(E1) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, phenyl, naphthyl, pyridyl, thienyl, C₃₋₈-cycloalkyl having a fused-on phenyl ring, it being possible for the abovementioned radicals to carry up to three identical or different substituents from the group consisting of C₁₋₆-alkyl, O—C₁₋₆-alkyl, F, Cl and Br;

R^(E1) is furthermore R^(E4)OCO—CH₂ (where R^(E4) is H, C₁₋₁₂-alkyl or C₁₋₃-alkylaryl;

R^(E2) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, phenyl, pyridyl, thienyl, furyl, imidazolyl, tetrahydropyranyl or tetrahydrothiopyranyl, it being possible for the abovementioned radicals to carry up to three identical or different substituents from the group consisting of C₁₋₆-alkyl, OH, O—C₁₋₆-alkyl, F, Cl and Br, or is CH(CH₃)OH or CH(CF₃)₂;

R^(E3) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl or phenyl, it being possible for the abovementioned radicals to carry up to three identical or different substituents from the group consisting of C₁₋₆-alkyl, O—C₁₋₆-alkyl, F, Cl and Br;

R^(E2) and R^(B1) together may furthermore form a bridge having (CH₂)₀₋₄, CH═CH, CH₂—CH═CH or CH═CH—CH₂ groups;

the groups stated under R^(E1) and R^(E3) may be linked to one another via a bond; the groups stated under R^(E2) and R^(E3) may also be linked to one another via a bond;

R^(E2) is furthermore COR^(E5) (where R^(E5) is OH, O—C₁₋₆-alkyl or O—C₁₋₃-alkylaryl);

if it is asymmetrically substituted, the building block E is preferably present in the R configuration;

E may also be D-Asp, D-Glu, D-Lys, D-Orn, D-His, D-Dab, D-Dap, D-Arg;

G is

where l^(G)=2, 3, 4 and 5, where a CH₂ group of the ring may be replaced by O, S, NH, CHF or CH(C₁₋₃-alkyl);

 where

m^(G) is 0, 1 or 2;

n^(G) is 0, 1 or 2;

p^(G) is 1 or 3;

R^(G1) is H;

R^(G2) is H;

R^(G1) and R^(G2) together may also be a CH═CH—CH═CH chain;

G is furthermore

 where

q^(G) is 0, 1 or 2;

r^(G) is 0, 1 or 2;

R^(G3) is H, C₁-C₆-alkyl or C₃₋₈-cycloalkyl;

R^(G4) is H, C₁-C₆-alkyl, C₃₋₈-cycloalkyl or phenyl;

K is

NH—(CH₂)_(n) _(^(k)) —Q^(K) where

n^(K) is 1 or 2;

Q^(K) is

X^(K) is O, S, NH or N—C₁₋₆-alkyl;

 where

R^(L1) is H, OH, O—C₁₋₆-alkyl, O—(CH₂)₀₋₃-phenyl, CO—C₁₋₆-alkyl, CO₂—C₁₋₆-alkyl or CO₂—C₁₋₅-alkylaryl.

The present invention also relates to the following novel compounds, their tautomers, physiologically tolerable salts and prodrugs of the formula A—B—D—E—G—K—L and drugs which contain these compounds. These compounds are furthermore suitable as particularly good complement inhibitors.

Here,

A is

H, C₁₋₆-alkyl, C₁₋₆-alkyl-SO₂, R^(A1)OCO (where R^(A1) is H, C₁₋₁₂-alkyl, C₃₋₈-cycloalkyl, C₁₋₃-alkyl-C₃₋₈-cycloalkyl or C₁₋₃-alkylaryl), R^(A2)R^(A3)NCO (where R^(A2) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl; R^(A3) is H, C₁₋₆-alkyl or C₀₋₃-alkylaryl), R^(A4)OCONR^(A2), R^(A4)CONR^(A2) (where R^(A4) is C₁₋₆-alkyl or C₁₋₃-alkylaryl), R^(A1)O, phenoxy, R^(A2)R^(A3)N, HO—SO₂, R^(A2)R^(A3)N—SO₂, Cl, Br, F, tetrazolyl, H₂O₃P, NO₂, R^(A1)—N(OH)—CO— or R^(A1)R^(A2)NCONR^(A3), where aryl in each case may be substituted by up to 2 identical or different substituents from the group consisting of F, Cl, Br, CH₃, CF₃, OCH₃ and NO₂;

B is

—(CH₂)₁ _(^(B)) —L^(B)—(CH₂)_(m) _(^(B)) — where

l^(B) is 0, 1, 2 or 3;

m^(B) is 0, 1, 2, 3, 4 or 5;

L^(B) is

where, in each of the abovementioned ring systems, a phenyl ring may be fused on, which phenyl ring may be substituted by up to 2 identical or different radicals from the group consisting of CH₃, CF₃, F, Cl and Br or may be substituted by R⁸OOC— (where R⁸ is H or C₁₋₃-alkyl);

R^(B3) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl, C₀₋₃-alkylheteroaryl, R^(B5)OCO (where R^(B5) is H, C₁₋₆-alkyl or C₁₋₃-alkylaryl), R^(B6)—O (where R^(B6) is H or C₁₋₆-alkyl), F, Cl, Br, NO₂ or CF₃;

R^(B4) is H, C₁₋₆-alkyl, R^(B6)—O, Cl, Br, F or CF₃;

T^(B) is CH₂, O, S, NH or N—C₁₋₆-alkyl;

X^(B) is O, S, NH or N—C₁₋₆-alkyl;

U^(B) is ═CH— or ═N—;

V^(B) is ═CH— or ═N—;

B may furthermore be

where h^(B) is 1, 2, 3 or 4

(R^(B7) is C₁₋₆-alkyl or C₃₋₈-cycloalkyl)

A—B may be

B may furthermore be

-1-adamantyl-, -2-adamantyl-, -1-adamantyl-CH₂—,

-2-adamantyl-CH₂,

B may furthermore be

where X^(B1) is a bond, O, S, or

r^(B) is 0, 1, 2 or 3;

R^(B9) is H or C₁₋₃-alkyl;

D is a single bond or

—NR^(D1)—CO (where R^(D1) is H, C₁₋₄-alkyl or C₀₋₃-alkylaryl) or

—NR^(D1)SO₂;

E is a single bond or

 where

k^(E) is 0, 1 or 2;

l^(E) is 0, 1 or 2;

m^(E) is 0, 1, 2 or 3;

n^(E) is 0, 1 or 2;

p^(E) is 0, 1 or 2;

R^(E1) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, aryl (in particular phenyl or naphthyl), pyridyl, thienyl, C₃₋₈-cycloalkyl having a fused-on phenyl ring, it being possible for the abovementioned radicals to carry up to three identical or different substituents from the group consisting of C₁₋₆-alkyl, O—C₁₋₆-alkyl, F, Cl and Br;

R^(E1) is furthermore R^(E4)OCO—CH₂ (where R^(E4) is H, C₁₋₁₂-alkyl or C₁₋₃-alkylaryl);

R^(E2) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, phenyl, pyridyl, furyl, thienyl, imidazolyl, tetrahydropyranyl or tetrahydrothiopyranyl, it being possible for the abovementioned radicals to carry up to three identical or different substituents from the group consisting of C₁₋₆-alkyl, O—C₁₋₆-alkyl, F, Cl and Br, or is CH(CH₃)OH or CH(CF₃)₂;

R^(E3) is H, C₁₋₆-alkyl or C₃₋₈-cycloalkyl, it being possible for the abovementioned radicals to carry up to three identical or different substituents from the group consisting of CI₆-alkyl, O—C₁₋₆-alkyl, F, Cl and Br;

R^(E2) and R^(B1) together may furthermore form a bridge having (CH₂)₀₋₄, CH═CH, CH₂—CH═CH or CH═CH-CH₂ groups;

the groups stated under R^(E1) and R^(E3) may be linked to one another via a bond; the groups stated under R^(E2) and R^(E3) may also be linked to one another via a bond;

R^(E2) is furthermore COR^(E5) (where R^(E5) is OH, O—C₁₋₆-alkyl or OC₁₋₃-alkylaryl);

if it is asymmetrically substituted, the building block E is preferably present in the R configuration;

E may also be D-Asp, D-Glu, D-Lys, D-Orn, D-His, D-Dab, D-Dap or D-Arg;

G is

where l^(G)=2, 3, 4 and 5, where a CH₂ group of the ring may be replaced by O, S, NH, CHF, CF₂ or CH(C₁₋₃-alkyl);

 where

m^(G) is 0, 1 or 2;

n^(G) is 0, 1 or 2;

p^(G) is 1 or 3;

R^(G1) is H;

R^(G2) is H;

R^(G1) and R^(G2) together may furthermore form a CH═CH—CH═CH chain;

G is furthermore

 where

q^(G) is 0, 1 or 2;

r^(G) is 0, 1 or 2;

R^(G3) is H, C₁-C₆-alkyl or C₃₋₈-cycloalkyl;

R^(G4) is H, C₁-C₆-alkyl, C₃₋₈-cycloalkyl or phenyl;

K is

NH—(CH₂)_(n) _(^(K)) —Q^(K) where

n^(K) is 1 or 2;

Q^(K) is

X^(K) is O, S, NH or N—C₁₋₆-alkyl;

 where

R^(L1) is —H, —OH, —O—C₁₋₆-alkyl, —O—(CH₂)₀₋₃-phenyl, —CO—C₁₋₆-alkyl, —CO₂—C₁₋₆-alkyl or CO₂—C₁₋₃-alkylaryl.

The present invention also relates to the following novel preferred compounds, their tautomers, physiologically tolerable salts and prodrugs of the formula A—B—D—E—G—K—L and drugs which contain these compounds. Furthermore, these compounds are suitable as particularly good complement inhibitors.

Here:

A is

H, C₁₋₆-alkyl, C₁₋₆-alkyl-SO₂, R^(A1)OCO (where R^(A1) is H, C₁₋₁₂-alkyl, C₃₋₈-cycloalkyl, C₃₋₈-cycloalkyl-C₁₋₃-alkyl or C₁₋₃-alkylaryl), R^(A2)R^(A3)NCO (where R^(A2) is H—, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl; R^(A3) is H, C₁₋₆-alkyl or C₀₋₃-alkylaryl); R^(A4)OCONR^(A2) (where RA⁴ is C₁₋₆-alkyl or C₁₋₃-alkylaryl), R^(A4)CONR^(A2), R^(A1)O, R^(A2)R^(A3)N, HO—SO₂—, phenoxy, R^(A2)R^(A3)N—SO₂, Cl, Br, F, tetrazolyl, H₂O₃P—, NO₂, R^(A1)—N(OH)—CO— or R^(A1)R^(A2)NCONR^(A3), where aryl in each case may be substituted by up to 2 identical or different radicals from the group consisting of F, Cl, Br, CF₃, CH₃, OCH₃ and NO₂;

B is

—(CH₂)_(l) _(^(B)) —L^(B)—(CH₂)_(m) _(^(B)) — where

l^(B) is 0, 1, 2 or 3;

m^(B) is 0, 1 or 2;

L^(B) is

where, in each of the abovementioned ring systems, a phenyl ring can be fused on, which phenyl ring may be substituted by up to 2 identical or different radicals from the group consisting of CH₃, CF₃, Br, Cl and F or may be substituted by R⁸OOC— (where R8 is H or C₁₋₃-alkyl);

 where

n^(B) is 0, 1 or 2;

p^(B) is 0, 1 or 2;

R^(B1) is C₀₋₃-alkylaryl, C₀₋₃-alkylheteroaryl, C₀₋₃-alkyl-C₃₋₈-cycloalkyl, OH or OCH₃;

R^(B2) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl;

R^(B3) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl; R^(B5)OCO (where R^(B5) is H, C₁₋₆-alkyl or C₁₋₃-alkylaryl), R^(B6)—O (where R^(B6) is H or C₁₋₆-alkyl), F, Cl, Br, NO₂ or CF₃;

R^(B4) is H, C₁₋₆-alkyl, R^(B6)—O, Cl, Br, F or CF₃;

R^(B1′) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl, C₀₋₃-alkylheteroaryl or C₀₋₃-alkyl-C₃₋₈-cycloalkyl;

R^(B1) and R^(B2) may also be bonded together;

X^(B) is O, S, NH or N—C₁₋₆-alkyl;

Y^(B) is ═CH— or ═N—;

Z^(B) is ═CH— or ═N—;

U^(B) is ═CH— or ═N—;

V^(B) is ═CH— or ═N—;

B is furthermore —(CH₂)_(l) _(^(B)) —L^(B)—M^(B)—L^(B)—(CH₂)_(m) _(^(B)) , where l^(B) and m^(B) have the abovementioned meanings and the two groups L^(B), independently of one another, are the radicals stated under L^(B);

M^(B) is a single bond, O, S, CH₂, CH₂—CH₂, CH₂—O, O—CH₂, CH₂—S, S—CH₂, CO, SO₂, CH═CH or C≡C;

B is furthermore -1-adamantyl-CH₂—, -2-adamantyl-CH₂—, -1-adamantyl-, -2-adamantyl-,

B may furthermore be

where h^(B) is 1, 2, 3 or 4

(RB⁷ is C₁₋₆-alkyl or C₃₋₈-cycloalkyl)

B may furthermore be

where X^(B1) is a bond, O, S, or

r^(B) is 0, 1, 2 or 3;

R^(B9) is H or C₁₋₃-alkyl;

A—B may be

D is a single bond or CO, OCO or NR^(D1)—CO (where R^(D1) is H, C₁₋₄-alkyl or C₀₋₃-alkylaryl), SO₂ or NR^(D1)SO₂;

E is

 where

k^(E) is 0 or 1;

l^(E) is 0 or 1;

m^(E) is 0 or 1;

n^(E) is 0 or 1;

p^(E) is 0 or 1;

R^(E1) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, aryl (in particular phenyl or naphthyl), pyridyl, thienyl or C₃₋₈-cycloalkyl having a fused-on phenyl ring;

R^(E1) is furthermore R^(E4)OCO—CH₂ (where R^(E4) is H, C₁₋₁₂-alkyl or C₁₋₃-alkylaryl);

R^(E2) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, phenyl, pyridyl, furyl, thienyl, imidazolyl, tetrahydropyranyl or tetrahydrothiopyranyl, where the abovementioned radicals may carry up to three identical or different substituents from the group consisting of C₁₋₆-alkyl, O—C₁₋₆-alkyl, F, Cl and Br, or is CH(CH₃)OH or CH(CF₃)₂;

R^(E3) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl or phenyl;

R^(E2) and R^(B1) together may also form a bridge with (CH₂)₀₋₄, CH═CH, CH₂—CH═CH or CH═CH—CH₂ groups;

the groups stated under R^(E1) and R^(E2) may be linked to one another via a bond; the groups stated under R^(E2) and R^(E3) may also be linked to one another via a bond;

if it is asymmetrically substituted, the building block E is preferably present in the R configuration;

E may also be D-Asp, D-Glu, D-Lys, D-Orn, D-His, D-Dab, D-Dap or D-Arg;

G is

where l^(G) is 2, 3 or 4, where a CH₂ group of the ring may be replaced by O, S, CF₂, CHF or CH(C₁₋₃-alkyl);

 where

m^(G) is 0, 1 or 2;

n^(G) is 0, 1 or 2;

R^(G1) and R^(G2) are each H;

G is furthermore

where r^(G) is 0 or 1;

R^(G3) is H, C₁-C₆-alkyl or C₃₋₈-cycloalkyl;

R^(G4) is H, C₁-C₆-alkyl, C₃₋₈-cycloalkyl or phenyl;

K is

NH—(CH₂)_(n) _(^(K)) —Q^(K), where

n^(K) is 1 or 2;

QK is

X^(K) is O or S;

 where

R^(L1) is H, OH, O—C₁₋₆-alkyl, O—(CH₂)₀₋₃-phenyl, CO—C₁₋₆-alkyl, CO₂—C₁₋₆-alkyl or CO₂—C₁₋₃-alkylaryl.

The present invention also relates to the following particularly preferred novel compounds, their tautomers, physiologically tolerable salts and prodrugs of the formula A—B—D—E—G—K—L and drugs which contain these compounds. Furthermore, these compounds are suitable as particularly good complement inhibitors.

Here:

A is

H, C₁₋₆-alkyl, C₁₋₆-alkyl-SO₂ or R^(A1)OCO (where R^(A1) is H, C₁₋₁₂-alkyl, C₃₋₈-cycloalkyl, C₃₋₈-cycloalkyl-C₁₋₃-alkyl or C₁₋₃-alkylaryl), R^(A2)R^(A3)NCO (where R^(A2) is H—, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl; R^(A3) is H, C₁₋₆-alkyl or C₀₋₃-alkylaryl); R^(A4)OCONR^(A2) (where R^(A4) is C₁₋₆-alkyl or C₁₋₃-alkylaryl), R^(A4)CONR^(A2), R^(A1)O, R^(A2)R^(A3)N, HO—SO₂—, phenoxy, R^(A2)R^(A3)N—SO₂, Cl, Br, F, tetrazolyl, H₂O₃P—, NO₂, R^(A1)—N(OH)—CO— or R^(A1)R^(A2)NCONR^(A3), where aryl in each case may be substituted by up to 2 identical or different radicals from the group consisting of F, Cl, Br, CF₃, CH₃, OCH₃ and NO₂;

B is

—(CH₂)₁ _(^(B)) —L^(B)—(CH₂)_(m) _(^(B)) — where

l^(B) is 0, 1 or 2;

m^(B) is 0, 1 or 2;

L^(B) is

where, in each of the abovementioned ring systems, a phenyl ring can be fused on, which phenyl ring may be substituted by up to 2 identical or different radicals from the group consisting of CH₃, CF₃, Br, Cland F or may be substituted by R⁸OOC— (where R⁸ is H or C₁₋₃-alkyl);

 where

n^(B) is 0 or 1;

p^(B) is 0 or 1;

R^(B1) is C₀₋₃-alkylaryl, C₀₋₃-alkylheteroaryl, C₀₃-alkyl-C₃₋₈-cycloalkyl, OH or OCH₃;

R^(B2) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl;

R^(B3) is H, C₁₋₆-alkyl; R^(B5)OCO (where R^(B5) is H, C₁₋₆-alkyl), R^(B6)—O (where R^(B6) is H or C₁₋₆-alkyl), F, Cl, Br, NO₂ or CF₃;

R^(B4) is H, C₁₋₆-alkyl, R^(B6)—O, Cl, Br, F or CF₃;

R^(B1) and R^(B2) may also be bonded together;

B is furthermore

—(CH₂)_(l) _(^(B)) —L^(B)—M^(B)—L^(B)—(CH₂)_(m) _(^(B)) , where

l^(B) and m^(B) have the abovementioned meanings and the two groups L^(B), independently of one another, are the radicals stated under L^(B);

M^(B) is a single bond, O, S, CH₂, CH₂—CH₂, CH₂—O, O—CH₂, CH₂—S, S—CH₂, CH═CH or C≡C;

B is furthermore

-1-adamantyl-CH₂—, -2-adamantyl-CH₂—,

B may furthermore be

where h^(B) is 1, 2, 3 or 4

(R^(B7) is C₁₋₆-alkyl or C₃₋₈-cycloalkyl)

B may furthermore be

where X^(B1) is a bond, O, S or

r^(B) is 0, 1, 2 or 3;

R^(B9) is H or C₁₋₃-alkyl;

A—B may be

D is a single bond or CO, OCO or NR^(D1)—CO (where R^(D1) is H, C₁₋₄-alkyl or C₀₋₃-alkylaryl), SO₂ or NR^(D1)SO₂;

E is

 where

m^(E) is 0 or 1;

R^(E1) is H or C₁₋₆-alkyl;

R^(E2) is H, C₁₋₆-alkyl or C₃₋₈-cycloalkyl, where the abovementioned radicals may carry up to three substituents from the group consisting of C₁₋₆-alkyl and F, or is CH(CH₃)OH or CH(CF₃)₂;

R^(E3) is H; the groups stated under R^(E1) and R^(E2) may be linked to one another via a bond;

if it is asymmetrically substituted, the building block E is preferably present in the R configuration;

E may also be D-Asp, D-Glu, D-Lys, D-Orn, D-His, D-Dab, D-Dap or D-Arg;

G is

where l^(G) is 2 or 3, where a CH₂ group of the ring may be replaced by S or CHCH₃;

 where

m^(G) is 1;

n^(G) is 0;

R^(G1) and R^(G2) are each H;

K is

NH—(CH₂)_(n) _(^(K)) —Q^(K), where

n^(K) is 1;

Q^(K) is

X^(K) is S;

Y^(K) is ═CH— or ═N—;

Z^(K) is ═CH— or ═N—;

L is

 where

R^(L1) is H, OH, CO—C₁₋₆-alkyl, CO₂—C₁₋₆-alkyl or CO₂—C₁₋₃-alkylaryl.

The present invention also relates to the following very particularly preferred novel compounds, their tautomers, physiologically tolerable salts and prodrugs of the formula A—B—D—E—G—K—L and drugs which contain these compounds. Furthermore, these compounds are suitable as particularly good complement inhibitors.

Here:

A is

H, C₁₋₆-alkyl, C₁₋₆-alkyl-SO₂ or R^(A1)OCO (where R^(A1) is H, C₁₋₁₂-alkyl, C₃₋₈-cycloalkyl, C₃₋₈-cycloalkyl-C₁₋₃-alkyl or C₁₋₃-alkylaryl), R^(A2)R^(A3)NCO (where R^(A2) is H—, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl; R^(A3) is H, C₁₋₆-alkyl or C₀₋₃-alkylaryl); R^(A4)OCONR^(A2) (where R^(A4) is C₁₋₆-alkyl or C₁₋₃-alkylaryl), RA⁴CONR^(A2), R^(A1)O, R^(A2)R^(A3)N, HO—SO₂—, phenoxy, R^(A2)R^(A3)N—SO₂, Cl, Br, F, tetrazolyl, H₂O₃P—, NO₂, R^(A1)—N(OH)—CO— or R^(A1)R^(A2)NCONR^(A3), where aryl in each case may be substituted by up to 2 identical or different radicals from the group consisting of F, Cl, Br, CF₃, CH₃, OCH₃ and NO₂;

B is

—(CH₂)_(l) _(^(B)) —L^(B)—(CH₂)_(m) _(^(B)) — where

l^(B) is 0 or 1;

m^(B) is 0, 1 or 2;

L^(B) is

where, in each of the abovementioned ring systems, a phenyl ring can be fused on, which phenyl ring may be substituted by up to 2 identical or different radicals from the group consisting of CH₃, CF₃, Br, Cl and F or may be substituted by R⁸OOC— (where R⁸ is H or C₁₋₃-alkyl);

 where

n^(B) is 0 or 1;

p^(B) is 0 or 1;

R^(B1) is C₀₋₃-alkylaryl, C₀₋₃-alkylheteroaryl, C₀₋₃-alkyl-C₃₋₈-cycloalkyl, OH or OCH₃;

R^(B2) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl;

R^(B3) is H, C₁₋₆-alkyl;

R^(B5)OCO (where R^(B5) is H or C₁₋₆-alkyl), RB6—O (where R^(B6) is H or C₁₋₆-alkyl), F, Cl, Br, NO₂ or CF₃;

R^(B4) is H, C₁₋₆-alkyl, R^(B6)—O, Cl, Br, F or CF₃;

R^(B1) and R^(B2) may also be bonded together;

X^(B) is O or S;

Y^(B) is ═CH— or ═N—;

Z^(B) is ═CH— or ═N—;

B is furthermore —(CH₂)_(l) _(^(B)) —L^(B)—M^(B)—L^(B)—(CH₂)_(m) _(^(B)) , where l^(B) and m^(B) have the abovementioned meanings and the two groups L^(B), independently of one another, are the radicals —C≡C— stated under L^(B),

M^(B) is a single bond, O, CH₂—S, S—CH₂, CO, SO₂ or CH₂—O;

B may furthermore be

where h^(B) is 1, 2, 3 or 4

(R^(B7) is C₁₋₆-alkyl or C₃₋₈-cycloalkyl)

B may furthermore be 1-fluorenyl-, 1-adamantyl- or 1-adamantyl-CH₂—,

A—B may be 2-pyridyl-CH₂—, 2-benzothienyl-, 3-benzothienyl-,

D is a single bond or CO or SO₂;

E is

 where

R^(E1) is H or CH₃;

R^(E2) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, thienyl, CH(CH₃)OH or CH(CF₃)₂;

R^(E3) is H;

the groups stated under R^(E1) and R^(E2) may be linked to one another via a bond; the groups stated under R^(E2) and R^(E3) may also be linked to one another via a bond;

if it is asymmetrically substituted, the building block E is preferably present in the R configuration;

E may also be D-Lys, D-Orn, D-Dab, D-Dap or D-Arg;

G is

where l^(G) is 2 or 3, where a CH₂ group of the ring may be replaced by CHCH₃;

 where

m^(G) is 1;

n^(G) is 0;

R^(G1) and R^(G2) are each H;

K is

NH—(CH₂)_(n) _(^(K)) —Q^(K), where

n^(K) is 1;

Q^(K) is

X^(K) is S;

Y^(K) is ═CH— or ═N—;

Z^(K) is ═CH— or ═N—;

 where

R^(L1) is H or OH.

The present invention also relates to the following preferred novel compounds, their tautomers, physiologically tolerable salts and prodrugs of the formula A—B—D—E—G—K—L and drugs which contain these compounds. Furthermore, these compounds are suitable as particularly good complement inhibitors.

Here:

A is

H, C₁₋₆-alkyl, C₁₋₆-alkyl-SO₂ or R^(A1)OCO (where R^(A1) is H, C₁₋₁₂-alkyl, C₃₋₈-cycloalkyl, C₁₋₃-alkyl-C₃ ₈-cycloalkyl or C₁₋₃-alkylaryl), R^(A2)R^(A3)NCO (where R^(A2) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl; R^(A3) is H, C₁₋₆-alkyl or C₀₋₃-alkylaryl), R^(A4)OCONR^(A2), R^(A4)CONR^(A2) (where R^(A4) is C₁₋₆-alkyl or C₁₋₃-alkylaryl), R^(A1)O, phenoxy, R^(A2)R^(A3)N, HO—SO₂, R^(A2)R^(A3)N—SO₂, Cl, Br, F, tetrazolyl, H₂O₃P, NO₂, R^(A1)—N(OH)—CO or R^(A1)R^(A2)NCONR^(A3), where aryl in each case may be substituted by up to 2 identical or different radicals from the group consisting of F, Cl, Br, OCH₃, CH₃, CF₃ and NO₂;

B is

—(CH₂)_(l) _(^(B)) —L^(B)—(CH₂)_(m) _(^(B)) —, where

l^(B) is 0, 1 or 2;

m^(B) is 0, 1 or 2;

L^(B) is

where, in each of the abovementioned ring systems, a phenyl ring can be fused on, which phenyl ring may be substituted by up to 2 identical or different radicals from the group consisting of CH₃₁ CF₃, Br, Cl and F or may be substituted by R⁸OOC— (where R⁸ is H or C₁₋₃-alkyl);

 where

n^(B) is 0, 1 or 2;

p^(B) is 0, 1 or 2;

R^(B1) is C₀₋₃-alkylaryl, C₀₋₃-alkylheteroaryl, C₀₋₃-alkyl-C₃₋₈-cycloalkyl, OH or OCH₃;

R^(B2) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl;

R^(B1) and R^(B2) may also be bonded together;

B is furthermore -1-adamantyl-CH₂—, -2-adamantyl-CH₂—,

B is furthermore —(CH₂)_(l) _(^(B)) —L^(B1)—M^(B)—L^(B2)—(CH₂)_(m) _(^(B)) —, where l^(B) and m^(B) have the abovementioned meanings and the two groups L^(B1) and L^(B2), independently of one another, are the following radicals:

where, in each of the abovementioned ring systems, a phenyl ring can be fused on;

where

n^(B) is 0, 1 or 2;

p^(B) is 0, 1 or 2;

R^(B1) is H (only for L^(B2)), C₁₋₆-alkyl (only for L^(B2)), C₀₋₃-alkylaryl, C₀₋₃-alkylheteroaryl, C₀₋₃-alkyl-C₃₋₈-cycloalkyl, OH or OCH₃;

R^(B2) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl;

R^(B3) is H, C₁₋₆-alkyl, aryl, heteroaryl, R^(B5)OCO (where R^(B5) is H or C₁₋₆-alkyl), R^(B6)—O (where R^(B6) is H or C₁₋₆-alkyl), F, Cl, Br, NO₂ or CF₃;

R^(B4) is H, C₁₋₆-alkyl, R^(B6)—O, Cl, Br, F or CF₃;

X^(B) is O or S;

Y^(B) is ═CH— or ═N—;

Z^(B) is ═CH— or ═N—;

R^(B1) and R^(B2) may also be bonded together;

M^(B) is a single bond, O, S, CH₂, CH₂—CH₂, CH₂—O, O—CH₂, CH₂—S, S—CH₂, CO, SO₂, CH═CH or C≡C;

B may furthermore be

where X^(B1) is a bond, O, S or

r^(B) is 0, 1, 2 or 3;

R^(B9) is H or C₁₋₃-alkyl;

A—B may be

D is a single bond or CO, OCO, NR^(D1)—CO (where R^(D1) is H, C₁₋₄-alkyl or C₀₋₃-alkylaryl), SO₂ or NR^(D1)SO₂;

B—D may be

E is

k^(E) is 0 or 1;

m^(E) is 0 or 1;

n^(E) is 0 or 1;

p^(E) is 0 or 1;

R^(E1) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, phenyl, naphthyl, pyridyl, thienyl or C₃₋₈-cycloalkyl having a fused-on phenyl ring;

R^(E2) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, phenyl, pyridyl, thienyl, furyl, imidazolyl, tetrahydropyranyl, tetrahydrothiopyranyl, CH(CH₃)OH or CH(CF₃)₂;

R^(E3) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl or phenyl;

the groups stated under R^(E1) and R^(E2) may be linked to one another via a bond; the groups stated under R^(E2) and R^(E3) may also be linked to one another via a bond;

if it is asymmetrically substituted, the building block E is preferably present in the R configuration;

E may also be D-Asp, D-Glu, D-Lys, D-Orn, D-His, D-Dab, D-Dap or D-Arg;

G is

where l^(G) is 2, 3 or 4, where a CH₂ group of the ring may be replaced by CHCH₃;

 where

m^(G) is 1;

n^(G) is 0 or 1;

R^(G1) is H;

R^(G2) is H;

G is furthermore

 where

q^(G) is 0 or 1;

r^(G) is 0 or 1;

R^(G3) is H, C₁-C₆-alkyl or C₃₋₈-cycloalkyl;

R^(G4) is H, C₁-C₆-alkyl, C₃₋₈-cycloalkyl or phenyl;

K is

NH—(CH₂)_(n) _(^(K)) —Q^(K), where

n^(K) is 1;

Q^(K) is

X^(K) is O or S;

Y^(K) is ═CH— or ═N—;

Z^(K) is ═CH— or ═N—;

L is

 where

R^(L1) is H, OH, CO—C₁₋₆-alkyl, CO₂—C₁₋₆-alkyl or CO₂—C₁₋₅-alkylaryl.

The present invention also relates to the following particularly preferred novel compounds, their tautomers, physiologically tolerable salts and prodrugs of the formula A—B—D—E—G—K—L and drugs which contain these compounds. Furthermore, these compounds are suitable as particularly good complement inhibitors.

Here:

A is

H, C₁₋₆-alkyl, C₁₋₆-alkyl-SO₂, R^(A1)OCO (where R^(A1) is H, C₁₋₁₂-alkyl, C₃₋₈-cycloalkyl, C₁₋₃-alkyl-C₃₋₈-cycloalkyl or C₁₋₃-alkylaryl), R^(A2)R^(A3)NCO (where R^(A2) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl; R^(A3) is H, C₁₋₆-alkyl or C₀₋₃-alkylaryl), R^(A4)OCONR^(A2), R^(A4)CONR^(A2) (where R^(A4) is C₁₋₆-alkyl or C₁₋₃-alkylaryl), R^(A1)O, phenoxy, R^(A2)R^(A3)N, HO—SO₂, R^(A2)R^(A3)N—SO₂, Cl, Br, F, tetrazolyl, H₂O₃P, NO₂, R^(A1)—N(OH)—CO or R^(A1)R^(A2)NCONR^(A3), where aryl in each case may be substituted by up to 2 identical or different radicals from the group consisting of F, Cl, Br, OCH₃, CH₃, CF₃ and NO₂;

B is

—(CH₂)_(l) _(^(B)) —L^(B)—(CH₂)_(m) _(^(B)) —, where

l^(B) is 0 or 1;

m^(B) is 0, 1 or 2;

L^(B) is

where, in each of the abovementioned ring systems, a phenyl ring can be fused on, which phenyl ring may be substituted by up to 2 identical or different radicals from the group consisting of CH₃, CF₃, Br, Cl and F or may be substituted by R⁸OOC— (where R⁸ is H or C₁₋₃-alkyl);

 where

n^(B) is 0 or 1;

p^(B) is 0 or 1;

B is furthermore -1-adamantyl-CH₂—, -2-adamantyl-CH₂—,

B is furthermore —(CH₂)_(l) _(^(B)) —L^(B1)—M^(B)—L^(B2)—(CH₂)_(m) _(^(B)) —, where l^(B) and m^(B) have the abovementioned meanings and the two groups L^(B1) and L^(B2), independently of one another, are the following radicals:

where, in each of the abovementioned ring systems, a phenyl ring can be fused on;

 where

n^(B) is 1;

p^(B) is 0 or 1;

R^(B1) is H (only for L^(B2)), C₁₋₆-alkyl (only for L^(B2)), C₀₋₃-alkylaryl, C₀₋₃-alkylheteroaryl, C₀₋₃-alkyl-C₃₋₈-cycloalkyl, OH or OCH₃;

R^(B2) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl;

R^(B3) is H, C₁₋₆-alkyl, R^(B6)—O (where R^(B6) is H, C₁₋₆-alkyl), F, Cl, Br, NO₂ or CF₃;

R^(B4) is H, C₁₋₆-alkyl, R^(B6)—O, Cl, Br, F or CF₃;

R^(B1) and R^(B2) may also be bonded together;

M^(B) is a single bond, O, S, CH₂, CH₂—CH₂, CH₂—O, O—CH₂, CH₂—S, S—CH₂, CO or SO₂;

A—B may be 2-pyridyl-CH₂—, 2-benzothienyl-,

D is a single bond or CO or SO₂;

B—D may be

E is

R^(E1) is H;

R^(E2) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, phenyl, pyridyl, thienyl, furyl, imidazolyl, tetrahydropyranyl, tetrahydrothiopyranyl, CH(CH₃)OH or CH(CF₃)₂;

R^(E3) is H; the groups stated under R^(E1) and R^(E2) may be linked to one another via a bond;

E may also be D-Lys, D-Orn, D-Dab, D-Dap or D-Arg;

G is

where l^(G) is 2 or 3, where a CH₂ group of the ring may be replaced by CHCH₃;

 where

m^(G) is 1;

n^(G) is 0;

R^(G1) is H;

R^(G2) is H;

K is

NH—(CH₂)_(n) _(^(K)) —Q^(K), where

n^(K) is 1;

Q^(K) is

X^(K) is S;

Y^(K) is ═CH— or ═N—;

Z^(K) is ═CH— or ═N—;

L is

 where

R^(L1) is H or OH.

The present invention also relates to the following preferred novel compounds, their tautomers, physiologically tolerable salts and prodrugs of the formula A—B—D—E—G—K—L and drugs which contain these compounds. Furthermore, these compounds are suitable as particularly good complement inhibitors.

Here:

A is

H, C₁₋₆-alkyl, C₁₋₆-alkyl-SO₂, R^(A1)OCO (where R^(A1) is H, C₁₋₁₂-alkyl, C₃₋₈-cycloalkyl, C₁₋₃-alkyl-C₃₋₈-cycloalkyl or C₁₋₃-alkylaryl), R^(A2)R^(A3)NCO (where R^(A2) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl; R^(A3) is H, C₁₋₆-alkyl or C₀₋₃-alkylaryl), R^(A4)OCONR^(A2), R^(A4)CONR^(A2) (where R^(A4) is C₁₋₆-alkyl or C₁₋₃-alkylaryl), R^(A1)O, phenoxy, R^(A2)R^(A3)N, HO—SO₂, R^(A2)R^(A3)N—SO₂, Cl, Br, F, tetrazolyl, H₂O₃P, NO₂, R^(A1)—N(OH)—CO— or R^(A1)R^(A2)NCONR^(A3), where aryl in each case may be substituted by up to 2 identical or different substituents from the group consisting of F, Cl, Br, CH₃, CF₃, OCH₃ and NO₂;

B is

—(CH₂)_(l) _(^(B)) —L^(B)—(CH₂)_(m) _(^(B)) , where

l^(B) is 0 or 1;

m^(B) is 0, 1 or 2;

L^(B) is

where, in each of the abovementioned ring systems, a phenyl ring can be fused on;

R^(B3) is H, C₁₋₆-alkyl, aryl, R^(B5)OCO (where R^(B5) is H, C₁₋₆-alkyl or C₁₋₃-alkylaryl), R^(B6)—O (where R^(B6) is H or C₁₋₆-alkyl), F, Cl, Br, NO₂ or CF₃;

R^(B4) is H, C₁₋₆-alkyl, R^(B6)—O, Cl, Br, F or CF₃;

X^(B) is O or S;

Y^(B) is ═CH— or ═N—;

Z^(B) is ═CH— or ═N—;

U^(B) is ═CH— or ═N—;

V^(B) is ═CH— or ═N—;

B may furthermore be

where q^(B) is 0, 1 or 2

(R^(B7) is C₁₋₆-alkyl or C₃₋₈-cycloalkyl)

A—B may be

D is a single bond;

E is

 where

R^(E1) is H;

R^(E2) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, phenyl, pyridyl, furyl, thienyl, imidazolyl, tetrahydropyranyl or tetrahydrothiopyranyl, where the abovementioned radicals may carry up to three identical or different substituents from the group consisting of O—C₁₋₆-alkyl and F, or is CH(CH₃)OH or CH(CF₃)₂;

R^(E3) is H;

the groups stated under R^(E1) and R^(E2) may be linked to one another via a bond;

if it is asymmetrically substituted, the building block E is preferably present in the R configuration;

E may also be D-Lys, D-Orn, D-Dab, D-Dap or D-Arg;

G is

where l^(G) is 2 or 3, where a CH₂ group of the ring may be replaced by CHCH₃;

 where

m^(G) is 1;

n^(G) is 0;

R^(G1) is H;

R^(G2) is H;

K is

NH—(CH₂)_(n) _(^(K)) —Q^(K), where

n^(K) is 1;

QK is

X^(K) is O or S;

Y^(K) is ═CH— or ═N—;

Z^(K) is ═CH— or ═N—;

 where

R^(L1) is —H or —OH.

If R^(L1) is not hydrogen in the compounds of the formula I, these substances are prodrugs from which the free amidine/guanidine compounds form under in vivo conditions. If the compounds of the formula I contain ester functions, these compounds can act in vivo as prodrugs from which the corresponding carboxylic acids form.

In addition to the substances stated in the examples, the following compounds are very particularly preferred and can be prepared by the stated preparation methods:

 1. C₆H₅—C≡C—CO—(D)Cpg-Pyr-NH—CH₂-5-(3-am)- thioph  2. C₆H₅—C≡C—CO—(D)Ile-Pyr-NH—CH₂-5-(3-am)-thioph  3. C₆H₅—C≡C—CO—(D)allo-Ile-Pyr-NH—CH₂-5-(3-am)- thioph  4. C₆H₅—C≡C—CO—(D)Pro-Pyr-NH—CH₂-5-(3-am)- thioph  5. C₆H₅—C≡C—CO—(D)(2-(2-Thienyl))gly-Pyr-NH—CH₂- 5-(3-am)-thioph  6. C₆H₅—C≡C—CO—(D)(2-(3-Thienyl))gly-Pyr-NH—CH₂- 5-(3-am)-thioph  7. C₆H₅—C≡C—CO—(D)Phg-Pyr-NH—CH₂-5-(3-am)- thioph  8. C₆H₅—C≡C—CO—(D)(2-Me)Chg-Pyr-NH—CH₂-5- (3-am)-thioph  9. C₆H₅—C≡C—CO—Aib-Pyr-NH—CH₂-5-(3-am)-thioph  10. C₆H₅—C≡C—CO—Acpc-Pyr-NH—CH₂-5-(3-am)-thioph  11. C₆H₅—C≡C—CO—Achc-Pyr-NH—CH₂-5-(3-am)-thioph  12. C₆H₅—C≡C—CO—(D)(2-(2-Furanyl))gly-Pyr-NH—CH₂- 5-(3-am)-thioph  13. C₆H₅—C≡C—CO—(D)(N-Me)Val-Pyr-NH—CH₂-5-(3- am)-thioph  14. C₆H₅—C≡C—CO—(D)Nva-Pyr-NH—CH₂-5-(3-am)- thioph  15. C₆H₅—C≡C—CO—(D)Thr-Pyr-NH—CH₂-5-(3-am)- thioph  16. C₆H₅—C≡C—CO—(D)(Tetrahydro-4-thiopyranyl)gly- Pyr-NH—CH₂-5-(3-am)-thioph  17. 4-HOOC—C₆H₄—CH₂—(D)Cpg-Pyr-NH—CH₂-5-(3-am)- thioph  18. 4-HOOC—C₆H₄—CH₂—(D)2-(2-Thienyl)gly-Pyr- NH—CH₂-5-(3-am)-thioph  19. 4-HOOC—C₆H₄—CH₂—(D)2-(3-Thienyl)gly-Pyr- NH—CH₂-5-(3-am)-thioph  20. 4-HOOC—C₆H₄—CH₂—(D)Phg-Pyr-NH—CH₂-5-(3-am)- thioph  21. 4-HOOC—C₆H₄—CH₂—(D)(2-Me)Chg-Pyr-NH—CH₂-5- (3-am)-thioph  22. 4-HOOC—C₆H₄—CH₂—Aib-Pyr-NH—CH₂-5-(3-am)- thioph  23. 4-HOOC—C₆H₄—CH₂—Achc-Pyr-NH—CH₂-5-(3-am)- thioph  24. 4-HOOC—C₆H₄—CH₂—(D)(2-(2-Furanyl))gly-Pyr- NH—CH₂-5-(3-am)-thioph  25. 4-HOOC—C₆H₄—CH₂—(D)Thr-Pyr-NH—CH₂-5-(3-am)- thioph  26. 4-HOOC—C₆H₄—CH₂—(D)(Tetrahydro-4-thiopyranyl)- gly-Pyr-NH—CH₂-5-(3-am)-thioph  27. C₆H₅—C≡C—CO—(D)Cpg-Pro-NH—CH₂-5-(3-am)- thioph  28. C₆H₅—C≡C—CO—(D)Ile-Pro-NH—CH₂-5-(3-am)-thioph  29. C₆H₅—C≡C—CO—(D)allo-Ile-Pro-NH—CH₂-5-(3-am)- thioph  30. C₆H₅—C≡C—CO—(D)Pro-Pro-NH—CH₂-5-(3-am)- thioph  31. C₆H₅—C≡C—CO—(D)(2-(2-Thienyl))gly-Pro-NH—CH₂- 5-(3-am)-thioph  32. C₆H₅—C≡C—CO—(D)(2-(3-Thienyl))gly-Pro-NH—CH₂- 5-(3-am)-thioph  33. C₆H₅—C≡C—CO—(D)Phg-Pro-NH—CH₂-5-(3-am)- thioph  34. C₆H₅—C≡C—CO—(D)(2-Me)Chg-Pro-NH—CH₂-5- (3-am)-thioph  35. C₆H₅—C≡C—CO—Aib-Pro-NH—CH₂-5-(3-am)-thioph  36. C₆H₅—C≡C—CO—Acpc-Pro-NH—CH₂-5-(3-am)-thioph  37. C₆H₅—C≡C—CO—Achc-Pro-NH—CH₂-5-(3-am)-thioph  38. C₆H₅—C≡C—CO—(D)(2-(2-Furanyl))gly-Pro-NH—CH₂- 5-(3-am)-thioph  39. C₆H₅—C≡C—CO—(D)(N-Me)Val-Pro-NH—CH₂-5- (3-am)-thioph  40. C₆H₅—C≡C—CO—(D)Abu-Pro-NH—CH₂-5-(3-am)- thioph  41. C₆H₅—C≡C—CO—(D)Nva-Pro-NH—CH₂-5-(3-am)- thioph  42. C₆H₅—C≡C—CO—(D)Thr-Pro-NH—CH₂-5-(3-am)- thioph  43. C₆H₅—C≡C—CO—(D)(Tetrahydro-4-thiopyranyl)gly- Pro-NH—CH₂-5-(3-am)-thioph  44. C₆H₅—C≡C—CO—(D)Cpg-(3S)-MePro-NH—CH₂-5- (3-am)-thioph  45. C₆H₅—C≡C—CO—(D)Ile-L-(3S)-3-MePro-NH—CH₂-5- (3-am)-thioph  46. C₆H₅—C≡C—CO—(D)2-(2-Thienyl)gly-((3S)-3-Me)Pro- NH—CH₂-5-(3-am)-thioph  47. C₆H₅—C≡C—CO—(D)2-(3-Thienyl)gly-((3S)-3-Me)Pro- NH—CH₂-5-(3-am)-thioph  48. C₆H₅—C≡C—CO—(D)Chg-((3S)-3-Me)Pro-NH—CH₂- 5-(3-am)-thioph  49. C₆H₅—C≡C—CO—(D)(Tetrahydro-4-thiopyranyl)gly- ((3S)-3-Me)-Pro-NH—CH₂-5-(3-am)-thioph  50. C₆H₅—C≡C—CO—(D)Cpg-(trans-4-F)Pro-NH—CH₂-5- (3-am)-thioph  51. C₆H₅—C≡C—CO—(D)Val-(trans-4-F)Pro-NH—CH₂-5- (3-am)-thioph  52. C₆H₅—C≡C—CO—(D)2-(2-Thienyl)gly-(trans-4-F)Pro- NH—CH₂-5-(3-am)-thioph  53. C₆H₅—C≡C—CO—(D)2-(3-Thienyl)gly-(trans-4-F)Pro- NH—CH₂-5-(3-am)-thioph  54. C₆H₅—C≡C—CO—(D)Chg-(trans-4-F)Pro-NH—CH₂-5- (3-am)-thioph  55. C₆H₅—C≡C—CO—(D)Cpg-(cis-4-F)-Pro-NH—CH₂-5- (3-am)-thioph  56. C₆H₅—C≡C—CO—(D)Val-(cis-4-F)Pro-NH—CH₂-5- (3-am)-thioph  57. C₆H₅—C≡C—CO—(D)(2-(2-Thienyl))gly-(cis-4-F)Pro- NH—CH₂-5-(3-am)-thioph  58. C₆H₅—C≡C—CO—(D)(2-(3-Thienyl))gly-(cis-4-F)Pro- NH—CH₂-5-(3-am)-thioph  59. C₆H₅—C≡C—CO—(D)Chg-(cis-4-F)Pro-NH—CH₂-5- (3-am)-thioph  60. C₆H₅—C≡C—CO—(D)Cpg-(5-Me)Pro-NH—CH₂-5- (3-am)-thioph  61. C₆H₅—C≡C—CO—(D)Val-(5-Me)Pro-NH—CH₂-5- (3-am)-thioph  62. C₆H₅—C≡C—CO—(D)(2-(2-Thienyl))gly-(5-Me)Pro- NH—CH₂-5-(3-am)-thioph  63. C₆H₅—C≡C—CO—(D)(2-(3-Thienyl))gly-(5-Me)Pro- NH—CH₂-5-(3-am)-thioph  64. C₆H₅—C≡C—CO—(D)Chg-(5-Me)Pro-NH—CH₂-5- (3-am)-thioph  65. C₆H₅—C≡C—CO—(D)Cpg-Ohii-1-CO—NH—CH₂-5- (3-am)-thioph  66. C₆H₅—C≡C—CO—(D)Val-Ohii-1-CO—NH—CH₂-5- (3-am)-thioph  67. C₆H₅—C≡C—CO—(D)(2-(2-Thienyl))gly-Ohii-1- CO—NH—CH₂-5-(3-am)-thioph  68. C₆H₅—C≡C—CO—(D)(2-(3-Thienyl))gly-Ohii-1- CO—NH—CH₂-5-(3-am)-thioph  69. C₆H₅—C≡C—CO—(D)Chg-Ohii-1-CO—NH—CH₂-5- (3-am)-thioph  70. C₆H₅—C≡C—CO—(D)Cpg-Ohi-2-CO—NH—CH₂-5- (3-am)-thioph  71. C₆H₅—C≡C—CO—(D)Val-Ohi-2-CO—NH—CH₂-5- (3-am)-thioph  72. C₆H₅—C≡C—CO—(D)(2-(2-Thienyl))gly-Ohi-2- CO—NH—CH₂-5-(3-am)-thioph  73. C₆H₅—C≡C—CO—(D)(2-(3-Thienyl))gly-Ohi-2- CO—NH—CH₂-5-(3-am)-thioph  74. C₆H₅—C≡C—CO—(D)Chg-Ohi-2-CO—NH—CH₂-5- (3-am)-thioph  75. C₆H₅—C≡C—CO—(D)Cpg-Ind-2-CO—NH—CH₂-5- (3-am)-thioph  76. C₆H₅—C≡C—CO—(D)Val-Ind-2-CO—NH—CH₂-5- (3-am)-thioph  77. C₆H₅—C≡C—CO—(D)(2-(2-Thienyl))gly-Ind-2- CO—NH—CH₂-5-(3-am)-thioph  78. C₆H₅—C≡C—CO—(D)(2-(3-Thienyl))gly-Ind-2- CO—NH—CH₂-5-(3-am)-thioph  79. C₆H₅—C≡C—CO—(D)Chg-Ind-2-CO—NH—CH₂-5- (3-am)-thioph  80. C₆H₅—C≡C—CO—(D)Cpg-Dhi-1-CO—NH—CH₂-5- (3-am)-thioph  81. C₆H₅—C≡C—CO—(D)Val-Dhi-1-CO—NH—CH₂-5- (3-am)-thioph  82. C₆H₅—C≡C—CO—(D)(2-(2-Thienyl))gly-Dhi-1- CO—NH—CH₂-5-(3-am)-thioph  83. C₆H₅—C≡C—CO—(D)(2-(3-Thienyl))gly-Dhi-1- CO—NH—CH₂-5-(3-am)-thioph  84. C₆H₅—C≡C—CO—(D)Chg-Dhi-1-CO—NH—CH₂-5- (3-am)-thioph  85. C₆H₅—C≡C—CO—(D)Cpg-Ohii-1-CO—NH—CH₂-5- (3-am)-thioph  86. C₆H₅—C≡C—CO—(D)Val-Ohii-1-CO—NH—CH₂-5- (3-am)-thioph  87. C₆H₅—C≡C—CO—(D)(2-(2-Thienyl))gly-Ohii-1- CO—NH—CH₂-5-(3-am)-thioph  88. C₆H₅—C≡C—CO—(D)(2-(3-Thienyl))gly-Ohii-1- CO—NH—CH₂-5-(3-am)-thioph  89. C₆H₅—C≡C—CO—(D)Chg-Ohii-1-CO—NH—CH₂-5- (3-am)-thioph  90. (D)HOOC—CH(CH₂—C₆H₅)-Gly-Pyr-NH—CH₂-5- (3-am)-thioph  91. HOOC—CH(CH₂—C₆H₅)-Gly-Pyr-NH—CH₂-5-(3-am)- thioph  92. (D)HOOC—CH(CH₂—C₆H₅)-(D)Val-Pyr-NH—CH₂-5- (3-am)-thioph  93. HOOC—CH(CH₂—C₆H₅)-(D)Val-Pyr-NH—CH₂-5- (3-am)-thioph  94. (D)HOOC—CH(CH₂—C₆H₁₀)-Gly-Pyr-NH—CH₂-5- (3-am)-thioph  95. HOOC—CH(CH₂—C₆H₁₀)-Gly-Pyr-NH—CH₂-5-(3-am)- thioph  96. (D)HOOC—CH(CH₂—C₆H₁₀)-(D)Val-Pyr-NH—CH₂-5- (3-am)-thioph  97. HOOC—CH(CH₂—C₆H₁₀)-(D)Val-Pyr-NH—CH₂-5- (3-am)-thioph  98. (D)HOOC—CH(CH₂—C₆H₅)-Gly-Pro-NH—CH₂-5- (3-am)-thioph  99. HOOC—CH(CH₂—C₆H₅)-Gly-Pro-NH—CH₂-5-(3-am)- thioph 100. (D)HOOC—CH(CH₂—C₆H₅)-(D)Val-Pro-NH—CH₂-5- (3-am)-thioph 101. HOOC—CH(CH₂—C₆H₅)-(D)Val-Pro-NH—CH₂-5- (3-am)-thioph 102. (D)HOOC—CH(CH₂—C₆H₁₀)-Gly-Pro-NH—CH₂-5- (3-am)-thioph 103. HOOC—CH(CH₂—C₆H₁₀)-Gly-Pro-NH—CH₂-5-(3-am)- thioph 104. (D)HOOC—CH(CH₂—C₆H₁₀)-(D)Val-Pro-NH—CH₂-5- (3-am)-thioph 105. HOOC—CH(CH₂—C₆H₁₀)-(D)Val-Pro-NH—CH₂-5- (3-am)-thioph 106. (D)HOOC—CH(C₆H₅)-Gly-Pyr-NH—CH₂-5-(3-am)-thioph 107. HOOC—CH(C₆H₅)-Gly-Pyr-NH—CH₂-5-(3-am)-thioph 108. (D)HOOC—CH(C₆H₁₀)-Gly-Pyr-NH—CH₂-5-(3-am)- thioph 109. HOOC—CH(C₆H₁₀)-Gly-Pyr-NH—CH₂-5-(3-am)-thioph 110. (D)HOOC—CH(C₆H₁₀)-Gly-Pro-NH—CH₂-5-(3-am)- thioph 111. HOOC—CH(C₆H₁₀)-Gly-Pro-NH—CH₂-5-(3-am)-thioph 112. HOOC—(CH₂)₅—(N-CH₂—C₆H₅)Gly-Pyr-NH—CH₂-5- (3-am)-thioph 113. HOOC—(CH₂)₅—(N-CH₂—C₆H₁₀)Gly-Pyr-NH—CH₂-5- (3-am)-thioph 114. HOOC—(CH₂)₄—(N-CH₂—C₆H₅)Gly-Pyr-NH—CH₂-5- (3-am)-thioph 115. HOOC—(CH₂)₄—(N-CH₂—C₆H₁₀)Gly-Pyr-NH—CH₂-5- (3-am)-thioph 116. HOOC—(CH₂)₅—(N-C₆H₅)Gly-Pyr-NH—CH₂-5-(3-am)- thioph 117. HOOC—(CH₂)₅—(N-C₆H₁₀)Gly-Pyr-NH—CH₂-5-(3-am)- thioph 118. HOOC—(CH₂)₄—(N-C₆H₅)Gly-Pyr-NH—CH₂-5-(3-am)- thioph 119. HOOC—(CH₂)₄—(N-C₆H₁₀)Gly-Pyr-NH—CH₂-5-(3-am)- thioph 120. HOOC—(CH₂)₄—SO₂—(N-CH₂—C₆H₅)Gly-Pyr- NH—CH₂-5-(3-am)-thioph 121. HOOC—(CH₂)₄—SO₂—(N-CH₂—C₆H₁₀)Gly-Pyr- NH—CH₂-5-(3-am)-thioph 122. HOOC—(CH₂)₃—SO₂—(N-CH₂—C₆H₅)Gly-Pyr- NH—CH₂-5-(3-am)-thioph 123. HOOC—(CH₂)₃—SO₂—(N-CH₂—C₆H₁₀)Gly-Pyr- NH—CH₂-5-(3-am)-thioph 124. 4-HOOC—C₆H₄—SO₂—Gly-Pyr-NH—CH₂-5-(3-am)- thioph 125. 3-HOOC—C₆H₄—SO₂—Gly-Pyr-NH—CH₂-5-(3-am)- thioph 126. 4-HOOC—C₆H₄—SO₂—D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 127. 3-HOOC—C₆H₄—SO₂—D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 128. 4-HOOC—C₆H₄—SO₂—Gly-Pro-NH—CH₂-5-(3-am)- thioph 129. 3-HOOC—C₆H₄—SO₂—Gly-Pro-NH—CH₂-5-(3-am)- thioph 130. 4-HOOC—C₆H₄—SO₂—D-Val-Pro-NH—CH₂-5-(3-am)- thioph 131. 3-HOOC—C₆H₄—SO₂—D-Val-Pro-NH—CH₂-5-(3-am)- thioph 132. MeHNOC-p-C₆H₄CH₂—(D)Chg-Pyr-NH—CH₂-5-(3-am)- thioph 133. H₂NO₂S-p-C₆H₄CH₂—(D)Chg-Pyr-NH—CH₂-5-(3-am)- thioph 134. BzHNO₂S-p-C₆H₄CH₂—(D)Chg-Pyr-NH—CH₂-5-(3-am)- thioph 135. 5-Tetrazolyl-p-C₆H₄CH₂—(D)Chg-Pyr-NH—CH₂-5- (3-am)-thioph 136. HO—CH₂-p-C₆H₄CH₂—(D)Chg-Pyr-NH—CH₂-5-(3-am)- thioph 137. HOOC-p-C₆H₄CH₂—(D)Chg-Pyr-NH—CH₂-5- (4-Me-3-am)-thioph 138. HOOC-p-C₆H₄CH₂—(D)Chg-Pyr-NH—CH₂-5- (3-Me-2-am)-thioph 139. HOOC-p-C₆H₄CH₂—(D)Chg-Pyr-NH-3-(6-am)-pico 140. HOOC-p-C₆H₄CH₂—(D)Chg-Pyr-NH—CH₂-5-(2-am)- thioph 141. HOOC-p-C₆H₄CH₂—(D)Chg-Pyr-NH—CH₂-5-(2-am)-fur 142. HOOC-p-C₆H₄CH₂—(D)Chg-Pyr-NH—CH₂-2-( 4-am)- thiaz 143. HOOC-p-C₆H₄CH₂—(D)Chg-Pyr-NH—CH₂-5- (3-am-4-Cl)-thioph 144. HOOC-p-C₆H₄CH₂—(D)Chg-Pyr-NH—CH₂-5- (2-am-3-Cl)-thioph 145. HOOC-p-C₆H₄CH₂—(D)Chg-Pyr-NH—CH₂-5-(3-am)-fur 146. HOOC-m-C₆H₄CH₂—(D)Chg-Pyr-NH—CH₂-5-(2-am)- thioph 147. HOOC-m-C₆H₄CH₂—(D)Chg-Pyr-NH—CH₂-5-(3-am)- thioph 148. HOOC-m-C₆H₄CH₂—(D)Chg-Pyr-NH-3-(6-am)-pico 149. MeOOC-m-C₆H₄CH₂—(D)Chg-Pyr-NH—CH₂-2-(4-am)- thiaz 150. H₂NCO-m-C₆H₄CH₂—(D)Chg-Pyr-NH—CH₂-5-(3-am)- thioph 151. HO₃S-m-C₆H₄CH₂—(D)Chg-Pyr-NH—CH₂-5-(3-am)- thioph 152. H₂NO₂S-m-C₆H₄CH₂—(D)Cha-Pyr-NH—CH₂-5-(2-am)- thioph 153. HO₃S-m-C₆H₄CH₂—(D)Cha-Pyr-NH—CH₂-5-(2-am)- thioph 154. (5-Tetrazolyl)-m-C₆H₄CH₂—(D)Chg-Pyr-NH—CH₂-5- (3-am)-thioph 155. trans-(4-HOOC—C₆H₁₀CH₂)—(D)Val-Pyr-NH—CH₂-5- (3-am)-thioph 156. HOOC—o-C₆H₄CH₂—Gly-Pyr-NH—CH₂-5-(3-am)-thioph 157. 4-Benzyloxyphenyl-NH—C(O)—(D)-Ala-Pyr-NH—CH₂-5- (3-am)-thioph 158. 4-Phenoxyphenyl-NH—C(O)—(D)-Ala-Pyr-NH—CH₂-5- (3-am)-thioph 159. 4-(6′-Methyl-2′-benzothiazolyl)-phenyl-NH—C(O)—(D)- Ala-Pyr-NH—CH₂-5-(3-am)-thioph 160. MeOC(O)—(CH₂)₅—NHC(O)—(D)-Ala-Pyr-5-(3-am)- thioph 161. 4-Benzyloxyphenyl-NH—C(O)—Gly-Pyr-NH—CH₂-5- (3-am)-thioph 162. 4-Phenoxyphenyl-NH—C(O)—Gly-Pyr-NH—CH₂-5- (3-am)-thioph 163. 4-(6′-Methyl-2′-benzothiazolyl)-phenyl-NH—C(O)—Gly- Pro-NH—CH₂-5-(3-am)-thioph 164. MeOC(O)—(CH₂)₅—NHC(O)—Gly-Pyr-5-(3-am)-thioph 165. 4-Carboxybenzenesulfonyl-(D)-Ala-Pyr-NH—CH₂-5- (3-am)-thioph 166. 3-Carboxybenzenesulfonyl-(D)-Ala-Pyr-NH—CH₂-5- (3-am)-thioph 167. 4-Methoxycarbonylbenzenesulfonyl-(D)-Ala-Pyr- NH—CH₂-5-(3-am)-thioph 168. 3-Methoxycarbonylbenzenesulfonyl-(D)-Ala-Pyr- NH—CH₂-5-(3-am)-thioph 169. 4-Acetamidobenzenesulfonyl-(D)-Ala-Pyr-NH—CH₂-5- (3-am)-thioph 170. 3-Acetamidobenzenesulfonyl-(D)-Ala-Pyr-NH—CH₂-5- (3-am)-thioph 171. 4-Phenylbenzenesulfonyl-(D)-Ala-Pro-NH—CH₂-5-(3-am)- thioph 172. 4-Carboxybenzenesulfonyl-(D)-Ala-Pro-NH—CH₂-5- (3-am)-thioph 173. 3-Carboxybenzenesulfonyl-(D)-Ala-Pro-NH—CH₂-5- (3-am)-thioph 174. 4-Methoxycarbonylbenzenesulfonyl-(D)-Ala-Pro- NH—CH₂-5-(3-am)-thioph 175. 3-Methoxycarbonylbenzenesulfonyl-(D)-Ala-Pro- NH—CH₂-5-(3-am)-thioph 176. 4-Acetamidobenzenesulfonyl-(D)-Ala-Pro-NH—CH₂-5- (3-am)-thioph 177. 3-Acetamidobenzenesulfonyl-(D)-Ala-Pro-NH—CH₂-5- (3-am)-thioph 178. 4-Carboxybenzenesulfonyl-Ala-Pyr-NH—CH₂-5-(3-am)- thioph 179. 3-Carboxybenzenesulfonyl-Ala-Pyr-NH—CH₂-5-(3-am)- thioph 180. 4-Methoxycarbonylbenzenesulfonyl-Gly-Pyr-NH—CH₂-5- (3-am)-thioph 181. 3-Methoxycarbonylbenzenesulfonyl-Gly-Pyr-NH—CH₂-5- (3-am)-thioph 182. 4-Acetamidobenzenesulfonyl-Gly-Pyr-NH—CH₂-5-(3-am)- thioph 183. 3-Acetamidobenzenesulfonyl-Gly-Pyr-NH—CH₂-5-(3-am)- thioph 184. 4-Phenylbenzenesulfonyl-Gly-Pro-NH—CH₂-5-(3-am)- thioph 185. 4-Carboxybenzenesulfonyl-Ala-Pro-NH—CH₂-5-(3-am)- thioph 186. 3-Carboxybenzenesulfonyl-Ala-Pro-NH—CH₂-5-(3-am)- thioph 187. 4-Methoxycarbonylbenzenesulfonyl-Gly-Pro-NH—CH₂-5- (3-am)-thioph 188. 3-Methoxycarbonylbenzenesulfonyl-Gly-Pro-NH—CH₂-5- (3-am)-thioph 189. 4-Acetamidobenzenesulfonyl-Gly-Pro-NH—CH₂-5-(3-am)- thioph 190. 3-Acetamidobenzenesulfonyl-Gly-Pro-NH—CH₂-5-(3-am)- thioph 191. 3-Benzoylbenzoyl-(D)-Ala-Pyr-NH—CH₂-5-(3-am)-thioph 192. 4-Phenylbenzoyl-(D)-Ala-Pyr-NH—CH₂-5-(3-am)-thioph 193. 4-Phenylphenylacetyl-(D)-Ala-Pyr-NH—CH₂-5-(3-am)- thioph 194. 2-(Benzylthio)-benzoyl-(D)-Ala-Pyr-NH—CH₂-5-(3-am)- thioph 195. 3-Phenylpropionyl-(D)-Ala-Pyr-NH—CH₂-5-(3-am)-thioph 196. 4-Phenylbutyryl-(D)-Ala-Pyr-NH—CH₂-5-(3-am)-thioph 197. 5-Phenylvaleryl-(D)-Ala-Pyr-NH—CH₂-5-(3-am)-thioph 198. (3-Phenyl)-acryloyl-(D)-Ala-Pyr-NH—CH₂-5-(3-am)- thioph 199. 3-Benzyloxycarbonylpropionyl-(D)-Ala-Pyr-NH—CH₂-5- (3-am)-thioph 200. 3-(4-Methoxycarbonyl(-phenyl)-acryloyl-(D)-Ala-Pyr- NH—CH₂-5-(3-am)-thioph 201. 4-Methoxycarbonylbenzoyl-(D)-Ala-Pyr-NH—CH₂-5- (3-am)-thioph 202. 6-(Acetylamino)-pyridyl-3-carbonyl-(D)-Ala-Pyr- NH—CH₂-5-(3-am)-thioph 203. 3-(3′-Pyridyl)-acryloyl-(D)-Ala-Pyr-NH—CH₂-5-(3-am)- thioph 204. HOOC-p-C₆H₄—C≡C—CO—(D)-Ala-Pyr-NH—CH₂-5- (3-am)-thioph 205. HOOC-m-C₆H₄—C≡C—CO—(D)-Ala-Pyr-NH—CH₂- 5-(3-am)-thioph 206. 4-(4′-Aminophenoxy)-benzoyl-(D)-Ala-Pyr-NH—CH₂-5- (3-am)-thioph 207. 3-(4′-Aminophenoxy)-benzoyl-(D)-Ala-Pyr-NH—CH₂-5- (3-am)-thioph 208. 4-(2′-Chloro-4′-aminophenoxy)-benzoyl-(D)-Ala-Pyr- NH—CH₂-5-(3-am)-thioph 209. 5-Phenylethynyl-nicotinoyl-(D)-Ala-Pyr-NH—CH₂-5- (3-am)-thioph 210. 4-Phenylethynyl-benzoyl-(D)-Ala-Pyr-NH—CH₂-5- (3-am)-thioph 211. 3-Phenylethynyl-benzoyl-(D)-Ala-Pyr-NH—CH₂-5- (3-am)-thioph 212. 3-Benzoylbenzoyl-Ala-Pyr-NH—CH₂-5-(3-am)-thioph 213. 4-Benzoylbenzoyl-Ala-Pyr-NH—CH₂-5-(3-am)-thioph 214. 4-Phenylbenzoyl-Ala-Pyr-NH—CH₂-5-(3-am)-thioph 215. 4-Phenylphenylacetyl-Ala-Pyr-NH—CH₂-5-(3-am)-thioph 216. 2-(Benzylthio)-benzoyl-Ala-Pyr-NH—CH₂-5-(3-am)-thioph 217. 3-Phenylpropionyl-Ala-Pyr-NH—CH₂-5-(3-am)-thioph 218. 4-Phenylbutyryl-Ala-Pyr-NH—CH₂-5-(3-ant)-thioph 219. 5-Phenylvaleryl-Ala-Pyr-NH—CH₂-5-(3-am)-thioph 220. Cinnamoyl-Ala-Pyr-NH—CH₂-5-(3-am)-thioph 221. C₆H₅—C≡C—CO—Ala-Pyr-NH—CH₂-5-(3-am)-thioph 222. 3-Benzyloxycarbonylpropionyl-Ala-Pyr-NH—CH₂-5- (3-am)-thioph 223. 4-Methoxycarbonylcinnamoyl-Ala-Pyr-NH—CH₂-5- (3-am)-thioph 224. 4-Methoxycarbonylbenzoyl-Ala-Pyr-NH—CH₂-5-(3-am)- thioph 225. 6-(Acetylamino)-pyridyl-3-carbonyl-Ala-Pyr-NH—CH₂-5- (3-am)-thioph 226. 3-(3′-Pyridyl)-acryloyl-Ala-Pyr-NH—CH₂-5-(3-am)-thioph 227. HOOC-p-C₆H₄—C≡C—CO—Ala-Pyr-NH—CH₂-5- (3-am)-thioph 228. HOOC-m-C₆H₄—C≡C—CO—Ala-Pyr-NH—CH₂-5- (3-am)-thioph 229. 4-(4′-Aminophenoxy)-benzoyl-Ala-Pyr-NH—CH₂-5- (3-am)-thioph 230. 3-(4′-Aminophenoxy)-benzoyl-Ala-Pyr-NH—CH₂-5- (3-am)-thioph 231. 4-(2′-Chloro-4′-aminophenoxy)-benzoyl-Ala-Pyr- NH—CH₂-5-(3-am)-thioph 232. 5-Phenylethynyl-nicotinoyl-Ala-Pyr-NH—CH₂-5-(3-am)- thioph 233. 4-Phenylethynyl-benzoyl-Ala-Pyr-NH—CH₂-5-(3-am)- thioph 234. 3-Phenylethynyl-benzoyl-Ala-Pyr-NH—CH₂-5-(3-am)- thioph 235. 3-Benzoylbenzoyl-(D)-Ala-Pyr-NH—CH₂-5-(2-am)-thioph 236. 4-Phenylbenzoyl-(D)-Ala-Pyr-NH—CH₂-5-(2-am)-thioph 237. 4-Phenylphenylacetyl-(D)-Ala-Pyr-NH—CH₂-5-(2-am)- thioph 238. 4-Phenylphenylacetyl-(D)-Ala-Pro-NH—CH₂-5-(2-am)- thioph 239. 3-Benzoylbenzoyl-(D)-Ala-Pro-NH—CH₂-5-(2-am)-thioph 240. 4-Benzoylbenzoyl-(D)-Ala-Pro-NH—CH₂-5-(2-am)-thioph 241. 4-Phenylbenzoyl-(D)-Ala-Pro-NH—CH₂-5-(2-am)-thioph 242. 3-Benzoylbenzoyl-(D)-Asp-Pro-NH—CH₂-5-(2-am)-thioph 243. 4-Phenylbenzoyl-(D)-Asp-Pro-NH—CH₂-5-(3-am)-thioph 244. 4-Phenylphenylacetyl-(D)-Asp-Pyr-NH—CH₂-5-(3-am)- thioph 245. 3-(3′-Pyridyl)-acryloyl-(D)-Asp-Pyr-NH—CH₂-5-(3-am)- thioph 246. 4-(4′-Aminophenoxy)-benzoyl-(D)-Asp-Pyr-NH—CH₂-5- (3-am)-thioph 247. 3-(4′-Aminophenoxy)-benzoyl-(D)-Asp-Pyr-NH—CH₂-5- (3-am)-thioph 248. 4-(2′-Chloro-4′-aminophenoxy)-benzoyl-(D)-Asp-Pyr- NH—CH₂-5-(3-am)-thioph 249. 3-Benzoylbenzoyl-Asp-Pyr-NH—CH₂-5-(3-am)-thioph 250. 4-Benzoylbenzoyl-Asp-Pyr-NH—CH₂-5-(3-am)-thioph 251. 4-Phenylbenzoyl-Asp-Pyr-NH—CH₂-5-(3-am)-thioph 252. 4-Phenylphenylacetyl-Asp-Pyr-NH—CH₂-5-(3-am)-thioph 253. C₆H₅—C≡C—CO—Asp-Pyr-NH—CH₂-5-(3-am)-thioph 254. 3-Benzoylbenzoyl-(D)-Ala-Pyr-NH-3-(6-am)-pico 255. 4-Benzoylbenzoyl-(D)-Ala-Pyr-NH-3-(6-am)-pico 256. 4-Phenylbenzoyl-(D)-Ala-Pyr-NH-3-(6-am)-pico 257. 4-Phenylphenylacetyl-(D)-Ala-Pyr-NH-3-(6-am)-pico 258. C₆H₅—C≡C—CO—(D)-Ala-Pyr-NH-3-(6-am)-pico 259. 3-Benzoylbenzoyl-(D)-Arg-Pyr-NH—CH₂-5-(3-am)-thioph 260. 4-Phenylphenylacetyl-(D)-Arg-Pyr-NH—CH₂-5-(3-am)- thioph 261. 3-Benzoylbenzoyl-Arg-Pyr-NH—CH₂-5-(3-am)-thioph 262. 4-Benzoylbenzoyl-Arg-Pyr-NH—CH₂-5-(3-am)-thioph 263. 4-Phenylbenzoyl-Arg-Pyr-NH—CH₂-5-(3-am)-thioph 264. 4-Phenylphenylacetyl-Arg-Pyr-NH—CH₂-5-(3-am)-thioph 265. C₆H₅—C≡C—CO—Arg-Pyr-NH—CH₂-5-(3-am)-thioph 266. 3-Benzoylbenzoyl-(D)-Val-Pyr-NH—CH₂-5-(3-am)-thioph 267. 4-Phenylbenzoyl-(D)-Val-Pyr-NH—CH₂-5-(3-am)-thioph 268. 4-Phenylphenylacetyl-(D)-Val-Pyr-NH—CH₂-5-(3-am)- thioph 269. 2-(Benzylthio)-benzoyl-(D)-Val-Pyr-NH—CH₂-5-(3-am)- thioph 270. 3-Phenylpropionyl-(D)-Val-Pyr-NH—CH₂-5-(3-am)-thioph 271. 4-Phenylbutyryl-(D)-Val-Pyr-NH—CH₂-5-(3-am)-thioph 272. 5-Phenylvaleryl-(D)-Val-Pyr-NH—CH₂-5-(3-am)-thioph 273. Cinnamoyl-(D)-Val-Pyr-NH—CH₂-5-(3-am)-thioph 274. 3-Benzyloxycarbonylpropionyl-(D)-Val-Pyr-NH—CH₂-5- (3-am)-thioph 275. 4-Methoxycarbonylcinnamoyl-(D)-Val-Pyr-NH—CH₂-5- (3-am)-thioph 276. 4-Methoxycarbonylbenzoyl-(D)-Val-Pyr-NH—CH₂-5- (3-am)-thioph 277. 6-(Acetylamino)-pyridyl-3-carbonyl-(D)-Val-Pyr- NH—CH₂-5-(3-am)-thioph 278. 3-(3′-Pyridyl)-acryloyl-(D)-Val-Pyr-NH—CH₂-5-(3-am)- thioph 279. HOOC-p-C₆H₄—C≡C—CO—(D)-Val-Pyr-NH—CH₂-5- (3-am)-thioph 280. HOOC-m-C₆H₄—C≡C—CO—(D)-Val-Pyr-NH—CH₂-5- (3-am)-thioph 281. 4-(4′-Aminophenoxy)-benzoyl-(D)-Val-Pyr-NH—CH₂-5- (3-am)-thioph 282. 3-(4′-Aminophenoxy)-benzoyl-(D)-Val-Pyr-NH—CH₂-5- (3-am)-thioph 283. 4-(2′-Chloro-4′-aminophenoxy)-benzoyl-(D)-Val-Pyr- NH—CH₂-5-(3-am)-thioph 284. 5-Phenylethynyl-nicotinoyl-(D)-Val-Pyr-NH—CH₂-5- (3-am)-thioph 285. 4-Phenylethynyl-benzoyl-(D)-Val-Pyr-NH—CH₂-5-(3-am)- thioph 286. 3-Phenylethynyl-benzoyl-(D)-Val-Pyr-NH—CH₂-5-(3-am)- thioph 287. 3-Benzoylbenzoyl-(D)-Val-Pyr-NH—CH₂-5-(2-am)-thioph 288. 4-Phenylbenzoyl-(D)-Val-Pyr-NH—CH₂-5-(2-am)-thioph 289. 4-Phenylphenylacetyl-(D)-Val-Pyr-NH—CH₂-5-(2-am)- thioph 290. 4-Phenylphenylacetyl-(D)-Val-Pro-NH—CH₂-5-(2-am)- thioph 291. 3-Benzoylbenzoyl-(D)-Val-Pro-NH—CH₂-5-(2-am)-thioph 292. 4-Benzoylbenzoyl-(D)-Val-Pro-NH—CH₂-5-(2-am)-thioph 293. 4-Phenylbenzoyl-(D)-Val-Pro-NH—CH₂-5-(2-am)-thioph 294. C₆H₅—C≡C—CO—(D)-Lys-Pyr-NH—CH₂-5-(2-am)- thioph 295. 3-Benzoylbenzoyl-(D)-Lys-Pyr-NH—CH₂-5-(3-am)-thioph 296. 4-Phenylbenzoyl-(D)-Lys-Pyr-NH—CH₂-5-(3-am)-thioph 297. 4-Phenylphenylacetyl-(D)-Lys-Pyr-NH—CH₂-5-(3-am)- thioph 298. 3-(3′-Pyridyl)-acryloyl-(D)-Lys-Pyr-NH—CH₂-5-(3-am)- thioph 299. 4-(4′-Aminophenoxy)-benzoyl-(D)-Lys-Pyr-NH—CH₂-5- (3-am)-thioph 300. 3-(4′-Aminophenoxy)-benzoyl-(D)-Lys-Pyr-NH—CH₂-5- (3-am)-thioph 301. 4-(2′-Chloro-4′-aminophenoxy)-benzoyl-(D)-Lys-Pyr- NH—CH₂-5-(3-am)-thioph 302. 3-Benzoylbenzoyl-Gly-Pyr-NH—CH₂-5-(3-am)-thioph 303. 4-Phenylbenzoyl-Gly-Pyr-NH—CH₂-5-(3-am)-thioph 304. 4-Phenylphenylacetyl-Gly-Pyr-NH—CH₂-5-(3-am)-thioph 305. 2-(Benzylthio)-benzoyl-Gly-Pyr-NH—CH₂-5-(3-am)-thioph 306. 3-Phenylpropionyl-Gly-Pyr-NH—CH₂-5-(3-am)-thioph 307. 4-Phenylbutyryl-Gly-Pyr-NH—CH₂-5-(3-am)-thioph 308. 5-Phenylvaleryl-Gly-Pyr-NH—CH₂-5-(3-am)-thioph 309. (3-Phenyl)-acryloyl-Gly-Pyr-NH—CH₂-5-(3-am)-thioph 310. 3-Benzyloxycarbonylpropionyl-Gly-Pyr-NH—CH₂-5- (3-am)-thioph 311. 3-(4-Methoxycarbonyl-phenyl)-acryloyl-Gly-Pyr- NH—CH₂-5-(3-am)-thioph 312. 4-Methoxycarbonylbenzoyl-Gly-Pyr-NH—CH₂-5-(3-am)- thioph 313. 6-(Acetylamino)-pyridyl-3-carbonyl-Gly-Pyr-NH—CH₂-5- (3-am)-thioph 314. 3-(3′-Pyridyl)-acryloyl-Gly-Pyr-NH—CH₂-5-(3-am)-thioph 315. HOOC-p-C₆H₄—C≡C—CO—Gly-Pyr-NH—CH₂-5- (3-am)-thioph 316. HOOC-m-C₆H₄—C≡C—CO—Gly-Pyr-NH—CH₂-5- (3-am)-thioph 317. 4-(4′-Aminophenoxy)-benzoyl-Gly-Pyr-NH—CH₂-5- (3-am)-thioph 318. 3-(4′-Aminophenoxy)-benzoyl-Gly-Pyr-NH—CH₂-5- (3-am)-thioph 319. 4-(2′-Chloro-4′-aminophenoxy)-benzoyl-Gly-Pyr- NH—CH₂-5-(3-am)-thioph 320. 5-Phenylethynyl-nicotinoyl-Gly-Pyr-NH—CH₂-5-(3-am)- thioph 321. 4-Phenylethynyl-benzoyl-Gly-Pyr-NH—CH₂-5-(3-am)- thioph 322. 3-Phenylethynyl-benzoyl-Gly-Pyr-NH—CH₂-5-(3-am)- thioph 323. HOOC-p-C₆H₄—C≡C—CO—Gly-Pro-NH—CH₂-5- (3-am)-thioph 324. HOOC-m-C₆H₄—C≡C—CO—Gly-Pro-NH—CH₂-5- (3-am)-thioph 325. 5-Phenylethynyl-nicotinoyl-Gly-Pro-NH—CH₂-5-(3-am)- thioph 326. 4-Phenylethynyl-benzoyl-Gly-Pro-NH—CH₂-5-(3-am)- thioph 327. 3-Phenylethynyl-benzoyl-Gly-Pro-NH—CH₂-5-(3-am)- thioph 328. 3-Benzoylbenzoyl-(D)-Val-Pyr-NH—CH₂-2-(4-am)-thiaz 329. 4-Benzoylbenzoyl-(D)-Val-Pyr-NH—CH₂-2-(4-am)-thiaz 330. 4-Phenylbenzoyl-(D)-Val-Pyr-NH—CH₂-2-(4-am)-thiaz 331. 4-Phenylphenylacetyl-(D)-Val-Pyr-NH—CH₂-2-(4-am)- thiaz 332. 3-Benzoylbenzoyl-(D)-Ala-Pyr-NH—CH₂-2-(4-am)-thiaz 333. 4-Benzoylbenzoyl-(D)-Ala-Pyr-NH—CH₂-2-(4-am)-thiaz 334. 4-Phenylbenzoyl-(D)-Ala-Pyr-NH—CH₂-2-(4-am)-thiaz 335. 4-Phenylphenylacetyl-(D)-Ala-Pyr-NH—CH₂-2-(4-am)- thiaz 336. 3-Benzoylbenzoyl-Gly-Pyr-NH—CH₂—2-(4-am)-thiaz 337. 4-Benzoylbenzoyl-Gly-Pyr-NH—CH₂-2-(4-am)-thiaz 338. 4-Phenylbenzoyl-Gly-Pyr-NH—CH₂-2-(4-am)-thiaz 339. 4-Phenylphenylacetyl-Gly-Pyr-NH—CH₂-2-(4-am)-thiaz 340. 3-Benzoylbenzoyl-Val-Pyr-NH—CH₂-5-(3-am)-thioph 341. 4-Benzoylbenzoyl-Val-Pyr-NH—CH₂-5-(3-am)-thioph 342. 4-Phenylbenzoyl-Val-Pyr-NH—CH₂-5-(3-am)-thioph 343. 4-Phenylphenylacetyl-Val-Pyr-NH—CH₂-5-(3-am)-thioph 344. 2-(Benzylthio)-benzoyl-Val-Pyr-NH—CH₂-5-(3-am)-thioph 345. 3-Phenylpropionyl-Val-Pyr-NH—CH₂-5-(3-am)-thioph 346. 4-Phenylbutyryl-Val-Pyr-NH—CH₂-5-(3-am)-thioph 347. 5-Phenylvaleryl-Val-Pyr-NH—CH₂-5-(3-am)-thioph 348. (3-Phenyl)-acryloyl-Val-Pyr-NH—CH₂-5-(3-am)-thioph 349. C₆H₅—C≡C—CO—Val-Pyr-NH—CH₂-5-(3-am)-thioph 350. 3-Benzyloxycarbonylpropionyl-Val-Pyr-NH—CH₂-5- (3-am)-thioph 351. 3-(4-Methoxycarbonyl-phenyl)-acryloyl-Val-Pyr- NH—CH₂-5-(3-am)-thioph 352. 4-Methoxycarbonylbenzoyl-Val-Pyr-NH—CH₂-5-(3-am)- thioph 353. 6-(Acetylamino)-pyridine-3-carbonyl-Val-Pyr-NH—CH₂-5- 3-am)-thioph 354. 3-(3′-Pyridyl)-acryloyl-Val-Pyr-NH—CH₂-5-(3-am)-thioph 355. HOOC-p-C₆H₄—C≡C—CO—Val-Pyr-NH—CH₂-5- (3-am)-thioph 356. HOOC-m-C₆H₄—C≡C—CO—Val-Pyr-NH—CH₂-5- (3-am)-thioph 357. 4-(4′-Aminophenoxy)-benzoyl-Val-Pyr-NH—CH₂-5- (3-am)-thioph 358. 3-(4′-Aminophenoxy)-benzoyl-Val-Pyr-NH—CH₂-5- (3-am)-thioph 359. 4-(2′-Chloro-4′-aminophenoxy)-benzoyl-Val-Pyr- NH—CH₂-5-(3-am)-thioph 360. 5-Phenylethynyl-nicotinoyl-Val-Pyr-NH—CH₂-5-(3-am)- thioph 361. 4-Phenylethynyl-benzoyl-Val-Pyr-NH—CH₂-5-(3-am)- thioph 362. 3-Phenylethynyl-benzoyl-Val-Pyr-NH—CH₂-5-(3-am)- thioph 363. 3-Benzoylbenzoyl-Sar-Pyr-NH—CH₂-5-(3-am)-thioph 364. 4-Phenylbenzoyl-Sar-Pyr-NH—CH₂-5-(3-am)-thioph 365. 4-Phenylphenylacetyl-Sar-Pyr-NH—CH₂-5-(3-am)-thioph 366. 3-Phenylpropionyl-Sar-Pyr-NH—CH₂-5-(3-am)-thioph 367. 4-Phenylbutyryl-Sar-Pyr-NH—CH₂-5-(3-am)-thioph 368. 5-Phenylvaleryl-Sar-Pyr-NH—CH₂-5-(3-am)-thioph 369. 3-Benzyloxycarbonylpropionyl-Sar-Pyr-NH—CH₂-5- (3-am)-thioph 370. 6-(Acetylamino)-pyridyl-3-carbonyl-Sar-Pyr-NH—CH₂-5- (3-am)-thioph 371. 3-(3′-Pyridyl)-acryloyl-Sar-Pyr-NH—CH₂-5-(3-am)- thioph 372. 4-(4′-Aminophenoxy)-benzoyl-Sar-Pyr-NH—CH₂-5-(3-am)- thioph 373. 3-(4′-Aminophenoxy)-benzoyl-Sar-Pyr-NH—CH₂-5-(3-am)- thioph 374. 4-(2′-Chloro-4′-aminophenoxy)-benzoyl-Sar-Pyr-NH—CH₂- 5-(3-am)-thioph 375. 3-Benzoylbenzoyl-Sar-Pro-NH—CH₂-5-(3-am)-thioph 376. 4-Benzoylbenzoyl-Sar-Pro-NH—CH₂-5-(3-am)-thioph 377. 4-Phenylbenzoyl-Sar-Pro-NH—CH₂-5-(3-am)-thioph 378. 4-Phenylphenylacetyl-Sar-Pro-NH—CH₂-5-(3-am)-thioph 379. 3-Phenylpropionyl-Sar-Pro-NH—CH₂-5-(3-am)-thioph 380. 4-Phenylbutyryl-Sar-Pro-NH—CH₂-5-(3-am)-thioph 381. 5-Phenylvaleryl-Sar-Pro-NH—CH₂-5-(3-am)-thioph 382. C₆H₅—C≡C—CO—Sar-Pro-NH—CH₂-5-(3-am)-thioph 383. 3-Benzyloxycarbonylpropionyl-Sar-Pro-NH—CH₂-5- (3-am)-thioph 384. 6-(Acetylamino)-pyridine-3-carbonyl-Sar-Pro-NH—CH₂-5- (3-am)-thioph 385. 3-(3′-Pyridyl)-acryloyl-Sar-Pro-NH—CH₂-5-(3-am)-thioph 386. 4-(4′-Aminophenoxy)-benzoyl-Sar-Pro-NH—CH₂-5-(3-am)- thioph 387. 3-(4′-Aminophenoxy)-benzoyl-Sar-Pro-NH—CH₂-5-(3-am)- thioph 388. 4-(2′-Chloro-4′-aminophenoxy)-benzoyl-Sar-Pro- NH—CH₂-5-(3-am)-thioph 389. 3-Benzoylbenzoyl-(D)-(N-Me)Ala-Pyr-NH—CH₂-5-(3-am)- thioph 390. 4-Benzoylbenzoyl-(D)-(N-Me)Ala-Pyr-NH—CH₂-5-(3-am)- thioph 391. 4-Phenylbenzoyl-(D)-(N-Me)Ala-Pyr-NH—CH₂-5-(3-am)- thioph 392. 4-Phenylphenylacetyl-(D)-(N-Me)Ala-Pyr-NH—CH₂-5- (3-am)-thioph 393. 3-Phenylpropionyl-(D)-(N-Me)Ala-Pyr-NH—CH₂-5- (3-am)-thioph 394. 4-Phenylbutyryl-(D)-(N-Me)Ala-Pyr-NH—CH₂-5-(3-am)- thioph 395. 5-Phenylvaleryl-(D)-(N-Me)Ala-Pyr-NH—CH₂-5-(3-am)- thioph 396. C₆H₅—C≡C—CO—(D)-(N-Me)Ala-Pyr-NH—CH₂-5- (3-am)-thioph 397. 3-Benzyloxycarbonylpropionyl-(D)-(N-Me)Ala-Pyr- NH—CH₂-5-(3-am)-thioph 398. 6-(Acetylamino)-pyridyl-3-carbonyl-(D)-(N-Me)Ala-Pyr- NH—CH₂-5-(3-am)-thioph 399. 3-(3′-Pyridyl)-acryloyl-(D)-(N-Me )Ala-Pyr-NH—CH₂-5- (3-am)-thioph 400. 4-(4′-Aminophenoxy)-benzoyl-(D)-(N-Me)Ala-Pyr- NH—CH₂-5-(3-am)-thioph 401. 3-(4′-Aminophenoxy)-benzoyl-(D)-(N-Me)Ala-Pyr- NH—CH₂-5-(3-am)-thioph 402. 4-(2′-Chloro-4′-aminophenoxy)-benzoyl-(D)-(N-Me)Ala- Pyr-NH—CH₂-5-(3-am)-thioph 403. 3-Benzoylbenzoyl-(D)-(N-Me)Ala-Pro-NH—CH₂-5-(3-am)- thioph 404. 4-Benzoylbenzoyl-(D)-(N-Me)Ala-Pro-NH—CH₂-5-(3-am)- thioph 405. 4-Phenylbenzoyl-(D)-(N-Me)Ala-Pro-NH—CH₂-5-(3-am)- thioph 406. 4-Phenylphenylacetyl-(D)-(N-Me)Ala-Pro-NH—CH₂-5- 3-am)-thioph 407. 3-Phenylpropionyl-(D)-(N-Me)Ala-Pro-NH—CH₂-5- (3-am)-thioph 408. 4-Phenylbutyryl-(D)-(N-Me)Ala-Pro-NH—CH₂-5-(3-am)- thioph 409. 5-Phenylvaleryl-(D)-(N-Me)Ala-Pro-NH—CH₂-5-(3-am)- thioph 410. C₆H₅—C≡C—CO—(D)-(N-Me)Ala-Pro-NH—CH₂-5- (3-am)-thioph 411. 3-Benzyloxycarbonylpropionyl-(D)-(N-Me)Ala-Pro- NH—CH₂-5-(3-am)-thioph 412. 6-(Acetylamino)-pyridyl-3-carbonyl-(D)-(N-Me)Ala-Pro- NH—CH₂-5-(3-am)-thioph 413. 3-(3′-Pyridyl)-acryloyl-(D)-(N-Me)Ala-Pro-NH—CH₂-5- (3-am)-thioph 414. 4-(4′-Aminophenoxy)-benzoyl-(D)-(N-Me)Ala-Pro- NH—CH₂-5-(3-am)-thioph 415. 3-(4′-Aminophenoxy)-benzoyl-(D)-(N-Me)Ala-Pro- NH—CH₂-5-(3-am)-thioph 416. 4-(2′-Chloro-4′-aminophenoxy)-benzoyl-(D)-(N-Me)Ala- Pro-NH—CH₂-5-(3-am)-thioph 417. 3-Benzoylbenzoyl-β-Ala-Pro-NH—CH₂-5-(3-am)-thioph 418. Cinnamoyl-β-Ala-Pro-NH—CH₂-5-(3-am)-thioph 419. C₆H₅—C≡C—CO—β-Ala-Pro-NH—CH₂-5-(3-am)-thioph 420. 3-Benzyloxycarbonylpropionyl-β-Ala-Pro-NH—CH₂-5- (3-am)-thioph 421. 4-Methoxycarbonylcinnamoyl-β-Ala-Pro-NH—CH₂-5- (3-am)-thioph 422. 4-Methoxycarbonylbenzoyl-β-Ala-Pro-NH—CH₂-5- (3-am)-thioph 423. 6-(Acetylamino)-pyridyl-3-carbonyl-β-Ala-Pro-NH—CH₂- 5-(3-am)-thioph 424. 3-(3′-Pyridyl)-acryloyl-β-Ala-Pro-NH—CH₂-5-(3-am)- thioph 425. HOOC-p-C₆H₄—C≡C—CO—β-Ala-Pro-NH—CH₂-5- (3-am)-thioph 426. HOOC-m-C₆H₄—C≡C—CO—β-Ala-Pro-NH—CH₂-5- (3-am)-thioph 427. 4-(4′-Aminophenoxy)-benzoyl-β-Ala-Pro-NH—CH₂-5- (3-am)-thioph 428. 3-(4′-Aminophenoxy)-benzoyl-β-Ala-Pro-NH—CH₂-5- (3-am)-thioph 429. 4-(2′-Chloro-4′-aminophenoxy)-benzoyl-β-Ala-Pro- NH—CH₂-5-(3-am)-thioph 430. 5-Phenylethynyl-nicotinoyl-β-Ala-Pro-NH—CH₂-5-(3-am)- thioph 431. 4-Phenylethynyl-benzoyl-β-Ala-Pro-NH—CH₂-5-(3-am)- thioph 432. 3-Phenylethynyl-benzoyl-β-Ala-Pro-NH—CH₂-5-(3-am)- thioph 433. 3-Benzoylbenzoyl-β-Ala-Pyr-NH—CH₂-5-(3-am)-thioph 434. 4-Phenylbenzoyl-β-Ala-Pyr-NH—CH₂-5-(3-am)-thioph 435. 4-Phenylphenylacetyl-β-Ala-Pyr-NH—CH₂-5-(3-am)- thioph 436. 2-(Benzylthio)-benzoyl-β-Ala-Pyr-NH—CH₂-5-(3-am)- thioph 437. 3-Phenylpropionyl-β-Ala-Pyr-NH—CH₂-5-(3-am)-thioph 438. 4-Phenylbutyryl-β-Ala-Pyr-NH—CH₂-5-(3-am)-thioph 439. 5-Phenylvaleryl-β-Ala-Pyr-NH—CH₂-5-(3-am)-thioph 440. 3-Benzyloxycarbonylpropionyl-β-Ala-Pyr-NH—CH₂-5- (3-am)-thioph 441. 4-Methoxycarbonylcinnamoyl-β-Ala-Pyr-NH—CH₂-5- (3-am)-thioph 442. 4-Methoxycarbonylbenzoyl-β-Ala-Pyr-NH—CH₂-5- (3-am)-thioph 443. 6-(Acetylamino)-pyridyl-3-carbonyl-β-Ala-Pyr-NH—CH₂- 5-(3-am)-thioph 444. 3-(3′-Pyridyl)-acryloyl-β-Ala-Pyr-NH—CH₂-5-(3-am)- thioph 445. HOOC-p-C₆H₄—C≡C—CO—β-Ala-Pyr- NH—CH₂-5-(3-am)-thioph 446. HOOC-m-C₆H₄—C≡C—CO—β-Ala-Pyr-NH—CH₂-5- (3-am)-thioph 447. 4-(4′-Aminophenoxy)-benzoyl-β-Ala-Pyr-NH—CH₂-5- (3-am)-thioph 448. 3-(4′-Aminophenoxy)-benzoyl-β-Ala-Pyr-NH—CH₂-5- (3-am)-thioph 449. 4-(2′-Chloro-4′-aminophenoxy)-benzoyl-β-Ala-Pyr- NH—CH₂-5-(3-am)-thioph 450. 5-Phenylethynyl-nicotinoyl-β-Ala-Pyr-NH—CH₂-5-(3-am)- thioph 451. 4-Phenylethynyl-benzoyl-β-Ala-Pyr-NH—CH₂-5-(3-am)- thioph 452. 3-Phenylethynyl-benzoyl-β-Ala-Pyr-NH—CH₂-5-(3-am)- thioph 453. 4-HOOC—C₆H₄—CH₂—(D)Cpg-Dhi-1-CO—NH—CH₂- 5-(3-am)-thioph 454. 4-HOOC—C₆H₄—CH₂—(D)Cpg-Ohii-1-CO—NH—CH₂- 5-(3-am)-thioph 455. 4-HOOC—C₆H₄—CH₂—(D)Cpg-(5-Me)Pro-NH—CH₂-5- (3-am)-thioph 456. 4-HOOC—C₆H₄—CH₂—(D)Cpg-Cis-(4-F)Pro-NH—CH₂- 5-(3-am)-thioph 457. 4-HOOC—C₆H₄—CH₂—(D)Cpg-trans-(4-F)Pro- NH—CH₂-5-(3-am)-thioph 458. 4-HOOC—C₆H₄—CH₂—(D)Cpg-(3S)(3-Me)Pro- NH—CH₂-5-(3-am)-thioph 459. 4-HOOC—C₆H₄—CH₂—(D)Cpg-Pyr-NH—CH₂-5-(2-am)- thioph 460. 4-HOOC—C₆H₄—CH(CH₃)—(D)Cpg-Pyr-NH—CH₂-5- (3-am)-thioph 461. 4-HOOC—C₆H₄—CO—(D)Cpg-Pyr-NH—CH₂-5-(3-am)- thioph 462. 4-HOOC—C₆H₄—CH(CH₃)—(D)Chg-Pyr-NH—CH₂-5- (3-am)-thioph 463. 4-HOOC—C₆H₄—CH₂—(N-Me)(D)Chg-Pyr-NH—CH₂-5- (3-am)-thioph 464. 4-HOOC—C₆H₄—C(CH₃)₂—(D)Chg-Pyr-NH—CH₂-5- (3-am)-thioph 465. 4-HOOC-3-Me—C₆H₄—CH₂—(D)Chg-Pyr-NH—CH₂-5- (3-am)-thioph 466. 4-HOOC-2-Me—C₆H₄—CH₂—(D)Chg-Pyr-NH—CH₂-5- (3-am)-thioph 467. 4-HOOC—CH₂—C₆H₄—CH₂—(D)Chg-Pyr-NH—CH₂- 5-(3-am)-thioph 468. 3-HOOC—CH₂—C₆H₄—CH₂—(D)Chg-Pyr-NH—CH₂- 5-(3-am)-thioph 469. 4-HOOC—C₆H₄—CH(CH₃)—(D)Cpg-Pyr-NH—CH₂-5- (3-am)-thioph 470. 4-HOOC—C₆H₄—CH₂—(N-Me)(D)Cpg-Pyr-NH—CH₂-5- (3-am)-thioph 471. 4-HOOC—C₆H₄—C(CH₃)₂—(D)Cpg-Pyr-NH—CH₂-5- (3-am)-thioph 472. 4-HOOC-3-Me—C₆H₄—CH₂—(D)Cpg-Pyr-NH—CH₂-5- (3-am)-thioph 473. 4-HOOC-2-Me—C₆H₄—CH₂—(D)Cpg-Pyr-NH—CH₂-5- (3-am)-thioph 474. 4-HOOC—CH₂—C₆H₄—CH₂—(D)Cpg-Pyr-NH—CH₂-5- (3-am)-thioph 475. 3-HOOC—CH₂—C₆H₄—CH₂—(D)Cpg-Pyr-NH—CH₂-5- (3-am)-thioph 476. 4-HOOC—C₆H₄—CH(CH₃)—(D)Chg-Pyr-NH—CH₂-5- (2-am)-thioph 477. 4-HOOC—C₆H₄—CH₂—(N-Me)(D)Chg-Pyr-NH—CH₂-5- (2-am)-thioph 478. 4-HOOC—C₆H₄—C(CH₃)₂—(D)Chg-Pyr-NH—CH₂-5- (2-am)-thioph 479. 4-HOOC-3-Me—C₆H₄—CH₂—(D)Chg-Pyr-NH—CH₂-5- (2-am)-thioph 480. 4-HOOC-2-Me—C₆H₄—CH₂—(D)Chg-Pyr-NH—CH₂-5- (2-am)-thioph 481. 4-HOOC—CH₂—C₆H₄—CH₂—(D)Chg-Pyr-NH—CH₂-5- (2-am)-thioph 482. 3-HOOC—CH₂—C₆H₄—CH₂—(D)Chg-Pyr-NH—CH₂-5- (2-am)-thioph 483. 4-HOOC—C₆H₄—CH(CH₃)—(D)Cpg-Pyr-NH—CH₂-5- (2-am)-thioph 484. 4-HOOC—C₆H₄—CH₂—(N-Me)(D)Cpg-Pyr-NH—CH₂-5- (2-am)-thioph 485. 4-HOOC—C₆H₄—C(CH₃)₂—(D)Cpg-Pyr-NH—CH₂-5- (2-am)-thioph 486. 4-HOOC-3-Me—C₆H₄—CH₂—(D)Cpg-Pyr-NH—CH₂-5- (2-am)-thioph 487. 4-HOOC-2-Me—C₆H₄—CH₂—(D)Cpg-Pyr-NH—CH₂-5- (2-am)-thioph 488. 4-HOOC—CH₂—C₆H₄—CH₂—(D)Cpg-Pyr-NH—CH₂-5- (2-am)-thioph 489. 3-HOOC—CH₂—C₆H₄—CH₂—(D)Cpg-Pyr-NH—CH₂-5- (2-am)-thioph 490. HOOC-p-C₆H₄—CH(CH₃)—D-Val-Pyr-NH—CH₂-5- (3-am)-thioph 491. HOOC-p-C₆H₄—(CH₂)₂—D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 492. HOOC-p-CH₂—C₆H₄—CH₂—D-Val-Pyr-NH—CH₂-5- (3-am)-thioph 493. p-Carboxy-tetrafluorobenzyl-D-Val-Pyr-NH—CH₂-5- (3-am)-thioph 494. p-Carboxy-2′-F-benzyl-D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 495. p-Carboxy-2′-methoxy-benzyl-D-Val-Pyr-NH—CH₂-5- (3-am)-thioph 496. p-Carboxy-3′-methoxy-benzyl-D-Val-Pyr-NH—CH₂-5- (3-am)-thioph 497. H₂O₃P-p-C₆H₄—CH₂—D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 498. 5-COOH-indan-1-yl-D-Val-Pyr-NH-5-(3-am)-thioph 499. 6-COOH-indan-1-yl-D-Val-Pyr-NH-5-(3-am)-thioph 500. HOOC-p-C₆H₄—CH₂—D-Val-Pyr-NH-4-amb 501. HOOC-p-C₆H₄—CH₂—D-Val-Pyr-NH—CH₂-5-(2-am)- thioph 502. HOOC-p-C₆H₄—CH₂—D-Val-Pyr-NH—CH₂-4-(2-am)- thioph 503. HOOC-p-C₆H₄—CH₂—D-Val-Pyr-NH-3-(6-am)pico 504. HOOC-p-C₆H₄—CH₂—D-Val-Pyr-NH—CH₂-5-(2-am)-fur 505. HOOC-p-C₆H₄—CH₂—D-Val-Pyr-NH—CH₂-5- (3-am-4-Cl)-thioph 506. HOOC-p-C₆H₄—CH₂—D-Val-Pyr-NH—CH₂-5- (2-am-3-Cl)-thioph 507. HOOC-p-C₆H₄—CH₂—D-Val-Pyr-NH—CH₂-2- (4-am)-thiaz 508. HOOC-p-C₆H₄—CH₂—D-Val-Pyr-NH—CH₂-2- (5-am)-thiaz 509. HOOC-p-C₆H₄—CH₂—D-Val-Pyr-NH—CH₂-5- (2-am)-thiaz 510. HOOC-p-C₆H₄—CH₂—D-Val-Pyr-NH—CH₂-4- (2-am)-thiaz 511. HOOC-p-C₆H₄—CH₂—D-Val-Pyr-NH—CH₂-5- (3-am-4-Me)-thioph 512. HOOC-p-C₆H₄—CH₂—D-Val-Pyr-NH—CH₂-5- (2-am-4-Me)-thioph 513. HOOC-p-C₆H₄—CH₂—D-Val-Pyr-NH—CH₂-2- (4-guan)-thiaz 514. HOOC-p-C₆H₄—CH₂—D-Val-Pyr-NH—CH₂-2- (5-guan)-thiaz 515. HOOC-p-C₆H₄—CH₂—D-Val-Pyr-NH—CH₂-5- (3-guan)-thioph 516. HOOC-p-C₆H₄—CH₂—D-Val-Pyr-NH—CH₂-5- (2-guan)-thioph 517. HOOC-p-C₆H₄—CH₂—D-Val-Pyr-NH—(4-guan)benzyl 518. HOOC-p-C₆H₄—CH₂—D-Val-Pyr-NH—(CH₂)₄-am 519. HOOC-p-C₆H₄—CH₂—D-Val-Pyr-NH—(CH₂)₅-am 520. HOOC-p-C₆H₄—CH₂—D-Val-Pyr-NH—(CH₂)₃-am 521. HOOC-p-C₆H₄—CH₂—D-Val-Pyr-NH—(CH₂)₄-guan 522. HOOC-p-C₆H₄—CH₂—D-Val-Pyr-NH—(CH₂)₅-guan 523. HOOC-p-C₆H₄—CH₂—D-Val-Pyr-NH—(CH₂)₃-guan 524. HOOC-p-C₆H₄—CH₂—D-Val-Pyr-NH-3-amb 525. HOOC-p-C₆H₄—CH₂—D-Val-Pyr-NH—CH₂-5- (3-C(NHCH₃)═NCH₃)-thioph 526. HOOC-p-C₆H₄—CH₂—D-Val-Pyr-NH—CH₂-5- (3-C(NH₂)═NCH₃)-thioph 527. HOOC-p-C₆H₄—CH_(2—D-Val-Pic-NH—CH) ₂-5-(3-am)- thioph 528. HOOC-p-C₆H₄—CH₂—D-Val-Aze-NH—CH₂-5-(3-am)- thioph 529. HOOC-p-C₆H₄—CH₂—D-Val-N-Me-Ala-NH—CH₂-5- (3-am)-thioph 530. HOOC-p-C₆H₄—CH₂—D-Val-4,4-Difluoro-Pro- NH—CH₂-5-(3-am)-thioph 531. HOOC-p-C₆H₄—CH₂—D-Val-Thz-4-CO—NH—CH₂-5- (3-am)-thioph 532. HOOC-p-C₆H₄—CH₂—D-(2-CF₃)Gly-Pyr-NH—CH₂-5- (3-am)-thioph 533. HOOC-p-C₆H₄—CH₂—D-(3-CF₃)Ala-Pyr-NH—CH₂-5- (3-am)-thioph 534. HOOC-p-C₆H₄—CH₂—D-3,3-(CF₃)₂-Ala-Pyr- NH—CH₂-5-(3-am)-thioph 535. HOOC-p-C₆H₄—CH₂—D-2-Methyl-Val-Pyr-NH—CH₂-5- (3-am)-thioph 536. (p-CH₃)-Benzoyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 537. (p-Ethyl)-benzoyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 538. (p-Propyl)-benzoyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 539. (p-Butyl)-benzoyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 540. (p-Isopropyl)benzoyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 541. (p-tBu)Benzoyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 542. (p-Pentyl)benzoyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 543. (p-Hexyl)benzoyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 544. (p-Trifluoromethyl)benzoyl-D-Val-Pyr-NH—CH₂-5- (3-am)-thioph 545. (o-Methyl)benzoyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 546. (o-Trifluoromethyl)benzoyl-D-Val-Pyr-NH—CH₂-5- (3-am)-thioph 547. (o-Methoxy)benzoyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 548. (o-Dimethyl)benzoyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 549. (o-Dimethoxy)benzoyl-D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 550. (p-Methoxy)benzoyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 551. (p-Ethoxy)benzoyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 552. (p-Propoxy)benzoyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 553. (p-Isopropoxy)benzoyl-D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 554. (p-Butyloxy)benzoyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 555. (p-tert-Butoxy)benzoyl-D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 556. (p-Aminomethyl)benzoyl-D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 557. 2,6-Dichlorophenyl-CH₂CO—D-Ala-Pyr-NH—CH₂-5- (3-am)-thioph 558. 2,6-Dichlorophenyl-CH₂CO—D-Ile-Pyr-NH—CH₂-5- (3-am)-thioph 559. 2,6-Dichlorophenyl-CH₂CO—D-allo-Ile-Pyr-NH—CH₂-5- (3-am)-thioph 560. 2,6-Dichlorophenyl-CH₂CO—D-tLeu-Pyr-NH—CH₂-5- (3-am)-thioph 561. 2,6-Dichlorophenyl-CH₂CO—D-hexafluoro-Val-Pyr- NH—CH₂-5-(3-am)-thioph 562. 2,6-Dichlorophenyl-CH₂CO—D-Thr-Pyr-NH—CH₂-5- (3-am)-thioph 563. 2,6-Dichlorophenyl-CH₂CO—D-Cpg-Pyr-NH—CH₂-5- (3-am)-thioph 564. 2,6-Dichlorophenyl-CH₂CO—D-2-methyl-Val-Pyr- NH—CH₂-5-(3-am)-thioph 565. 2,6-Dichlorophenyl-CH₂CO—D-Val-Pyr-NH-4-amb 566. 2,6-Dichlorophenyl-CH₂CO—D-Val-Pyr-NH—CH₂-5- (2-am)-thioph 567. 2,6-Dichlorophenyl-CH₂CO—D-Val-Pyr-NH-3-(6-am)- pico 568. 2,6-Dichlorophenyl-CH₂CO—D-Val-Pyr-NH—CH₂-5- (2-am)-fur 569. 2,6-Dichlorophenyl-CH₂CO—D-Val-Pyr-NH—CH₂-5- (3-am-4-Cl)-thioph 570. 2,6-Dichlorophenyl-CH₂CO—D-Val-Pyr-NH—CH₂-5- (2-am-3-Cl)-thioph 571. 2,6-Dichlorophenyl-CH₂CO—D-Val-Pyr-NH—CH₂-2- (4-am)-thiaz 572. 2,6-Dichlorophenyl-CH₂CO—D-Val-Pyr-NH—CH₂-2- (5-am)-thiaz 573. 2,6-Dichlorophenyl-CH₂CO—D-Val-Pyr-NH—CH₂-5- (2-am)-thiaz 574. 2,6-Dichlorophenyl-CH₂CO—D-Val-Pyr-NH—CH₂-4- (2-am)-thiaz 575. 2,6-Dichlorophenyl-CH₂CO—D-Val-Pyr-NH—CH₂-2- (4-guan)-thiaz 576. 2,6-Dichlorophenyl-CH₂CO—D-Val-Pyr-NH—CH₂-2- (5-guan)-thiaz 577. 2,6-Dichlorophenyl-CH₂CO—D-Val-Pyr-NH—CH₂-5- (3-guan)-thioph 578. 2,6-Dichlorophenyl-CH₂CO—D-Val-Pyr-NH—CH₂-5- (2-guan)-thioph 579. 2,6-Dichlorophenyl-CH₂CO—D-Val-Pyr-NH—CH₂-4- (2-am)-thioph 580. 2,6-Dichlorophenyl-CH₂CO—D-Val-Pyr-NH—(4-guan)- benzyl 581. 2,6-Dichlorophenyl-CH₂CO—D-Val-Pyr-NH—(CH₂)₄-am 582. 2,6-Dichlorophenyl-CH₂CO—D-Val-Pyr-NH—(CH₂)₅-am 583. 2,6-Dichlorophenyl-CH₂CO—D-Val-Pyr-NH—(CH₂)₃-am 584. 2,6-Dichlorophenyl-CH₂CO—D-Val-Pyr-NH—(CH₂)₄- guan 585. 2,6-Dichlorophenyl-CH₂CO—D-Val-Pyr-NH—(CH₂)₅- guan 586. 2,6-Dichlorophenyl-CH₂CO—D-Val-Pyr-NH—(CH₂)₃- guan 587. 2,6-Dichlorophenyl-CH₂CO—D-Val-Pyr-NH-3-amb 588. 2,6-Dichlorophenyl-CH₂CO—D-Val-Pyr-NH—CH₂-5- (3-C(NHCH₃)═NCH₃)-thioph 589. 2,6-Dichlorophenyl-CH₂CO—D-Val-Pyr-NH—CH₂-5- (3-C(NH₂)═NCH₃)-thioph 590. 1R-Indanyl-D-Cpg-Pyr-NH—CH₂-5-(3-am)-thioph 591. 1R-Indanyl-D-Ala-Pyr-NH—CH₂-5-(3-am)-thioph 592. 1R-Indanyl-D-Thr-Pyr-NH—CH₂-5-(3-am)-thioph 593. 1R-Indanyl-D-allo-Ile-Pyr-NH—CH₂-5-(3-am)-thioph 594. 1R-Indanyl-D-tLeu-Pyr-NH—CH₂-5-(3-am)-thioph 595. 1R-Indanyl-D-hexafluoro-Val-Pyr-NH—CH₂-5-(3-am)- thioph 596. 1R-Indanyl-D-2-methyl-Val-Pyr-NH—CH₂-5-(3-am)- thioph 597. 1R-Indanyl-CO—D-Cpg-Pyr-NH—CH₂-5-(3-am)-thioph 598. 1R-Indanyl-CO—D-Ala-Pyr-NH—CH₂-5-(3-am)-thioph 599. 1R-Indanyl-CO—D-allo-Ile-Pyr-NH—CH₂-5-(3-am)-thioph 600. 1R-Indanyl-CO—D-tLeu-Pyr-NH—CH₂-5-(3-am)-thioph 601. 1S-Indanyl-D-Cpg-Pyr-NH—CH₂-5-(3-am)-thioph 602. 1S-Indanyl-D-Ala-Pyr-NH—CH₂-5-(3-am)-thioph 603. 1S-Indanyl-D-Thr-Pyr-NH—CH₂-5-(3-am)-thioph 604. 1S-Indanyl-D-allo-Ile-Pyr-NH—CH₂-5-(3-am)-thioph 605. 1S-Indanyl-D-tLeu-Pyr-NH—CH₂-5-(3-am)-thioph 606. 1S-Indanyl-D-hexafluoro-Val-Pyr-NH—CH₂-5-(3-am)- thioph 607. 1S-Indanyl-D-2-methyl-Val-Pyr-NH—CH₂-5-(3-am)-thioph 608. 1S-Indanyl-CO—D-Cpg-Pyr-NH—CH₂-5-(3-am)-thioph 609. 1S-Indanyl-CO—D-Ala-Pyr-NH—CH₂-5-(3-am)-thioph 610. 1S-Indanyl-CO—D-allo-Ile-Pyr-NH—CH₂-5-(3-am)-thioph 611. 1S-Indanyl-CO—D-tLeu-Pyr-NH—CH₂-5-(3-am)-thioph 612. (5,6-Dimethyl)-1-indanyl-CO—D-Val-Pyr-NH—CH₂-5- (3-am)-thioph 613. (5,7-Dimethyl)-1-indanyl-CO—D-Val-Pyr-NH—CH₂-5- (3-am)-thioph 614. (p-Aminomethyl)-benzyl-CO—D-Val-Pyr-NH—CH₂-5- (3-am)-thioph 615. (o-Carboxy)-benzyl-CO—D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 616. (m-Carboxy)-benzyl-CO—D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 617. (p-Carboxy)-benzyl-CO—D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 618. (p-Carboxy-methyl)-benzyl-CO—D-Val-Pyr-NH—CH₂-5- (3-am)-thioph 619. 2-Indanyl-CO—D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 620. (2,4,6-Trimethoxy)-benzyl-CO—D-Val-Pyr-NH—CH₂-5- (3-am)-thioph 621. Tetrahydronaphthyl(1S)-CO—D-Val-Pyr-NH—CH₂-5- (3-am)-thioph 622. Tetrahydronaphthyl(1R)-CO—D-Val-Pyr-NH—CH₂-5- (3-am)-thioph 623. 2,6-Dibromophenyl-CH₂CO—D-Val-Pyr-NH—CH₂-5- (3-am)-thioph 624. 2,6-Ditrifluoromethyl-phenyl-CH₂CO—D-Val-Pyr- NH—CH₂-5-(3-am)-thioph 625. 3-Indolyl-CO—D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 626. N-Methyl-3-indolyl-CO—D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 627. 3-Benzothienyl-CO—D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 628. (5-Carboxy)-1R-indanyl-D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 629. (6-Carboxy)-1R-indanyl-D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 630. (4-Carboxy-2,6-dichloro)benzyl-CO—D-Val-Pyr- NH—CH₂-5-(3-am)-thioph 631. (5-Carboxy)-1S-indanyl-D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 632. (6-Carboxy)-1S-indanyl-D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 633. (5-Carboxy)-1R-indanyl-CO—D-Val-Pyr-NH—CH₂-5- (3-am)-thioph 634. (6-Carboxy)-1R-indanyl-CO—D-Val-Pyr-NH—CH₂-5- (3-am)-thioph 635. (5-Carboxy)-1S-indanyl-CO—D-Val-Pyr-NH—CH₂-5- (3-am)-thioph 636. (6-Carboxy)-1S-indanyl-CO—D-Val-Pyr-NH—CH₂-5- (3-am)-thioph 637. (p-CH₃)-Benzyl-CO—D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 638. (p-Ethyl)-benzyl-CO—D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 639. (p-Propyl)-benzyl-CO—D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 640. (p-Butyl)-benzyl-CO—D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 641. (p-Isopropyl)benzyl-CO—D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 642. (p-tBu)Benzyl-CO—D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 643. (p-Pentyl)benzyl-CO—D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 644. (p-Hexyl)benzyl-CO—D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 645. (p-Trifluoromethyl)benzyl-CO—D-Val-Pyr-NH—CH₂-5- (3-am)-thioph 646. (o-Methyl)benzyl-CO—D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 647. (o-Trifluoromethyl)benzyl-CO—D-Val-Pyr-NH—CH₂-5- (3-am)-thioph 648. (o-Methoxy)benzyl-CO—D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 649. (o-Dimethyl)benzyl-CO—D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 650. (o-Dimethoxy)benzyl-CO—D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 651. (p-Methoxy)benzyl-CO—D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 652. (p-Ethoxy)benzyl-CO—D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 653. (p-Propoxy)benzyl-CO—Val-Pyr-NH—CH₂-5-(3-am)- thioph 654. (p-Isopropoxy)benzyl-CO—D-Val-Pyr-NH—CH₂-5- (3-am)-thioph 655. (p-Butoxy)benzyl-CO—D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 656. (p-tert-Butoxy)benzyl-CO—D-Val-Pyr-NH—CH₂-5- (3-am)-thioph 657. (p-CN)-Benzyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 658. (p-Dimethylamino)-benzyl-D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 659. (p-Methoxy)-benzyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 660. (p-Ethoxy)-benzyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 661. (p-Propoxy)benzyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 662. (p-Isopropoxy)benzyl-D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 663. (p-Butoxy)benzyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 664. (p-tert-Butoxy)benzyl-D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 665. (p-Pentoxy)benzyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 666. (p-Trifluoromethyl)benzyl-D-Val-Pyr-NH—CH₂-5-(3-am)- thioph 667. (p-Ethyl)benzyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 668. (p-Propyl)benzyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 669. (p-Butyl)benzyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 670. (p-tert-Butyl)benzyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 671. (p-Pentyl)benzyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 672. (p-Hexyl)benzyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 673. (p-MeSO₂)Benzyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 674. (p-Nitro)benzyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 675. (p-Carboxy)benzyl-D-Val-Pyr-NH—CH₂-5-(3-ham)-thioph 676. (p-Carboxy)benzyl-D-Ala-Pyr-NH—CH₂-5-(3-ham)-thioph 677. (p-Carboxy)benzyl-D-Abu-Pyr-NH—CH₂-5-(3-ham)-thioph 678. (p-Carboxy)benzyl-D-Nva-Pyr-NH—CH₂-5-(3-ham)-thioph 679. (p-Carboxy)benzyl-D-tLeu-Pyr-NH—CH₂-5-(3-ham)-thioph 680. (p-Carboxy)benzyl-D-Ile-Pyr-NH—CH₂-5-(3-ham)-thioph 681. (p-Carboxy)benzyl-D-allo-Ile-Pyr-NH—CH₂-5-(3-ham)- thioph 682. (p-Carboxy)benzoyl-D-Val-Pyr-NH—CH₂-5-(3-ham)- thioph 683. (p-Carboxy)benzyl-D-Cpg-Pyr-NH—CH₂-5-(3-ham)-thioph 684. 2,6-Dichlorobenzyl-CO—D-Val-Pyr-NH—CH₂-5-(3-ham)- thioph 685. 2,6-Dichlorobenzyl-CO—D-Ala-Pyr-NH—CH₂-5-(3-ham)- thioph 686. 2,6-Dichlorobenzyl-CO—D-Abu-Pyr-NH—CH₂-5-(3-ham)- thioph 687. 2,6-Dichlorobenzyl-CO—D-Nva-Pyr-NH—CH₂-5-(3-ham)- thioph 688. 2,6-Dichlorobenzyl-CO—D-tLeu-Pyr-NH—CH₂-5- (3-ham)-thioph 689. 2,6-Dichlorobenzyl-CO—D-Ile-Pyr-NH—CH₂-5-(3-ham)- thioph 690. 2,6-Dichlorobenzyl-CO—D-alloIle-Pyr-NH—CH₂-5- (3-ham)-thioph 691. 2,6-Dichlorobenzyl-CO—D-Cpg-Pyr-NH—CH₂-5-(3-ham)- thioph 692. p-Benzoyl-benzoyl-D-Val-Pyr-NH—CH₂-5-(3-ham)-thioph 693. (p-Phenyl-NH—CO—NH)benzoyl-D-Val-Pyr-NH—CH₂- 5-(3-ham)-thioph 694. 2,4,6-Trimethyl-benzyl-CO—D-Val-Pyr-NH—CH₂-5- (3-ham)-thioph 695. Benzhydryl-CO—D-Val-Pyr-NH—CH₂-5-(3-ham)-thioph 696. (p-Carboxy)benzyl-CO—D-Val-Pyr-NH—CH₂-5-(3-ham)- thioph 697. (p-COOMe)Benzyl-D-Val-Pyr-NH—CH₂-5-(3-ham)-thioph 698. (p-COOEt)Benzyl-D-Val-Pyr-NH—CH₂-5-(3-ham)-thioph 699. (p-COOPr)Benzyl-D-Val-Pyr-NH—CH₂-5-(3-ham)-thioph 700. (p-COOiPr)Benzyl-D-Val-Pyr-NH—CH₂-5-(3-ham)-thioph 701. (p-COOtBu)Benzyl-D-Val-Pyr-NH—CH₂-5-(3-ham)-thioph 702. (p-COOCyclohexyl)benzyl-D-Val-Pyr-NH—CH₂-5- (3-ham)-thioph 703. (p-COOCyclopentyl)benzyl-D-Val-Pyr-NH—CH₂-5- (3-ham)-thioph 704. (p-COOMe)Benzyl-D-Ala-Pyr-NH—CH₂-5-(3-ham)-thioph 705. (p-COOEt)Benzyl-D-Ala-Pyr-NH—CH₂-5-(3-ham)-thioph 706. (p-COOPr)Benzyl-D-Ala-Pyr-NH—CH₂-5-(3-ham)-thioph 707. (p-COOiPr)Benzyl-D-Ala-Pyr-NH—CH₂-5-(3-ham)-thioph 708. (p-COOtBu)Benzyl-D-Ala-Pyr-NH—CH₂-5-(3-ham)-thioph 709. (p-COOCyclohexyl)benzyl-D-Ala-Pyr-NH—CH₂-5- (3-ham)-thioph 710. (p-COOCyclopentyl)benzyl-D-Ala-Pyr-NH—CH₂-5- (3-ham)-thioph 711. (p-COOMe)Benzyl-D-Abu-Pyr-NH—CH₂-5-(3-ham)- thioph 712. (p-COOEt)Benzyl-D-Abu-Pyr-NH—CH₂-5-(3-ham)-thioph 713. (p-COOPr)Benzyl-D-Abu-Pyr-NH—CH₂-5-(3-ham)-thioph 714. (p-COOiPr)Benzyl-D-Abu-Pyr-NH—CH₂-5-(3-ham)-thioph 715. (p-COOtBu)Benzyl-D-Abu-Pyr-NH—CH₂-5-(3-ham)- thioph 716. (p-COOCyclohexyl)benzyl-D-Abu-Pyr-NH—CH₂-5- (3-ham)-thioph 717. (p-COOCyclopentyl)benzyl-D-Abu-Pyr-NH—CH₂-5- (3-ham)-thioph 718. (p-COOMe)Benzyl-D-Ile-Pyr-NH—CH₂-5-(3-ham)- thioph 719. (p-COOEt)Benzyl-D-Ile-Pyr-NH—CH₂-5-(3-ham)-thioph 720. (p-COOPr)Benzyl-D-Ile-Pyr-NH—CH₂-5-(3-ham)-thioph 721. (p-COOiPr)Benzyl-D-Ile-Pyr-NH—CH₂-5-(3-ham)-thioph 722. (p-COOtBu)Benzyl-D-Ile-Pyr-NH—CH₂-5-(3-ham)-thioph 723. (p-COOCyclohexyl)benzyl-D-Ile-Pyr-NH—CH₂-5- (3-ham)-thioph 724. (p-COOCyclopentyl)benzyl-D-Ile-Pyr-NH—CH₂-5- (3-ham)-thioph 725. (p-COOMe)Benzoyl-D-Val-Pyr-NH—CH₂-5-(3-ham)- thioph 726. (p-COOEt)Benzoyl-D-Val-Pyr-NH—CH₂-5-(3-ham)-thioph 727. (p-COOPr)Benzoyl-D-Val-Pyr-NH—CH₂-5-(3-ham)-thioph 728. (p-COOiPr)Benzoyl-D-Val-Pyr-NH—CH₂-5-(3-ham)- thioph 729. (p-COOtBu)Benzoyl-D-Val-Pyr-NH—CH₂-5-(3-ham)- thioph 730. (p-COOCyclohexyl)benzoyl-D-Val-Pyr-NH—CH₂-5- (3-ham)-thioph 731. (p-COOCyclopentyl)benzoyl-D-Val-Pyr-NH—CH₂-5- (3-ham)-thioph 732. (p-COOMe)Benzoyl-D-Ala-Pyr-NH—CH₂-5-(3-ham)- thioph 733. (p-COOEt)Benzoyl-D-Ala-Pyr-NH—CH₂-5-(3-ham)-thioph 734. (p-COOPr)Benzoyl-D-Ala-Pyr-NH—CH₂-5-(3-ham)-thioph 735. (p-COOiPr)Benzoyl-D-Ala-Pyr-NH—CH₂-5-(3-ham)- thioph 736. (p-COOtBu)Benzoyl-D-Ala-Pyr-NH—CH₂-5-(3-ham)- thioph 737. (p-COOCyclohexyl)benzoyl-D-Ala-Pyr-NH—CH₂-5- (3-ham)-thioph 738. (p-COOCyclopentyl)benzoyl-D-Ala-Pyr-NH—CH₂-5- (3-ham)-thioph 739. (p-COOMe)Benzoyl-D-Abu-Pyr-NH—CH₂-5-(3-ham)- thioph 740. (p-COOEt)Benzoyl-D-Abu-Pyr-NH—CH₂-5-(3-ham)- thioph 741. (p-COOPr)Benzoyl-D-Abu-Pyr-NH—CH₂-5-(3-ham)- thioph 742. (p-COOiPr)Benzoyl-D-Abu-Pyr-NH—CH₂-5-(3-ham)- thioph 743. (p-COOtBu)Benzoyl-D-Abu-Pyr-NH—CH₂-5-(3-ham)- thioph 744. (p-COOCyclohexyl)benzoyl-D-Abu-Pyr-NH—CH₂-5- (3-ham)-thioph 745. (p-COOCyclopentyl)benzoyl-D-Abu-Pyr-NH—CH₂-5- (3-ham)-thioph 746. (p-COOMe)Benzoyl-D-Ile-Pyr-NH—CH₂-5-(3-ham)-thioph 747. (p-COOEt)Benzoyl-D-Ile-Pyr-NH—CH₂-5-(3-ham)-thioph 748. (p-COOPr)Benzoyl-D-Ile-Pyr-NH—CH₂-5-(3-ham)-thioph 749. (p-COOiPr)Benzoyl-D-Ile-Pyr-NH—CH₂-5-(3-ham)-thioph 750. (p-COOtBu)Benzoyl-D-Ile-Pyr-NH—CH₂-5-(3-ham)-thioph 751. (p-COOCyclohexyl)benzoyl-D-Ile-Pyr-NH—CH₂-5- (3-ham)-thioph 752. (p-COOCyclopentyl)benzoyl-D-Ile-Pyr-NH—CH₂-5- (3-ham)-thioph 753. (p-COOMe)Benzyl-CO—D-Val-Pyr-NH—CH₂-5-(3-ham)- thioph 754. (p-COOEt)Benzyl-CO—D-Val-Pyr-NH—CH₂-5-(3-ham)- thioph 755. (p-COOPr)Benzyl-CO—D-Val-Pyr-NH—CH₂-5-(3-ham)- thioph 756. (p-COOiPr)Benzyl-CO—D-Val-Pyr-NH—CH₂-5-(3-ham)- thioph 757. (p-COOtBu)Benzyl-CO—D-Val-Pyr-NH—CH₂-5-(3-ham)- thioph 758. (p-COOCyclohexyl)benzyl-CO—D-Val-Pyr-NH—CH₂-5- (3-ham)-thioph 759. (p-COOCyclopentyl)benzyl-CO—D-Val-Pyr-NH—CH₂-5- (3-ham)-thioph 760. (p-COOMe)Benzyl-CO—D-Ala-Pyr-NH—CH₂-5-(3-ham)- thioph 761. (p-COOEt)Benzyl-CO—D-Ala-Pyr-NH—CH₂-5-(3-ham)- thioph 762. (p-COOPr)Benzyl-CO—D-Ala-Pyr-NH—CH₂-5-(3-ham)- thioph 763. (p-COOiPr)Benzyl-CO—D-Ala-Pyr-NH—CH₂-5-(3-ham)- thioph 764. (p-COOtBu)Benzyl-CO—D-Ala-Pyr-NH—CH₂-5-(3-ham)- thioph 765. (p-COOCyclohexyl)benzyl-CO—D-Ala-Pyr-NH—CH₂-5- (3-ham)-thioph 766. (p-COOCyclopentyl)benzyl-CO—D-Ala-Pyr-NH—CH₂-5- (3-ham)-thioph 767. (p-COOMe)Benzyl-CO—D-Abu-Pyr-NH—CH₂-5-(3-ham)- thioph 768. (p-COOEt)Benzyl-CO—D-Abu-Pyr-NH—CH₂-5-(3-ham)- thioph 769. (p-COOPr)Benzyl-CO—D-Abu-Pyr-NH—CH₂-5-(3-ham)- thioph 770. (p-COOiPr)Benzyl-CO—D-Abu-Pyr-NH—CH₂-5-(3-ham)- thioph 771. (p-COOtBu)benzyl-CO—D-Abu-Pyr-NH—CH₂-5-(3-ham)- thioph 772. (p-COOCyclohexyl)benzyl-CO—D-Abu-Pyr-NH—CH₂-5- (3-ham)-thioph 773. (p-COOCyclopentyl)benzyl-CO—D-Abu-Pyr-NH—CH₂-5- (3-ham)-thioph 774. (p-COOMe)Benzyl-CO—D-Ile-Pyr-NH—CH₂-5-(3-ham)- thioph 775. (p-COOEt)Benzyl-CO—D-Ile-Pyr-NH—CH₂-5-(3-ham)- thioph 776. (p-COOPr)Benzyl-CO—D-Ile-Pyr-NH—CH₂-5-(3-ham)- thioph 777. (p-COOiPr)Benzyl-CO—D-Ile-Pyr-NH—CH₂-5-(3-ham)- thioph 778. (p-COOtBu)Benzyl-CO—D-Ile-Pyr-NH—CH₂-5-(3-ham)- thioph 779. (p-COOCyclohexyl)benzyl-CO—D-Ile-Pyr-NH—CH₂-5- (3-ham)-thioph 780. (p-COOCyclopentyl)benzyl-CO—D-Ile-Pyr-NH—CH₂-5- (3-ham)-thioph 781. 5-EtOOC-1R-Indanyl-CO—D-Val-Pyr-NH—CH₂-5- (3-ham)-thioph 782. 6-EtOOC-1R-Indanyl-CO—D-Val-Pyr-NH—CH₂-5- (3-ham)-thioph 783. 5-EtOOC-1R-Indanyl-D-Val-Pyr-NH—CH₂-5-(3-ham)- thioph 784. 6-EtOOC-1R-Indanyl-D-Val-Pyr-NH—CH₂-5-(3-ham)- thioph 785. 5-EtOOC-1S-Indanyl-CO—D-Val-Pyr-NH—CH₂-5- (3-ham)-thioph 786. 6-EtOOC-1S-Indanyl-CO—D-Val-Pyr-NH—CH₂-5- (3-ham)-thioph 787. 5-EtOOC-1S-Indanyl-D-Val-Pyr-NH—CH₂-5-(3-ham)- thioph 788. 6-EtOOC-1S-Indanyl-D-Val-Pyr-NH—CH₂-5-(3-ham)- thioph 789. 4-(Benzylamino-methyl)-benzoyl-D-Val-Pyr-NH—CH₂-5- (3-am)-thioph 790. 4-(Cyclohexylmethylamino-methyl)-benzoyl-D-Val-Pyr- NH—CH₂-5-(3-am)-thioph 791. 4-(Isobutylamino-methyl)-benzoyl-D-Val-Pyr-NH—CH₂-5- (3-am)-thioph 792. 4-(Isopropylamino-methyl)-benzoyl-D-Val-Pyr-NH—CH₂- 5-(3-am)-thioph 793. 4-(Benzylamino-methyl)-benzoyl-D-Ala-Pyr-NH—CH₂-5- (3-am)-thioph 794. 4-(Cyclohexylmethylamino-methyl)-benzoyl-D-Ala-Pyr- NH—CH₂-5-(3-am)-thioph 795. 4-(Isobutylamino-methyl)-benzoyl-D-Ala-Pyr-NH—CH₂-5- (3-am)-thioph 796. 4-(Isopropylamino-methyl)-benzoyl-D-Ala-Pyr-NH—CH₂- 5-(3-am)-thioph 797. 4-(Cyclohexylmethylamino-methyl)-benzoyl-D-Abu-Pyr- NH—CH₂-5-(3-am)-thioph 798. 4-(Benzylamino-methyl)-benzoyl-D-Abu-Pyr-NH—CH₂-5- (3-am)-thioph 799. 3-(Benzylamino-methyl)-benzoyl-D-Val-Pyr-NH—CH₂-5- (3-am)-thioph 800. 3-(Cyclohexylmethylamino-methyl)-benzoyl-D-Val-Pyr- NH—CH₂-5-(3-am)-thioph 801. 3-(Isobutylamino-methyl)-benzoyl-D-Val-Pyr-NH—CH₂-5- (3-am)-thioph 802. 3-(Isopropylamino-methyl)-benzoyl-D-Val-Pyr-NH—CH₂- 5-(3-am)-thioph 803. 3-(Benzylamino-methyl)-benzoyl-D-Ala-Pyr-NH—CH₂-5- (3-am)-thioph 804. 3-(Cyclohexylmethylamino-methyl)-benzoyl-D-Ala-Pyr- NH—CH₂-5-(3-am)-thioph 805. 3-(Isobutylamino-methyl)-benzoyl-D-Ala-Pyr-NH—CH₂-5- (3-am)-thioph 806. 3-(Isopropylamino-methyl)-benzoyl-D-Ala-Pyr-NH—CH₂- 5-(3-am)-thioph 807. 4-(Benzylamino-methyl)-phenylacetyl-D-Val-Pyr- NH—CH₂-5-(2-am)-thioph 808. 4-(Cyclohexylmethylamino-methyl)-phenylacetyl-D-Val- Pyr-NH—CH₂-5-(2-am)-thioph 809. 4-(Isobutylamino-methyl)-phenylacetyl-D-Val-Pyr- NH—CH₂-5-(2-am)-thioph 810. 4-(Isopropylamino-methyl)-phenylacetyl-D-Val-Pyr- NH—CH₂-5-(2-am)-thioph 811. 4-(Benzylamino-methyl)-phenylacetyl-D-Ala-Pyr- NH—CH₂-5-(2-am)-thioph 812. 4-(Cyclohexylmethylamino-methyl)-phenylacetyl-D-Ala- Pyr-NH—CH₂-5-(2-am)-thioph 813. 4-(Isobutylamino-methyl)-phenylacetyl-D-Ala-Pyr- NH—CH₂-5-(2-am)-thioph 814. 4-(Isopropylamino-methyl)-phenylacetyl-D-Ala-Pyr- NH—CH₂-5-(2-am)-thioph 815. 4-(Benzylamino-methyl)-phenylacetyl-D-Abu-Pyr- NH—CH₂-5-(2-am)-thioph 816. 4-(Cyclohexylmethylamino-methyl)-phenylacetyl-D-Abu- Pyr-NH—CH₂-5-(2-am)-thioph 817. 4-(Benzylamino-methyl)-phenylacetyl-D-Val-Pyr- NH—CH₂-5-(3-am)-thioph 818. 4-(Cyclohexylmethylamino-methyl)-phenylacetyl-D-Val- Pyr-NH—CH₂-5-(3-am)-thioph 819. 4-(Isobutylamino-methyl)-phenylacetyl-D-Val-Pyr- NH—CH₂-5-(3-am)-thioph 820. 4-(Isopropylamino-methyl)-phenylacetyl-D-Val-Pyr- NH—CH₂-5-(3-am)-thioph 821. 4-(Benzylamino-methyl)-phenylacetyl-D-Ala-Pyr- NH—CH₂-5-(3-am)-thioph 822. 4-(Cyclohexylmethylamino-methyl)-phenylacetyl-D-Ala- Pyr-NH—CH₂-5-(3-am)-thioph 823. 4-(Isobutylamino-methyl)-phenylacetyl-D-Ala-Pyr- NH—CH₂-5-(3-am)-thioph 824. 4-(Isopropylamino-methyl)-phenylacetyl-D-Ala-Pyr- NH—CH₂-5-(3-am)-thioph 825. 4-(Benzylamino-methyl)-phenylacetyl-D-Abu-Pyr- NH—CH₂-5-(3-am)-thioph 826. 4-(Cyclohexylmethylamino-methyl)-phenylacetyl-D-Abu- Pyr-NH—CH₂-5-(3-am)-thioph 827. 3-[4-(Benzylamino-methyl)-phenyl]-propionyl-D-Val-Pyr- NH—CH₂-5-(3-am)-thioph 828. 3-[4-(Cyclohexylmethylamino-methyl)-phenyl]-propionyl- D-Val-Pyr-NH—CH₂-5-(3-am)-thioph 829. 3-[4-(Isobutylamino-methyl)-phenyl]-propionyl-D-Val-Pyr- NH—CH₂-5-(3-am)-thioph 830. 3-[4-(Isopropylamino-methyl)-phenyl]-propionyl-D-Val- Pyr-NH—CH₂-5-(3-am)-thioph 831. 3-[4-(Benzylamino-methyl)-phenyl]-propionyl-D-Ala-Pyr- NH—CH₂-5-(3-am)-thioph 832. 3-[4-(Cyclohexylmethylamino-methyl)-phenyl]-propionyl- D-Ala-Pyr-NH—CH₂-5-(3-am)-thioph 833. 3-[4-(Isobutylamino-methyl)-phenyl]-propionyl-D-Ala-Pyr- NH—CH₂-5-(3-am)-thioph 834. 3-[4-(Isopropylamino-methyl)-phenyl]-propionyl-D-Ala- Pyr-NH—CH₂-5-(3-am)-thioph 835. 3-[4-(Benzylamino-methyl)-phenyl]-propionyl-D-Abu-Pyr- NH—CH₂-5-(3-am)-thioph 836. 3-[4-(Isopropylylamino-methyl)-phenyl]-propionyl-D-Abu- Pyr-NH—CH₂-5-(3-am)-thioph 837. 3-[4-(Cyclohexylmethylamino-methyl)-phenyl]-propionyl- D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph 838. 3-[4-(Benzylamino-methyl)-phenyl]-propionyl-D-Abu-Pyr- NH—CH₂-5-(2-am)-thioph 839. 3-[4-(Isopropylylamino-methyl)-phenyl]-propionyl-D-Abu- Pyr-NH—CH₂-5-(2-am)-thioph 840. 3-[4-(Cyclohexylmethylamino-methyl)-phenyl]-propionyl- D-Abu-Pyr-NH—CH₂-5-(2-am)-thioph 841. 3-[4-(Benzylamino-methyl)-phenyl]-propionyl-D-Ala-Pyr- NH—CH₂-5-(2-am)-thioph 842. 3-[4-(Isopropylamino-methyl)-phenyl]-propionyl-D-Val- Pyr-NH—CH₂-5-(2-am)-thioph

List of Abbreviations:

Abu: 2-Aminobutyric acid AIBN: Azobisisobutyronitrile Ac: Acetyl Acpc: 1-Aminocyclopentane-1-carboxylic acid Achc: 1-Aminocyclohexane-1-carboxylic acid Aib: 2-Aminoisobutyric acid Ala: Alanine β-Ala: β-Alanine (3-Aminopropionic acid) am: Amidino amb: Amidinobenzyl 4-amb: 4-Amidinobenzyl (p-amidinobenzyl) Arg: Arginine Asp: Aspartic acid Aze: Azetidine-2-carboxylic acid Bn: Benzyl Boc: tert-Butoxycarbonyl Bu: Butyl Cbz: Benzyloxycarbonyl Cha: Cyclohexylalanine Chea: Cycloheptylalanine Cheg: Cycloheptylglycine Chg: Cyclohexylglycine Cpa: Cyclopentylalanine Cpg: Cyclopentylglycine d: Doublet Dab: 2,4-diaminobutyric acid Dap: 2,3-diaminopropionic acid TLC: Thin-layer chromatography DCC: Dicyclohexylcarbodiimide Dcha: Dicyclohexylamine DCM: Dichloromethane Dhi-1-COOH: 2,3-Dihydro-1H-isoindole-1-carboxylic acid DMF: Dimethylformamide DIPEA: Diisopropylethylamine EDC: N′-(3-Dimethylaminopropyl)-N-ethylcarbodiimide Et: Ethyl Eq: Equivalents Gly: Glycine Glu: Glutamic acid fur: Furan guan: Guanidino ham: Hydroxyamidino HCha Homocyclohexylalanine, 2-amino-4-cyclohexylbutyric acid His: Histidine HOBT: Hydroxybenzotriazole HOSucc: Hydroxysuccinimide HPLc: High-performance liquid chromatography Hyp: Hydroxyproline Ind-2-COOH: Indoline-2-carboxylic acid iPr: Isopropyl Leu: Leucine Soln: Solution Lys: Lysine m: Multiplet Me: Methyl MPLC: Medium-pressure liquid chromatography MTBE: Methyl-tert-butyl-ether NBS: N-Bromosuccinimide Nva: Norvaline Ohi-2-COOH: Octahydroindole-2-carboxylic acid Ohii-1-COOH: Octahydroisoindole-1-carboxylic acid Orn: Ornithine Oxaz: Oxazole p-amb: p-Amidinobenzyl Ph: Phenyl Phe: Phenylalanine Phg: Phenylglycine Pic: Pipecolinic acid pico: Picolyl PPA: Propylphosphonic anhydride Pro: Proline Py: Pyridine Pyr: 3,4-Dehydroproline q: Quartet RT: Room temperature RP-18 Reversed Phase C-18 s: Singlet Sar: Sarcosine (N-methylglycine) sb: Singlet broad t: Triplet t: Tertiary tBu: tertiary-Butyl tert: Tertiary TBAB: Tetrabutylammonium bromide TEA: Triethylamine TFA: Trifluoroacetic acid TFFA: Trifluoroacetic anhydride thiaz: Thiazole Thz-2-COOH: 1,3-Thiazolidine-2-carboxylic acid Thz-4-COOH: 1,3-Thiazolidine-4-carboxylic acid thioph: Thiophene 1-Tic: 1-Tetrahydroisoquinolinecarboxylic acid 3-Tic: 3-Tetrahydroisoquinolinecarboxylic acid TOTU: O-(Cyano-ethoxycarbonylmethylene)-amino-]- N,N,N′,N′-tetramethyluronium tetrafluoroborate Z: Benzyloxycarbonyl

EXPERIMENTAL SECTION

The compounds of the formula I can be prepared according to Schemes I-III.

The building blocks A—B—D, E, G and K are preferably synthesized separately and used in suitably protected form (cf. Schemes I-III, is in each case of orthogonal protective groups compatible with the synthesis method used (P or P*).

Scheme I describes the linear synthesis of the molecule I by eliminating the protective group from P—K—L* (where L* is CONH₂, CSNH₂, CN or C(═NH)NH—COOR*; and R* is a protective group or polymeric carrier with a spacer (solid-phase synthesis)), coupling the amine H—K—L* to the N-protected amino acid P—G—OH to give P—G—K—L*, eliminating the N-terminal protective group to give H—G—K—L*, coupling to the N-protected amino acid P—E—OH to give P—E—G—K—L*, eliminating the protective group P to give H—E—G—K—L*, then coupling or alkylating with the unprotected or protected (P)—A—B—D—U building block (where U is a leaving group) or reductive alkylation with (P)—A—B—D′—U (where U is an aldehyde or ketone) or Michael-Addition with a suitable (P)—A—B—D″—C═C derivative to give (P)—A—B—D—E G—K—L*. If L* is an amide function, it can be converted at the respective protected stages by dehydration with trifluoroacetic anhydride into the corresponding nitrile function. Amidine syntheses for the benzamidine, picolylamidine, thienylamidine, furylamidine and thiazolylamidine compounds of the structure type I starting from the corresponding carboxamides, nitriles, carboxylic acid thioamides and hydroxyamidines are described in a number of patent applications (cf. for example WO 95/35309, WO 96/178860, WO 96/24609, WO 96/25426, WO 98/06741 and WO 98/09950). Any protective groups still present are then eliminated. If L* is a C(═NH)NH-spacer-polymeric carrier, these compounds are cleaved from the polymeric carrier in the final step and the active substance thus liberated.

Scheme II describes the linear synthesis of the molecule I by coupling, alkylation, reductive amination or Michael-Addition of H—E—P with suitable unprotected or protected (P*)—A—B—D building blocks [(P*)—A—B—D—U (where U is a leaving group) or (P*)—A—B—D′—U (where U is an aldehyde, ketone) or (P*)—A—B—D″—C═C derivative] to give (P*)—A—B—D—E—P. This is followed by elimination of the C-terminal protective group to give (P*)—A—B—D—E—OH, coupling with H—G—P to give (P*)—A—B—D—E—G—P, further elimination of the C-terminal protective group to give (P*)—A—B—D—E—G—OH and coupling with H—K—L** (where L** is CONH2, CSNH2, CN, NH—C(═NH)NH₂, C(═NH)NH—R** and R** is a hydrogen atom or protective group) to give (P*)—A—B—D—E—G—K—L**. The conversion of this intermediate into the end product is carried out analogously to scheme I. The synthesis sequence according to scheme II is also suitable for solid-phase synthesis if the A—B—D building block has a corresponding anchor function, e.g. a carboxyl or amino function.

Scheme III describes a very efficient route for preparing the compounds I by a convergent synthesis. The appropriately protected building blocks (P*)—A—B—D—E—OH and H—C—K—L* or H—G—K—L** are coupled to one another and the resulting intermediate (P*)—A—B—D—E—G—K—L* and (P*)—A—B—D—E—G—K—L** respectively, are reacted according to scheme I to give the end product.

The N-terminal protective groups used are Boc, Cbz or Fmoc, and C-terminal protective groups are methyl, tert-butyl and benzyl esters. Amidine protective groups are preferably BOC, Cbz and groups derived therefrom, for the solid-phase synthesis. If the intermediates contain olefinic double bonds, protective groups which are eliminated hydrogenolytically are unsuitable.

The required coupling reactions and the customary reactions for introducing and eliminating protective groups are carried out according to standard conditions of peptide chemistry (cf. M. Bodanszky, A. Bodanszky “The Practice of Peptide Synthesis”, 2^(nd) edition, Springer Verlag Heidelberg, 1994).

Boc-protective groups are eliminated by means of dioxane/HCl or TFA/DCM, Cbz-protective groups are eliminated hydrogenolytically or with HF, and Fmoc protective groups are eliminated with piperidine. The hydrolysis of ester functions is effected with LiOH in an alcoholic solvent or in dioxane/water. t-Butylester are cleaved using TFA or dioxane/HCl.

The reactions were monitored by TLC, the following were mobile phases usually being used:

A. DCM/MeOH 95:5  B. DCM/MeOH 9:1 C. DCM/MeOH 8:2 D. DCM/MeOH/50% strength HOAc 40:10:5 E. DCM/MeOH/50% strength HOAc 35:15:5

Where separation by means of column chromatography are mentioned, these were separations over silica gel, for which the abovementioned mobile phases were used.

Reversed-phase HPLC separation were carried out using acetonitrile/water and HOAc buffer.

The starting compounds can be prepared by the following methods:

A—B—D Building Blocks:

The compounds suitable as A—B—D building blocks are for the most part commercially available, e.g. tert-butyl α-bromoacetate, methylsulfonyl chloride, benzenesulfonyl chloride, 4-chlorosulfonylbenzoic acid, cinnamic acid, hydrocinnamic acid, 5-bromovaleric acid, phenylpropiolic acid, 4-phenylbutyric acid, 5-phenylvaleric acid, 4-phenylbenzoic acid, 4-biphenyl acetic acid, etc. Where these compounds have a plurality of functional groups, protective groups are introduced at the required sites. If necessary, functional groups are converted into reactive or leaving groups (e.g. active esters, mixed anhydrides, sulfonyl chlorides, etc.), in order to permit appropriate chemical linkage with the other building blocks.

The synthesis of the E building blocks was carried out as follows:

The compounds used as E building blocks, i.e. glycine, (D)- and (L)-alanine, (D)- and (L)-valine, (D)-phenylalanine, (D)-cyclohexylalanine, (D)-cycloheptylglycine, etc., are commercially available either as free amino acids, as Boc-protected compounds or as corresponding methyl esters.

The preparation of cycloheptylglycine and cyclopentylglycine was carried out by reacting cycloheptanone and cyclopentanone, respectively, with ethyl isonitriloacetate by known methods (H.-J. Prätorius, J. Flossdorf, M. Kula, Chem. Ber. 108, 1985, 3079 or U. Schöllkopf and R. Meyer, Liebigs Ann. Chem. (1977), 1174).

Said amino acids were provided, as required, with either an N-terminal or a C-terminal protective groups.

The synthesis of the G building blocks was carried out as follows:

The compounds used as G building blocks, i.e. (L)-proline, (L)-4,4-difluoroproline, (L)-3-methylproline, (L)-5-methylproline, (L)-3,4-dehydroproline, (L)-octahydroindole-2-carboxylic acid, (L)-thiazolidine-4-carboxylic acid and (L)-azetidinecarboxylic acid, are commercially available either as free amino acids, as Boc-protective compounds or as corresponding methyl esters. Methyl (−)-thiazolidine-2-carboxylate was prepared according to R. L. Johnson, E. E. Smissman, J. Med. Chem. 21, (1978) 165.

The synthesis of K building blocks was carried as follows:

p-Cyanobenzylamine

This building block was prepared as described in WO 95/35309.

3-(6-Cyano)-picolylamine

This building block was prepared as described in WO 96/25426 or WO 96/24609.

5-Aminomethyl-2-cyanothiophene

This building block was prepared as described in WO 95/23609.

5-Aminomethyl-3-cyanothiophene

This building block was prepared as described in WO 96/17860.

2-Aminomethyl-thiazole-4-thiocarboxamide

The preparation was carried out according to G. Videnov, D. Kaier, C. Kempter and G. Jung, Angew. Chemie 108 (1996), 1604, the protective group being eliminated from the N-Boc-protected compound described there by means of ethereal hydrochloric acid in methylene chloride.

5-Aminomethyl-2-cyanofuran

This building block was prepared as described in WO 96/17860.

5-Aminomethyl-3-cyanofuran

This building block was prepared as described in WO 96/17860.

5-Aminomethyl-3-methylthiophene-2-carbonitrile

a) 5-Formyl-3-methylthiophene-2-carbonitrile:

112 ml (179 mmol) of a 1.6 molar solution of n-butyllithium in n-hexane were added in the course of 20 minutes to a solution, cooled to −78° C., of 25.1 ml (179 mmol) of diisopropylamine in 400 ml of tetrahydrofuran. The solution was allowed to reach −35° C. and was cooled again to −78° C., and a solution of 20.0 g (162 mmol) of 2-cyano-3-methylthiophene in 80 ml of tetrahydrofuran was slowly added dropwise at this temperature. The solution acquired a dark red color. Stirring was continued for 45 minutes, 63 ml (811 mmol) of dimethylformamide were slowly added dropwise and stirring was carried out for a further 30 minutes. For working up, a solution of 27 g of citric acid and 160 ml of water was added at −70° C. Evaporating down was carried out in a rotary evaporator, 540 ml of saturated sodium chloride solution were added and extraction was effected with three times 250 ml of diethyl ether. The combined organic extracts were dried over magnesium sulfate. After the drying agent had been filtered off, the solvent was distilled off under reduced pressure from a water jet pump and the residue was purified by column chromatography (mobile phase: 4/1 hexane/ethyl acetate). 23 g (94%) of the title compound were obtained.

¹H-NMR (270 MHz, DMSO-d₆): δ=2.4 (s, 3H), 8.0 (s, 1H), 9.8 (s, 1H).

b) 5-Hydroxymethyl-3-methylthiophene-2-carbonitrile:

5.75 g (152 mmol) of sodium borohydride were added a little at a time at room temperature to a solution of 23 g (152 mmol) of 5-formyl-3-methylthiophene-2-carbonitrile. Stirring was carried out for 5 minutes, the reaction mixture was evaporated down under reduced pressure from a waterjet pump, the residue was taken up in ethyl acetate, extraction was carried out with 5% strength citric acid solution and with saturated sodium chloride solution, the organic phase was dried over magnesium sulfate, the drying agent was filtered off and the solvent was distilled off under reduced pressure from a waterjet pump at room temperature. This gave 24 g of the title compound as a dark red oil which still contains solvent and was used in the following reactions without further purification.

¹H-NMR (270 MHz, DMSO-d₆): δ=2.4 (s, 3H), 4.7 (m, 2H), 5.9 (m, 1H), 7.0 (s, 1H).

c) 5-Bromomethyl-3-methylthiophene-2-carbonitrile:

44 g (167 mmol) of triphenylphosphine were added to a solution of 24 g (152 mmol) of 5-hydroxymethyl-3-methylthiophene-2-carbonitrile in 180 ml of tetrahydrofuran. A solution of 55 g (167 mmol) of tetrabromomethane in 100 ml of tetrahydrofuran was then added. Stirring was carried out for 90 minutes at room temperature. The reaction mixture was evaporated down in a rotary evaporator under reduced pressure from a waterjet pump and the residue was purified by column chromatography (mobile phase: 8:2 hexane, ethyl acetate). 34 g of the title compound, which still contained a little solvent, were obtained.

¹H-NMR (270 MHz, DMSO-d₆): δ=2.4 (s, 3H), 5.0 (s, 2H), 7.3 (s, 1H).

d) 5-N,N-bis(tert-Butoxycarbonyl)aminomethyl-3-methylthiophene-2-carbonitrile:

5.0 g (167 mmol) of sodium hydride (80% strength suspension in mineral oil) were added a little at a time to a solution, cooled to 0° C., of 33.8 g (152 mmol) of 5-bromomethyl-3-methylthiophene-2-carbonitrile in 255 ml of tetrahydrofuran. A solution of 36.4 g (167 mmol) of di-tert-butyl iminodicarboxylate in 255 ml of tetrahydrofuran was then added dropwise, the temperature not exceeding 5° C. The mixture was allowed to reach room temperature and was stirred overnight. Heating was carried out for a further three hours at 35° C. to complete the reaction, after which the mixture was allowed to cool to room temperature and 510 ml of a saturated ammonium chloride solution was slowly added. The solvent was distilled off under reduced pressure from a waterjet pump, the residue was extracted several times with ethyl acetate and the combined organic phases were washed with saturated sodium chloride solution, dried over magnesium sulfate and evaporated down in a rotary evaporator. 57.6 g of an oily residue which still contained di-tert-butyl iminodicarboxylate were obtained and said residue was used as a crude product in the following reaction.

¹H-NMR (270 MHz, DMSO-d₆): δ=1.45 (s, 18H), 2.35 (s, 3H), 4.85 (s, 2H), 7.05 (s, 1H).

e) 5-Aminomethyl-3-methylthiophene-2-carbonitrile hydrochloride:

52.6 g of 5-N,N-bis(tert-butoxycarbonyl)aminomethyl-3-methylthiophene-2-carbonitrile (crude product from d), not more than 139 mmol) were dissolved in 950 ml of ethyl acetate and cooled to 0° C. The solution was saturated with hydrogen chloride gas, white precipitate separating out after 10 minutes. Stirring was carried out for two hours at room temperature and for one hour at 30° C., the resulting suspension was then evaporated down in a rotary evaporator, the residue was stirred with diethyl ether and filtered off from the solvent and the solid residue was dried at room temperature under reduced pressure. 24.7 g (94%) of the title compound were obtained as a white powder.

¹H-NMR (270 MHz, DMSO-d₆): δ=2.4 (s, 3H), 4.25 (s, 2H), 7.3 (S, 1H), 8.8-9.0 (bs, 3H). ¹³C-NMR (DMSO-d₆): 15.0 (CH₃), 36.4 (CH₂), 104.8 (C-2), 113.8 (CN), 131.5 (C-4), 142.8 (C-5), 149.6 (C-3).

5-Aminomethyl-3-chlorothiophene-2-carbonitrile Hydrochloride

This compound was prepared analogously to 5-aminomethyl-3-methylthiophene-2-carbonitrile, the 3-chloro-2-cyanothiophene used having been prepared by dehydrating 3-chlorothiophene-2-carboxamide (substances commercially available) with trifluoroacetic anhydride.

5-Aminomethyl-4-methylthiophene-3-thiocarboxamide

a) Ethyl 2-Amino-3-cyano-4-methylthiophene-5-carboxylate

Ethyl 2-amino-3-cyano-4-methylthiophene-5-carboxylate was prepared according to “Organikum”, 19^(th) edition, Dt. Verlag der Wissenschaften, Leipzig, Heidelberg, Berlin, 1993, Chapter 6, pages 374-375, starting from 130 g (1.0 mol) of 45 ethyl acetoacetate, 66 g (1.0 mol) of malonodinitrile, 32 g (1.0 mol) of sulfur and 80 g (0.92 mol) of morpholine.

¹H-NMR (270 MHz, DMSO-d₆): δ=1.25 (t, 3H), 2.3 (s, 3H), 4.2 (q, 2H), 7.9 (bs, 2H).

b) Ethyl-4-cyano-3-methylthiophene-2-carboxylate

A solution of 20.5 g (97.5 mmol) of ethyl 2-amino-3-cyano-4-methylthiophene-5-carboxylate in 600 ml of a 1:1 mixture of acetonitrile and dimethylformamide was cooled to 5° C., and 15.7 g (146 mmol) of tert-butyl nitrite were added dropwise, the reaction mixture heating up and vigorous gas evolution beginning. Stirring was carried out for seven hours at room temperature, the mixture was evaporated down in a rotary evaporator and under greatly reduced pressure, the residue was purified by column chromatography (mobile phase: dichloromethane) and 9.1 g (48%) of the desired compound were obtained as a yellow oil.

¹H-NMR (270 MHz, DMSO-d_(6): δ=)1.3 (t, 3H), 2.55 (s, 3H), 4.3 (q, 2H), 8.8 (s, 1H).

c) 5-Hydroxymethyl-4-methylthiophene-3-carbonitrile:

2.44 g (64 mmol) of lithium aluminum hydride were added a little at a time at 0° C. to a solution of 25.1 g (129 mmol) of ethyl 3-cyano-4-methylthiophene-5-carboxylate in 400 ml of tetrahydrofuran. Stirring was carried out for five hours at room temperature, excess reducing agent was destroyed by adding 0.5 N hydrochloric acid, and the reaction mixture was evaporated down under reduced pressure from a waterjet pump, diluted with water and extracted three times with ethyl acetate. The combined organic phases were then washed once with 0.5 N hydrochloric acid and once with saturated sodium chloride solution. The organic phase was dried over magnesium sulfate, the drying agent was filtered off and the solvent was distilled off under reduced pressure from a waterjet pump at room temperature. The residue was purified by column chromatography (mobile phase: 95:5 dichloromethane/methanol) and 16.1 g (83%) of the desired compound were obtained as light yellow oil.

¹H-NMR (270 MHz, DMSO-d₆): δ=2.2 (s, 3H), 4.6 (d, 2H), 5.7 (m, 1H), 8.35 (s, 1H).

d) 5-Bromomethyl-4-methylthiophene-3-carbonitrile:

30 g (115 mmol) of triphenylphosphine were added at 5° C. to a 45 solution of 16 g (104 mmol) of 5-hydroxymethyl-4-methylthiophene-3-carbonitrile in 300 ml of tetrahydrofuran. A solution of 38 g (115 mmol) of tetrabromomethane in 100 ml of tetrahydrofuran was then added. Stirring was carried out overnight at room temperature. The reaction mixture was evaporated down in a rotary evaporator under reduced pressure from a waterjet pump and the residue was purified by column chromatography (mobile phase: 1:1 petroleum ether: dichloromethane). 17 g (76%) of the title compound were obtained as a yellow oil.

¹H-NMR (270 MHz, DMSO-d₆): δ=2.25 (s, 3H), 5.0 (s, 2H), 8.5 (s, 1H).

e) 5-N,N-bis(tert-Butoxycarbonyl)aminomethyl-4-methylthiophene-3-carbonitrile:

3.5 g (103 mmol) of sodium hydride (oil-free) were added a little at a time to a solution, cooled to 0° C., of 17.2 g (79.5 mmol)of 5-bromomethyl-4-methylthiophene-3-carbonitrile in 250 ml of tetrahydrofuran. A solution of 22.5 g (103 mmol) of di-tert-butyl iminodicarboxylate in 100 ml of tetrahydrofuran was then added dropwise, the temperature not exceeding 5° C. The mixture was allowed to warm up to room temperature and was stirred for two hours. 400 ml of a saturated ammonium chloride solution was slowly added. The solvent was distilled off under reduced pressure from a waterjet pump and the residue was diluted with a little water and extracted three times with ethyl acetate. The combined organic phases were washed with saturated ammonium dichloride solution and with saturated sodium chloride solution, dried over magnesium sulfate and evaporated down in a rotary evaporator. 28 g of an oil which still contained di-tert-butyl iminodicarboxylate were obtained and said oil was used as a crude product in the following reaction.

¹H-NMR (270 MHz, DMSO-d₆): δ=1.4 (s, 9H), 1.45 (s, 9H), 2.3 (s, 3H), 4.8 (s, 2H), 8.4 (s, 1H).

f) 5-N,N-bis(tert-Butoxycarbonyl)aminomethyl-4-methylthiophene-3-thiocarboxamide

The crude product (max. 79 mmol) obtained from e) was dissolved in 280 ml of pyridine and 140 ml of triethylamine and saturated with hydrogen sulfide at room temperature. The previously yellow solution became green. Stirring was carried out overnight at room temperature. To complete the reaction, hydrogen sulfide was passed in for a further 15 minutes and stirring was carried out for a further two hours at room temperature. Excess hydrogen sulfide was expelled with the aid of a stream of nitrogen via a scrubbing tower. Thereafter, the reaction mixture was evaporated down in a rotary evaporator, taken up in ethyl acetate, washed several times with a 20% strength sodium bisulfate solution, dried over magnesium sulfate and evaporated down in a rotary evaporator. 27 g of a light yellow firm foam were obtained, and said foam was used without further purification in the following reaction.

¹H-NMR (270 MHz, DMSO-d₆): δ=1.4 (s, 18H), 2.15 (s, 3H), 4.8 (s, 2H), 7.5 (s, 1H), 9.3 (bs, 1H), 9.75 (bs, 1H).

g) 5-Aminomethyl-4-methylthiophene-3-thiocarboxamide Hydrochloride

27 g of 5-N,N-bis(tert-butoxycarbonyl)aminomethyl-4-methylthiophene-3-thiocarboxamide (crude product from f), not more than 70 mmol) were dissolved in 400 ml of ethyl acetate and cooled to 0° C. The solution was saturated with hydrogen chloride gas, a white precipitate separating out after 10 minutes. Stirring was carried out after two hours at room temperature, the precipitate was filtered off and washed with ethyl acetate and the solid residue was dried at room temperature under reduced pressure. 13.6 g (87%) of the title compound were obtained as a white powder.

EI-MS: M⁺=186.

5-Aminomethyl-4-chlorothiophene-3-thiocarboxamide

a) 5-Formyl-4-chlorothiophene-3-carbonitrile:

35 g (325 mmol) of tert-butyl nitrite were added dropwise at room temperature to a solution of 53.0 g (250 mmol) of 2-amino-4-chloro-5-formylthiophene-3-carbonitrile (the preparation of this compound is described in the patent DB 3738910) in 600 ml of a 1:1 mixture of acetonitrile and dimethylformamide, the reaction mixture warming up from 20° C. to 37° C. and vigorous gas evolution beginning. The mixture was cooled to 25° C. and stirred for seven hours at room temperature, the black solution was evaporated down in a rotary evaporator and under greatly reduced pressure, the residue was purified by column chromatography (mobile phase: dichloromethane) and 29 g (68%) of the desired compound were obtained as a yellow oil.

¹H-NMR (270 MHz, DMSO-d₆): δ=9.1 (s, 1H), 10.0 (s, 1H).

b) 5-Hydroxymethyl-4-chlorothiophene-3-carbonitrile:

6.3 g (166 mmol) of sodium borohydride were added a little at a time at 5° C. to a solution of 28.5 g (166 mmol) of 5-formyl-4-chlorothiophene-3-carbonitrile in 400 ml of absolute methanol. The reaction mixture warmed up slightly and acquired a dark red color. Vigorous gas evolution was observed. After ten minutes, the reaction mixture was evaporated down under reduced pressure from a waterjet pump, the residue was taken up in 200 ml of ethyl acetate and the solution was extracted with 200 ml of 1 M hydrochloric acid and the organic phase was washed with twice 250 ml of water and with saturated sodium chloride solution and dried over magnesium sulfate, the drying agent was filtered off and the solvent was distilled off under reduce pressure from a waterjet pump at room temperature. 22 g (76%) of the title compound were obtained as a dark red oil, which was used without further purification in the following reactions.

¹H-NMR (270 MHz, DMSO-d₆): δ=4.65 (bs, 1H), 5.95 (t, 2H), 8.6 (s, 1H).

c) 5-Bromomethyl-4-chlorothiophene-3-carbonitrile:

36.1 g (137 mmol) of triphenylphosphine were added at 5° C. to a solution of 21.7 g (125 mmol) of 5-hydroxymethyl-4-chlorothiophene-3-carbonitrile in 250 ml of tetrahydrofuran. A solution of 45.6 g (137 mmol) of tetrabromomethane in 100 ml of tetrahydrofuran was then added. Stirring was carried overnight at room temperature. The precipitate was filtered off, the filtrate was evaporated down in a rotary evaporator under reduced pressure from a waterjet pump and the residue was purified by column chromatography (mobile phase: 1:1 petroleum ether: dichloromethane). 26.0 g (88%) of the title compound were obtained as an oil.

¹H-NMR (270 MHz, DMSO-d₆): δ=4.95 (s, 2H), 8.8 (s, 1H).

d) 5-N,N-bis(tert-Butoxycarbonyl)aminomethyl-4-chlorothiophene-3-carbonitrile:

6.9 g (159 mmol) of sodium hydride (oil-free) were added a little at a time to a solution, cooled to 0° C., of 25.0 g (106 mmol) of 5-bromomethyl-4-chlorothiophene-3-carbonitrile in 300 ml of tetrahydrofuran. A solution of 34.4 g (159 mmol) of di-tert-butyl iminodicarboxylate in 100 ml of tetrahydrofuran was then added dropwise, the temperature not exceeding 5° C. The mixture was allowed to warm up to room temperature and was stirred for two hours. 300 ml of saturated ammonium chloride solution was slowly added. The solvent was distilled off under reduced pressure from a waterjet pump and the residue was diluted with a little water and extracted three times with ethyl acetate. The combined organic phases were washed with saturated ammonium chloride solution and with saturated sodium chloride solution, dried over magnesium sulfate and evaporated down in a rotary evaporator. 51.3 g of an oil which still contained di-tert-butyl iminodicarboxylate and solvent residues were obtained, and said oil was used as a crude product in the following reaction.

¹H-NMR (270 MHz, DMSO-d₆): δ=1.4 (s, 9H), 1.45 (s, 9H), 4.8 (s, 2H), 8.65 (s, 1H).

e) 5-N,N-bis(tert-Butoxycarbonyl)aminomethyl-4-methylthiophene-3-thiocarboxamide

A part of the crude product (39.4 g, max. 106 mmol) obtained from d) was dissolved in 400 ml of pyridine and 40 ml of triethylamine and saturated with hydrogen sulfide at room temperature. The previously yellow solution acquired a green color. Stirring was carried out overnight at room temperature. Excess hydrogen sulfide was expelled with the aid of a stream of nitrogen via a scrubbing tower. Thereafter the reaction mixture was poured into ice-cooled, 20% strength sodium bisulfate solution and extracted three times with ethyl acetate. The organic phase was then washed several times with 20% strength sodium bisulfate solution, dried over magnesium sulfate and evaporated down in a rotary evaporator. 49.0 g of a solvent-containing residue were obtained, and said residue was used without further purification in the following reaction.

¹H-NMR (270 MHz, DMSO-d₆): δ=1.4, 1.45 (s, 18H), 4.8 (s, 2H), 7.75 (s, 1H), 9.4 (bs, 1H), 10.0 (bs, 1H).

f) 5-Aminomethyl-4-chlorothiophene-3-thiocarboxamide Hydrochloride

38.0 g of the crude product from e), not more than 93 mmol, were dissolved in 400 ml of ethyl acetate and cooled to 0° C. The solution was saturated with hydrogen chloride gas, white precipitate separating out after 10 minutes. Since the reaction was not yet complete, 200 ml of ethyl acetate were added, the solution was saturated again with hydrogen chloride gas and stirring was carried out overnight at room temperature. The precipitate was filtered off, washed with petroleum ether and dried at room temperature under reduced pressure. 21.1 g of the title compound were obtained as a white powder which contained ammonium chloride as an impurity.

EI-MS: M⁺=206.

5-Aminomethyl-2-guanidinothiazole Bishydrochloride

a) N-Phthaloyl-5-aminomethyl-2-guanidinothiazole

A solution of 31 g (130 mmol) of N-phthaloyl-3-amino-2-chloropropionaldehyde (S. Marchais et al., Tetrahedron Letters 39 (1998), 8085-8088) and 15.4 g (130 mmol) of amidinothiourea in 200 ml of butanol was heated at 110° C. for 75 minutes under a nitrogen atmosphere, after which the reaction mixture was evaporated down under reduced pressure (1 mbar, bath temperature up to 50° C.) and methylene chloride and concentrated ammonia were added to the residue. A part of the product was precipitated from water. This was purified, together with the part obtained from the methylene chloride phase after drying and evaporating down, by column chromatography (silica gel; mobile phase: methylene chloride with a methanol content increasing from 0 to 5%). The predominantly pure fractions were then crystallized from acetone, 12.3 g of the title compound being obtained.

b) 5-Aminomethyl-2-guanidinothiazole Bishydrochloride

A solution of 5 g (16.6 mmol) of N-phthaloyl-5-aminomethyl-2-guanidinothiazole and 4.15 g (83 mmol) of hydrazine hydrate in 100 ml of methanol was stirred under a nitrogen atmosphere for one hour at room temperature, after which the reaction mixture was evaporated down under reduced pressure (1 mbar, bath temperature to 50° C.) and 70 ml of water and 20% strength hydrochloric acid were added to the residue until the pH reached 1, phthalylhydrazide being precipitated and then filtered off. The filtrate was evaporated down under reduced pressure and the residue was codistilled three times with methanol, dried at 50° C. under reduced pressure and then recrystallized from ethanol. 3.7 g of the title compound were obtained.

5-Amino-3-amidino-thiophene Bishydrochloride

The synthesis of this compound was carried out starting from 5-aminomethyl-3-cyanothiophene (WO 96/17860) by reaction with (Boc)₂O to give 5-tert-butoxycarbonylaminomethyl-3-cyanothiophene, conversion of the nitrile function into the corresponding thioamide by addition of hydrogen sulfide, methylation of the thioamide function with methyliodide, reaction with ammonium acetate to give the corresponding amidine and subsequent elimination of the protective group with hydrochloric acid and isopropanol to give 5-aminomethyl-3-amidinothiophene bishydrochloride.

3-Amidino-5-[N-1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl]-aminomethylthiophene Hydrochloride

3-Amidino-5-aminomethylthiophene bishydrochloride (1.3 g, 5.7 mmol) in DMF (15 ml) was initially taken and N,N-diisopropylethylamine (0.884 g, 6.84 mmol) was added. Stirring was carried out for 5 minutes at room temperature, after which 2-acetyldimedone (1.25 g, 6.84 mmol) and trimethyl orthoformate (3.02 g, 28.49 mmol) were added. Stirring was carried out for 2.5 hours at room temperature, after which the DMF was removed under greatly reduced pressure and the residue was stirred thoroughly with DCM (5 ml) and petroleum ether (20 ml). The solvent was decanted from slightly yellowish product, and the solid was dried under reduced pressure at 40° C. Yield: 1.84 g (5.2 mmol, 91%).

1H-NMR (400 MHz, [D₆]DMSO, 25° C., TMS): δ=0.97 (s, 6H); 2.30 (s, 4H); 2.60 (s, 4H); 4.96 (d, J=7 Hz, 2H); 7.63 (s, 1H); 8.60 (s, 1H); 9.07 (sbr, 2H); 9.37 (sbr, 1H).

Syntheses of Building Blocks:

A—B—D—E—OH (in appropriately protected form):

The E building blocks were partly converted into the corresponding benzyl esters (or methyl esters) and linked to the appropriately protected A—B—D—U building blocks (U is a leaving group). In the case of compounds still having a free N—H-function, this was then protected with a Boc-group, the benzyl ester group was eliminated by hydrogenolysis (or the corresponding methyl ester group was hydrolyzed) and the building block A—B—D—E—OH was purified by crystallization, salt precipitation or column chromatography. This route is described by way of example for tBuOOC—CH₂-(Boc)(D)Cha-OH in WO 98/06741.

A—B—D—E—G—OH (in appropriately protected form):

The preparation of the A—B—D—E—G—OH building blocks in appropriately protected form is described by way of example for N-Boc-N-(tert-butoxycarbonylmethylene)-(D)-cyclohexylalanyl-3,4-dehydroproline in WO 98/06741.

H—G—K—CN:

The preparation of the H—G—K—CN building block is described by way of example for prolyl-4-cyanobenzylamide in WO 95/35309, for 3,4-dehydroprolyl-4-cyanobenzylamide in WO 98/06740 and for 3,4-dehydroprolyl-5-(2-cyano)-thienylmethylamide in WO 98/06741.

In the examples which follow, complement inhibitors are mentioned:

EXAMPLE 1 CF₃—CH₂—SO₂-(D)Phe-Pro-NH-p-amb.CH₃COOH (WO 96/17860 Example 13) EXAMPLE 2 n-Octyl-SO₂-(D)Phe-Pro-NH-p-amb.CH₃COOH (WO 96/17860 Example 14) EXAMPLE 3 3-Py-SO₂-(D)Phe-Pro-NH-p-amb.CH₃COOH (WO 96/17860 Example 4) EXAMPLE 4 CH₃—SO₂-(D)Cha-Pyr-NH-p-amb.CH₃COOH

(Preparation analogous to WO 96/17860 Example 1) FAB-MS: (M+H⁺)=476.

EXAMPLE 5 H-(D)Val-Pro-NH-p-amb.2HCl (WO 95/35309 Example 151) EXAMPLE 6 Boc-(D)Asp(OBn)-Pro-NH-p-amb.CH₃COOH (WO 95/35309, intermediate of Example 179) FAB-MS: (M+H⁺)=552 EXAMPLE 7 2-C₆H₁₀—CH₂-Gly-Pro-NH-p-amb.2HCl

(Preparation analogous to WO 95/35309 Example 166) FAB-MS: (M+H⁺)=444.

EXAMPLE 8 C₆H₅—CH₂—CH₂—CO-Gly-Pro-NH-p-amb.HI

(Preparation analogous to WO 95/35309 Example 6) FAB-MS: (M+H⁺)=436.

EXAMPLE 9 C₆H₅—(CH₂)₃—CO-Gly-Pro-NH-p-amb.HI

(Preparation analogous to WO 95/35309 Example 6) FAB-MS: (M+H⁺)=450.

EXAMPLE 10 (D)(4-Me)Pic-Pro-NH-p-amb.2CH₃COOH

(Preparation analogous to WO 95/35309 Example 112) FAB-MS: (M+H⁺)=372.

EXAMPLE 11 H-(D)3-Tic-Pro-NH-p-amb.2CH₃COOH (WO 95/35309 Example 112) EXAMPLE 12 HO₃S—(CH₂)₃-(D)Phe-Pro-NH-p-amb.HCl

(The preparation of this compound was carried out by alkylating H-(D)Phe-Pro-NH—CH₂—pC₆H₄—CN with

The nitrile function was converted into the amidino group by hydrogenating the hydroxyamidine intermediate.) FAB-MS: (M+H⁺)=516.

EXAMPLE 13 CH₃—SO₂-(D)Cha-Pyr-NH-3-(6-am)-pico.CH₃COOH

(WO 96/24609 Example 8).

EXAMPLE 14 CH₃—SO₂-(D)Chg-Pro-NH-3-(6-am)-pico.CH₃COOH

(WO 96/24609 Example 6).

EXAMPLE 15 C₆H₅—CH₂—SO₂-(D)Cha-Pyr-NH-3-(6-am)-pico.CH₃COOH

(Preparation analogous to WO 96/24609 Example 8) FAB-MS: (M+H⁺)=553.

EXAMPLE 16 HOOC—CH₂—SO₂-(D)Chg-Pro-NH-3-(6-am)-pico.CH₃COOH

(WO 96/24609 Example 10).

EXAMPLE 17 CH₃OOC—CH₂—SO₂-(D)Chg-Pro-NH-3-(6-am)-pico.CH₃COOH

(WO 96/24609, intermediate in the preparation of Example 10) FAB-MS: (M+H⁺)=523.

EXAMPLE 18 HOOC—CH₂-(D)Chg-Pyr-NH-3-(6-am)-pico.CH₃COOH

(Preparation analogous to WO 96/25426 Example 93; described as a byproduct in the synthesis of Example 95 (WO 96/25426)) FAB-MS: (M+H⁺)=443.

EXAMPLE 19 HOOC—CH₂-HCha-Pyr-NH-3-(6-am)-pico

(Preparation analogous to WO 96/25426 Example 93) FAB-MS: (M+H⁺)=471.

EXAMPLE 20 Boc-NH-p-C₆H₄CH₂—SO₂-(D)Cha-Pyr-NH-3-(6-am)-pico-CH₃COOH

a) Methyl N-(4-Nitrobenzylsulfonyl)-(D)-cyclohexylalanine

2.6 g (25 mmol) of triethylamine, 2.6 g (25 mmol) of N-methylmorpholine and a solution of 5.9 g (25 mmol) of p-nitrobenzylsulfonyl chloride (J. E. Macor et al., THL 33 (1992), 8011) in 50 ml of methylene chloride were added dropwise at 0° C., while stirring, to a solution of 5.53 g (25 mmol) of methyl (D)-cyclohexylalanine hydrochloride in 150 ml of methylene chloride and 10 ml of acetonitrile. Stirring was carried out for a further 30 minutes, after which the yellow reaction solution was washed with water, 5% strength citric acid solution, 5% strength NaHCO₃-solution and again with water and was dried over Na₂SO₄ and the solvent was distilled off under reduced pressure. 10 g of slightly yellowish oil remained.

b) Methyl N-(4-Aminobenzylsulfonyl)-(D)-cyclohexylalanine

The above oil was dissolved in 250 ml of methanol, 1.5 g of 10% strength Pd/C were added and hydrogenation was carried out at room temperature with hydrogen. After the catalyst had been filtered off with suction, the methanol was distilled off under reduced pressure, crystallization beginning toward the end. The methanol-moist residue was substantially free from methanol by dissolving in methylene chloride and evaporating down again and, after dispersing with 1:4 toluene/n-hexane, was filtered off with suction. 8 g of the title compound (90% of theory), based on methyl D-cyclohexylalanine hydrochloride) were isolated as slightly yellowish crystals, m.p. 134-136° C., TLC: (9:1)CH₂Cl₂/acetone.

c) Methyl N-(4-tert-Butoxycarbonylaminobenzylsulfonyl)-(D)-cyclohexylalanine

A solution of 7.95 g (22.45 mmol) of the above compound and 5.4 g (24.7 mmol) of Boc₂O in 80 ml of THF was refluxed for 10 hours under nitrogen. The dark brown residue remaining after the solvent had been stripped off was purified over a silica gel column (eluent: 50:2.5 CH₂Cl₂/acetone). 8.85 g of the title compound (86.7% of theory) were isolated as white crystals (m.p. 143-144° C., TLC: 47:3 CH₂Cl₂/acetone) from the uniform fractions after treatment with n-hexane.

d) N-(4-tert-Butoxycarbonylaminobenzylsulfonyl)-(D)-cyclohexyl-alanine

40 ml of 1 n LiOH were added dropwise at 5° C., while stirring, to a solution of 8.85 g (19.5 mmol) of the above ester in 70 ml of dioxane, and stirring was continued for 20 hours at room temperature. According to TLC (9:1 CH₂Cl₂/acetone) traces of ester were still detectable. After the dropwise addition of 1 N HCl the pH was brought to 8, the dioxane was substantially distilled off and the residue was diluted with 1 liter of water. The aqueous phase was brought to pH 2 by adding KHSO₄ solution, covered with a layer of 500 ml of ethyl acetate and stirred for 2 hours. The organic phase was separated off, washed with water and dried over Na₂SO₄. The residue obtained after the solvent had been distilled off was digested at elevated temperature of 1,2-dichloroethane to remove traces of ester. After filtration with suction and washing with n-hexane, 7.1 g of the title compound were isolated as white crystals (m.p. 186-187° C. (decomposition), TLC: 20:5:1 CH₂Cl₂/acetone/acetic acid).

BocNH-p-C₆H₄CH₂—SO₂-(D)Cha-Pyr-NH-3-(6-CN)-pico

5.8 g of diisopropylamine followed by 11 ml (15 mmol) of a 50% strength solution of propanephosphoric anhydride in ethyl acetate were added dropwise at 0° C. to a suspension of 4.4 g (10 mmol) of N-(4-tert-butoxycarbonylaminobenzylsulfonyl)-(D)-cyclohexylalanine and 2.7 g (10 mmol) of 3,4-dehydroprolyl-(3-(6-cyano)picolyl)amide (prepared from Boc-3,4-dehydroprolyl(3-(6-carboxamido)picolylamide (WO 96/25426) by dehydration by means of trifluoroacetic anhydride and subsequent elimination of the Boc group) in 70 ml of methylene chloride, and stirring was carried out for 3 hours at 0° C.

The organic phase was washed with water, 5% strength NaHCO₃ solution and 5% strength citric acid solution, dried over Na₂SO₄ and evaporated to dryness. The remaining oily residue was purified by column chromatography (eluent: 45:5:4 CH₂Cl₂/acetone/methanol). The residue remaining after the eluent had been stripped off was converted into 5 g of white powder, m.p. 175-180° C. (decomposition), by treatment with ether.

f) Boc-NH-p-C₆H₄CH₂—SO₂-(D)Cha-Pyr-NH-3-(6-am)-pico.CH₃COOH

A solution of 3.12 g (4.8 mmol) are Boc-NH-p-C₆H₄—CH₂—SO₂-(D)Cha-Pyr-NH-3-(6-CN)-pico and 0.94 g (5.8 mmol) of L-acetylcysteine in 6 ml of methanol was heated at 50° C. for 4 hours while passing in ammonia.

To remove the ammonia, the methanol was distilled off and the residue was taken up again in 50 ml of methanol and converted into the acetate by means of an ion exchanger (acetate on polymeric carrier, Fluka 00402). After the methanol had been stripped off, the residue was purified by column chromatography (eluent: 43:7:1.5 CH₂Cl₂/methanol/50% strength acetic acid). 2.25 g of the title compound were obtained as the slightly yellowish powder by treating the pure acetate with ethyl acetate. FAB-MS: 668 (M+H⁺).

EXAMPLE 21 H₂N-p-C₆H₄CH₂—SO₂-(D)Cha-Pyr-NH-3-(6-am)-pico-HCl

1.7 g (2.3 mmol) of the compound of Example 20 were dissolved in 10 ml of isopropanol and 4.5 ml of 4 N hydrochloric acid and heated at 50° C. for 3 hours. After the solvent had been stripped off, the residue was treated with ether and the precipitated amorphous hydrochloride was filtered off with suction. This was dissolved in 200 ml of isopropanol with the addition of a little water at elevated temperatures, active carbon was added and the solution was filtered and was evaporated down to a volume of about 40 ml. The precipitated hydrochloride of the compound was filtered off with suction, 1.65 g of slightly yellowish crystals being obtained; TLC: 43:7:2 CH₂Cl₂/methanol/50% strength of acetic acid; FAB-MS: (M+H⁺)=568.

EXAMPLE 22

Boc-NH-p-C₆H₄—CH₂—SO₂-(D)Chg-Pyr-NH-3-(6-am)-pico.CH₃COOH (The preparation was carried out analogously to Example 20) FAB-MS (M+H⁺)=654.

EXAMPLE 23 H₂N-p-C₆H₄—CH₂—SO₂-(D)Chg-Pyr-NH-CH₂-3-(6-am)-pico.HCl

(The preparation was carried out starting from Example 22, analogously to Example 21); FAB-MS: (M+H⁺)=554.

EXAMPLE 24 HOOC—(CH₂)₅-(D)Chg-Pro-NH-3-(6-am)-pico.CH₃COOH

(The preparation was carried out analogously to WO 95/35309 Example 221) FAB-MS: (M+H⁺)=501.

EXAMPLE 25 C₂H₅OOC—(CH₂)₅-(D)Chg-Pro-NH-3-(6-am)-pico.CH₃COOH

(Preparation analogous to WO 95/35309 Example 221) FAB-MS: (M+H⁺)=529.

EXAMPLE 26 HOOC—(CH₂ )₄-(D)Chg-Pro-NH-3-(6-am)-pico.CH₃COOH

(Preparation analogous to WO 95/35309 Example 221) FAB-MS: (M+H⁺)=487.

EXAMPLE 27 t-BUOOC—(CH₂)₃-(D)Chg-Pro-NH-3-(6-am)-pico.CH₃COOH

(Preparation analogous to WO 95/35309 Example 221 stage c) FAB-MS: (M+H⁺)=529.

EXAMPLE 28 (C₆H₅—CH₂)₂-Gly-Pyr-NH-3-(6-am)-pico.CH₃COOH

(Preparation analogous to WO 96/25426 Example 33 from (C₆H₅—CH₂)₂-Gly-OH and H-Pyr-NH-CH₂-3-(6-CN-pico) FAB-MS: (M+H⁺)=483.

EXAMPLE 29 HOOC—CH₂-(D)Chg-Pyr-NH-CH₂-5-(2-am)-thioph.CH₃COOH (WO 98/06741 Example 3). EXAMPLE 30 HOOC—CH₂—CH₂-(D)Cha-Pro-NH-CH₂-5-(2-am)-thioph.CH₃COOH

(Preparation analogous to WO 98/06741 Example 1) FAB-MS: (M+H⁺)=479.

EXAMPLE 31 HOOC—CH₂-(D)Chg-Aze-NH-CH₂-5-(2-am)-thioph

(Preparation analogous to WO 98/06741 Example 3) FAB-MS: (M+H⁺)=436.

EXAMPLE 32 HOOC—CH₂-(D)Cha-Pyr-NH—CH₂-5-(2-am)-thioph.CH₃COOH

(WO 98/06741 Example 1).

EXAMPLE 33 HOOC—CH₂-(D)Cha-Thz-4-CO—NH—CH₂-5-(2-am)-thioph.2HCl

(Preparation analogous to WO 98/06741 Example 1) FAB-MS: (M+H⁺)=482.

EXAMPLE 34 HOOC—CH₂-(D)Cha-Pro-NH—CH₂-5-(3-am)-fur.CH₃COOH

(Preparation analogous to WO 98/06741 Example 10) FAB-MS: (M+H⁺)=448.

EXAMPLE 35 HOOC—CH₂-(D)Chg-Pyr-NH—CH₂-2-(4-am)-thiaz.2HCl

(WO 98/06741 Example 22).

EXAMPLE 36 HOOC—CH₂-(D)Chg-Pyr-NH—CH₂-5-(2-am-3-Cl)-thioph.2HCl

(Preparation analogous to WO 98/06741 Example 3) FAB-MS: (M+H⁺)=482.

EXAMPLE 37 HOOC—CH₂-(D)Cha-Pyr-NH—CH₂-5-(2-am-3-Cl)-thioph.2HCl

(Preparation analogous to WO 98/06741 Example 1) FAB-MS: (M+H⁺)=496.

EXAMPLE 38

HOOC—CH₂-(D)Cha-Pyr-NH—CH₂-5-(3-am)-thioph.CH₃COOH

(WO 98/06741 Example 5).

EXAMPLE 39 HOOC—CH₂-(D)Chg-Aze-NH—CH₂-5-(3-am)-thioph

(Preparation analogous to WO 98/06741 Example 8) FAB-MS: (M+H⁺)=436.

EXAMPLE 40 HOOC—CH₂(D)Chg-Pyr-NH—CH₂-5-(3-am)-thioph.CH₃COOH (WO 98/06741 Example 8) EXAMPLE 41 HOOC—CH₂-Cheg-Pyr-NH—CH₂-5-(3-am)-thioph.CH₃COOH

(Preparation analogous to WO 98/06741 Example 8) FAB-MS: (M+H⁺)=462.

EXAMPLE 42 HOOC—CH₂-Cpg-Pyr-NH—CH₂-5-(3-am)-thioph.CH₃COOH

(Preparation analogous to WO 98/06741 Example 8) FAB-MS: (M+H⁺)=434.

EXAMPLE 43 HOOC—CH₂-(D)Chg-Pro-NH—CH₂-5-(3-am).thioph.2HCl

(Preparation analogous to WO 98/06741 Example 8) FAB-MS: (M+H⁺)=450.

EXAMPLE 44 HOOC—CH₂-(D)Cha-Pyr-NH—CH₂-5-(3-am)-fur.CH₃COOH (WO 98/0671 Example 13) EXAMPLE 45 HOOC—CH₂-(D)Chg-Thz-2-CO—NH—CH₂-5-(3-am)-thioph

(Preparation analogous to WO 98/06741 Example 5) FAB-MS: (M+H⁺)=468.

EXAMPLE 46 HOOC—CH₂-(D)Cha-Thz-2-CO—NH—CH₂-5-(3-am)-thioph.2HCl

(Preparation analogous to WO 98/06741 Example 8) FAB-MS: (M+H⁺)=482.

EXAMPLE 47 HOOC—CH₂-(D)Cha-(L)Ohi-2-CO—NH—CH₂-5-(3-am)-thioph.HCl

(Preparation analogous to WO 98/06741 Example 8) FAB-MS: (M+H⁺)=518.

EXAMPLE 48 HOOC—CH₂-(D)Chg-(L)Ohi-2-CO—NH—CH₂-5-(3-am)-thioph.HCl

(Preparation analogous to WO 98/06741 Example 5) FAB-MS: (M+H⁺)=504.

EXAMPLE 49 HOOC—CH₂-(D)Chg-Pyr-NH—CH₂-5-(4-Cl-3-am)-thioph.CH₃COOH

(Preparation analogous to WO 98/06741 Example 5) FAB-MS: (M+H⁺)=482.

EXAMPLE 50 HOOC—CH₂(D)Cha-Pyr-NH—CH₂-5-(4-Cl-3-am)-thioph.CH₃COOH

(Preparation analogous to WO 98/06741 Example 8) FAB-MS: (M+H⁺)=496.

EXAMPLE 51 HOOC—CH₂-(D)Chg-Pyr-NH—CH₂-5-(4-Me-3-am)-thioph.CH₃COOH

(Preparation analogous to WO 98/06741 Example 5) FAB-MS: (M+H⁺)=462.

EXAMPLE 52 HOOC—CH₂-(D,L)Cpg-Pyr-NH—CH₂-5-(3-Me-3-am)-thioph.CH₃COOH

(Preparation analogous to WO 98/06741 Example 5) FAB-MS: (M+H⁺)=448.

EXAMPLE 53 HOOC—CH₂-(D)Cha-Pyr-NH—CH₂-5-(3-Me-2-am)-thioph.CH₃COOH

(Preparation analogous to WO 98/06741 Example 8) FAB-MS: (M+H⁺)=462.

EXAMPLE 54 N-(Hydroxycarbonyl-methylene)-(D)cyclohexylalanyl-

3,4-dehydroprolyl-[5-(2-guanidino)thiazolylmethyl]amide Bishydrochloride

a) N-(tert-Butoxycarbonyl-methylene)-(N-Boc)-(D)-cyclohexylalanyl-3,4-dehydroprolyl-[5-(2-guanidino)-thiazolylmethyl]-amide

7.28 g (15.15 mmol) of N-(t-BuO₂C—CH₂)-(N-Boc)-(D)-Cha-Pyr-OH, 3.7 g (15.15 mmol) of 5-aminomethyl-2-guanidinothiazole bishydrochloride and 7.8 g (10.3 ml of 60.6 mmol) of diisopropylethylamine in 90 ml of dichloromethane and 6 ml of DMF were initially taken and 6.46 g (19.7 mmol) of TOTU were added a little at a time, the temperature being kept at 20° C. After 90 minutes, (the TLC check indicated complete conversion), the reaction mixture was evaporated down under gentle conditions under a reduced pressure, and the residue was taken up in ethyl acetate, the solution was extracted in succession with water, dilute hydrochloric acid (pH 1.5) and saturated to sodium chloride solution (three times) and the organic phase was dried over magnesium sulfate and was evaporated down under reduced pressure. The crude product (9.3 g) was purified by column chromatography (silica gel; mobile phase, methylene chloride with a methanol content increasing from 0 to 5%). The virtually pure fractions (3.2 g) were further purified by crystallization from a hexane-ether mixture, 2.7 g of the title compound being obtained.

b) N-(Hydroxycarbonyl-methylene)-(D)-cyclohexylalanyl-3,4-dehydroprolyl-[5-(2-guanidino)thiazolylmethyl]amide Bishydrochloride

2.7 g (4.03 mmol) of N-(tert-butoxycarbonyl-methylene)-(N-Boc)-(D)-cyclohexylalanyl-3,4-dehydroprolyl-[5-(2-guanidino)-thiazolylmethyl]-amide were stirred in 190 ml of dichloromethane and 50 ml of 5 M solution of hydrochloric acid in ether for 17 hours at room temperature, a precipitate separating out. The reaction mixture was evaporated down under reduced pressure, codistilled several times with dichloromethane and finally thoroughly stirred in 1:1 ether/dichloromethane, 2.2 g of the title compound being obtained. FAB-MS (M+H⁺): 478.

EXAMPLE 55 HOOC-p-C₆H₄CH₂-(D)Cha-Pyr-NH—CH₂-5-(3-am)-thioph

The compound was prepared analogously to Example 56, starting from methyl D-cyclohexylalanine hydrochloride.

White, amorphous powder, FAB-MS (M−H⁺)=538. The intermediate N-(tert-butoxycarbonyl)-N-(4-tert-butoxycarbonylbenzyl)-D-cyclohexylamine was obtained in crystalline form, m.p. 119° C.

EXAMPLE 56 HOOC-p-C₆H₄—CH₂-(D)Chg-Pyr-NH—CH₂-5-(3-am)-thioph

a) Methyl N-(4-tert-Butoxycarbonylbenzyl)-D-cyclohexylglycine

A solution of 10 g (48.2 mmol) of methyl D-cyclohexylglycine hydrochloride, 13.1 g (38.3 mmol) of tert-butyl 4-bromomethyl-benzoate (A. Rosowsky et al. J. Med. Chem. 32 (1989), 709) and 15.6 g (121 mmol) of diisopropylethylamine in 50 ml of dimethylformamide were stirred for 16 hours at room temperature.

After the addition of 300 ml of water, extraction was carried out with methyl-tert-butylether (MTBE) and the organic phase was washed with 5% strength citric acid solution and water, dried over MgSO₄ and evaporated to dryness. The oily residue was purified by column chromatography (eluent: 50:1 CH₂Cl₂/MTBE) and gave 11.5 g (66% of theory) of the title compound as a colorless oil.

b) Methyl N-(tert-Butoxycarbonyl)-N-(4-tert-butoxycarbonylbenzyl)-D-cyclohexylglycine

A solution of 11.5 g (31.8 mmol) of the above compound, 10.4 g (47.7 mmol) of di-tert-butyl dicarbonate and 1.5 ml of diisopropylethylamine was stirred for 40 hours at room temperature under nitrogen. The acetonitrile was distilled off, the residue was taken up in MTBE and the solution was washed with 5% strength citric acid solution and water, dried over MgSO₄ and evaporated to dryness. After purification by column chromatography (eluent: 99:2 CH₂Cl₂/acetone), the residue gave 14 g (95% of theory) of the title compound as a colorless oil.

c) N-(tert-Butoxycarbonyl)-N-(4-tert-butoxycarbonylbenzyl)-D-cyclohexylglycine

60 ml of 1 N sodium hydroxide solution were added dropwise at 10° C. to a solution of 14 g (30.3 mmol) of the above compound in 100 ml of dioxane and stirring was carried out for 20 hours at 40° C. The pH of the reaction solution was brought to about 8 by adding citric acid, the dioxin was distilled off and aqueous phase was extracted with MTBE, acidified by further addition of citric acid and extracted several times with MTBE. The combined MTBE extract were dried over MgSO₄, the solvent was distilled off and the residue was crystallized by treatment with water-saturated n-hexane.

Yield: 7.2 g of the title compound (53% of theory), m.p. 154° C., R_(f) 0,39 (95:5 CH₂Cl₂/methanol).

d) N-(tert-Butoxycarbonyl)-N-(4-tert-butoxycarbonylbenzyl)-D-cyclohexylglycyl-3,4-dehydroproline

5.3 g (40.5 mmol) of diisopropylethylamine, followed by 10 ml of a 50% strength solution of propane phosphonic anhydride in ethyl acetate, were added dropwise at 0° C. to a suspension of 4.1 g (9 mmol) of the above compound and 1.5 g (9 mmol) of methyl 3,4-dehydroproline hydrochloride in 40 ml of CH₂Cl₂, and stirring was carried out for 2 hours at 0° C. and for 12 hours at room temperature. The working up was carried out analogously to Example 20, stage e). After purification by column chromatography (eluent: 50:5 CH₂Cl₂/ether), 2.1 g (41.2% of theory) of a slightly yellowish, amorphous powder were isolated. The hydrolysis to the acid was carried out analogously to stage c), a reaction time of 3 hours and a reaction temperature of 10° C. being sufficient. 1.8 g of the title compound were isolated as a white amorphous powder, TLC 50:1 ether/acetic acid.

e) N-Boc-N-(t-BuOOC-p-C₆H₄CH₂)-(D)Chg-Pyr-NH—CH₂-5-(3-am)-thio-phacetate

0.68 g (6.6 mmol) of N-methylmorpholine was added at 0° C., under nitrogen, to a suspension of 1.8 g (3.3 mmol) of the above acid and 0.75 g (3.3 mmol) of 5-aminomethyl-3-amidino-thiophene dihydrochloride. Addition of 1.9 g (5.8 mmol) of O-[cyano(ethoxycarbonyl)methyleneamino]-N,N,N′,N′-tetra-methyluronium tetrafluoroborate (TOTU) a little at a time gave a clear solution, which was stirred for 3 hours. The yellow reaction solution was evaporated down under reduced pressure at from 35 to 40° C. and the residue was digested three times with diisopropyl ether and, after dissolution in methanol, was converted into the acetate by means of an ion exchanger (acetate on polymeric carrier, Fluka 00402). After the eluent had been evaporated down, the crude acetate was purified by column chromatography (eluent: 40:10:0.5 CH₂Cl₂/methanol/50% strength acetic acid). 1.8 g of the title compound were isolated as a white amorphous powder, FAB-MS (M−H⁺)=580.

f) HOOC-p-C₆H₄CH₂-(D)Chg-Pyr-NH—CH₂-5-(3-am)-thioph

1.8 g of the above amidine compound were dissolved in 12 ml of glacial acetic acid, 12 ml of 4 N HCl in dioxane and 0.5 ml of water were added and the mixture was left to stand for 2.5 hours at room temperature.

After the solvent had been stripped off, the residue was treated with acetonitrile, the dihydrochloride separating out. This was dissolved in water for conversion into a monohydrochloride and was brought to a pH of 4.5 with a weakly basic ion exchanger (3-X4 Resin, BioRad). The aqueous solution was lyophilized after treatment with active carbon. 1.0 g of the title compound was obtained as lyophilized product, which was converted into a crystalline state by treatment with isopropanol, m.p. 230-233° C. (decomposition), FAB-MS (M+H⁺)=524.

EXAMPLE 57 MeOOC-p-C₆H₄CH₂-(D)Chg-Pyr-NH—CH₂-5-(3-am)-thioph.HCl

0.75 g (20 mmol) of hydrogen chloride was passed into a solution of 1.1 g (2 mmol) of the compound described in Example 56 in 70 ml of methanol and refluxing was then carried out for 8 hours.

The cooled solution was brought to pH 6 with a weakly basic ion exchanger (3-X4 Resin, BioRad), the methanol was distilled off and the viscous, oily residue was converted, by treatment with acetonitrile, into a slightly yellowish monohydrochloride which could be filtered off with suction. By dissolution in methanol, treatment with active carbon and removal of the methanol by distillation, finally with the addition of acetonitrile, 1.9 g of the title compound were isolated as white crystals, m.p. 215-220° C. (decomposition), FAB-MS (M+H⁺)=538; TLC: 20:5:1 CH₂Cl₂/methanol/50% strength acetic acid.

EXAMPLE 58 H₂N—CO-p-C₆H₄CH₂-(D)Chg-Pyr-NH—CH₂-5-(3-am)-thioph.HCl

0.6 g of the above compound (Example 57) was dissolved in 40 ml of methanol and the solution was heated at about 45° C. for 4 days while passing in ammonia. After the solvent had been stripped off, purification was carried out by column chromatography (eluent: 35:15:2.5 CH₂Cl₂/methanol/50% strength acetic acid). The residue was dissolved in water, the solution was brought to pH 2 with 1 N hydrochloric acid and was evaporated to dryness and the residue was again taken up in water, brought to pH 6 with a weakly basic ion exchanger and, after treatment with an active carbon, lyophilized. 0.28 g of the title compound was obtained as white, amorphous powder, FAB-MS M−H⁺)=523.

EXAMPLE 59 HOOC-m-C₆H₄CH₂-D(Chg)-Pyr-NH—CH₂-5-(3-am)-thioph

The title compound was obtained analogously to Example 56, starting from tert-butyl 3-bromomethylbenzoate (N. Shirai et al., J. Org. Chem. 55, (1990), 2767). White, amorphous powder, FAB-MS (M+H⁺)=524.

EXAMPLE 60 HOOC-p-C₆H₄CH₂-(D)Cha-Pyr-NH-3-(6-am)-pico.HCl

The preparation was carried out by reacting N-(tert-butoxycarbonyl)-N-(4-tert-butoxycarbonylbenzyl)-D-cyclo-hexylalanine (Example 55) with 3,4-dehydroprolyl-(3-(6-cyano)picolyl)amide (Example 20, stage e), then forming the amidine (Example 20, stage f) and eliminating the protective groups (Example 56, stage f).

Colorless, amorphous powder, FAB-MS (M+H⁺)=533.

EXAMPLE 61 HOOC-p-C₆H₄CH₂-(D)Chg-Pyr-NH-3-(6-am)-pico.HCl

The preparation was carried out analogously to Example 60. The starting material N-(tert-butoxycarbonyl)-N-(tert-butoxycarbonylbenzyl)-D-cyclohexylglycine is described in Example 56, stages a) to c).

Colorless, amorphous powder, FAB-MS (M+H⁺)=519.

EXAMPLE 62

N-(4-Hydroxycarbonyl-phenylsulfonyl)-(D)-cyclohexylglycyl-3,4-dehydroprolyl-[5-(3-amidino)thienylmethyl]amide: This compound is prepared by coupling (PPA, dichloromethane) H-Pyr-NH—CH₂-5-(3-CN)-thioph with Boc(D)Chg-OH to give Boc(D)Chg-Pyr-NH—CH₂-5-(3-CN)-thioph, eliminating the protective group (HCl in isopropanol) and then reacting (dichloromethane, DIPEA) with 4-HOOC—C₆H₄-SO₂Cl to give 4-HOOC—C₆H₄-SO₂-(D)Chg-Pyr-NH—CH₂-5-(3-CN)-thioph. After conversion of the nitrile function into the amidine function and purification by MPL chromatography, the title compound was obtained as a white amorphous powder. FAB-MS (M+H⁺): 574.

EXAMPLE 63

N-(3-Hydroxycarbonyl-phenylsulfonyl)-(D)-cyclohexylglycyl-3,4-dehydroprolyl-[5-(3-amidino)thienylmethyl]amide: This compound is prepared by coupling (PPA, dichloromethane) H-Pyr-NH—CH₂-5-(3-CN)-thioph with Boc(D)Chg-OH to give Boc(D)Chg-Pyr-NH—CH₂-5-(3-CN)-thioph, eliminating the protective group (HCl in isopropanol) and then reacting (dichloromethane, DIPEA) with 3-HOOC—C₆H₄-SO₂Cl to give 3-HOOC—C₆H₄—SO₂-(D)Chg-Pyr-NH—CH₂-5-(3-CN)-thioph. After conversion of the nitrile function into the amidine function and purification by MPL chromatography, the title compound was obtained as a white amorphous powder.

FAB-MS (M+H⁺): 574.

EXAMPLE 64 t-BuOOC-p-C₆H₄CH₂-(D)Chg-Pyr-NH—CH₂-5-(3-am)-thiop Acetate

a) N-(4-tert-Butoxycarbonylbenzyl)-D-cyclohexylglycine

96.3 ml (96.3 mmol) of 1 N sodium hydroxide solution were added dropwise at 10° C. to a solution of 29 g (80 mmol) of methyl N-(4-tert-butoxycarbonylbenzyl)-D-cyclohexylglycine (Example 56, stage a) and stirring was carried out for 48 hours at room temperature. After the addition of a further 0.3 equivalent of 1 N NaOH, stirring was carried out for a further 10 hours at 50° C. By adding 5% strength citric acid solution, the pH of the solution was brought to about 8, the dioxane was distilled off and the aqueous phase was extracted with MTBE and acidified by further addition of citric acid. The precipitated acid was taken up in ethyl acetate, the aqueous phase was extracted several times with ethyl acetate, the combined ethyl acetate extracts were dried with MgSO₄ and the solvent was then distilled off, the acid crystallizing out toward the end. Yield: 17.5 g of white crystals (63% of theory), m.p.>225° C. (decomposition).

b) N-(tert-Butoxycarbonyl)-3,4-dehydroprolyl-[2-(4-hydroxyamidino)thienylmethyl]amide

8 g of concentrated ammonia were added to a suspension of 15.6 g (224.5 mmol) of hydroxylamine hydrochloride in 300 ml of ethanol, stirring was carried out for 30 minutes, the precipitated NH₄Cl was filtered off with suction, 30 g (90 mmol) of N-(tert-butoxycarbonyl)-3,4-dehydroprolyl-[2-(4-cyano)thienylmethyl]amide (WO 98/06741, Examples 1 and 5) were then added and stirring was carried out overnight at room temperature. Thereafter, no starting material was detectable (TLC, mobile phase: CH₂Cl₂/MeOH, 9/1 or CH₂Cl₂/MeOH/concentrated ammonia, 4.5/5/0.3).

After the solvent had been distilled off, the residue was taken up in 300 ml of methylene chloride, and the solution was washed with water and aqueous NaHCO₃ solution and dried over Na₂SO₄. After evaporating down, 31.5 g (95.5% of theory) of amorphous residue remained, RF 0.32 (CH₂Cl₂/MeOH) [lacuna]/1, FAB-MS: 366 (M+).

c) N-(tert-Butoxycarbonyl)-3,4-dehydroprolyl-[2-(4-hydroxyamidino)thienylmethyl]amide

31.5 g (86 mmol) of the above hydroxyamidine compound were dissolved in 300 ml of glacial acetic acid under nitrogen, 17 g of zinc dust (<10 μm) were added a little at a time at from 40 to 50° C. and stirring was carried out for 6 hours at 40° C. Thereafter, no starting material was detectable (TLC, mobile phase: CH₂Cl₂/methanol, 9/1).

After removal of the solids by filtration with suction and washing with glacial acetic acid, the acetic acid was substantially distilled off, with addition of toluene toward the end. The residue was taken up in 350 ml of water, brought to pH 7 with 1 N sodium hydroxide solution and extracted once with 180 ml of MTBE. After addition of 200 ml of CH₂Cl₂, the aqueous phase was brought to pH 12, the CH₂Cl₂ phase was separated off and then extraction was carried out again and the combined CH₂Cl₂ phases were dried over Na₂SO₄. After distillation, 28.4 g (94% of theory) of amorphous residue remained, RF 0.35 (CH₂Cl₂/MeOH/50% strength acetic acid, 12/3/1), FAB-MS: 350 (M⁺).

c) 3,4-Dehydroprolyl-[2-(4-amidino)thienylmethyl]amide Dihydrochloride

28.4 g (81 mmol) of the above amidine were suspended in 450 ml of isopropanol, and 1215 ml of 4 N HCl in dioxane were added with stirring, a clear solution resulted in a short time, from which the dihydrochloride was slowly precipitated. The reaction mixture was stirred for 3 hours at room temperature and the crystals were filtered off with suction and washed thoroughly with cold isopropanol and finally with MTBE. After drying, 19.5 g (74.4% of theory) of the hygroscopic dihydrochloride remained, RF 0.53 (CH₂Cl₂/MeOH/H₂O/CF₃COOH, 24/9/1/0.5), FAB-MS: 250 (M⁺), m.p. 220-223° C. (decomposition).

d) t-BuOOC-p-C₆H₄CH₂-(D)Chg-Pyr-NH—CH₂-5-(3-am)-thioph Acetate

N-(4-t-Butoxycarbonylbenzyl)-D-cyclohexylglycine (stage a) and 3,4-dehydroprolyl-[2-(4-amidino)thienylmethyl]amide dihydrochloride were coupled analogously to Example 56, stage e, to give the end product. White amorphous powder, FAB-MS: 579 (M⁺).

EXAMPLE 65

HOOC-p-C₆H₄CH₂-(D)Val-Pyr-NH—CH₂-5-(3-am)-thioph HCl

a) Methyl N-(4-tert-Butoxycarbonylbenzyl)-D-valine

Prepared by reaction of methyl D-valine hydrochloride and tert-butyl 4-bromomethylbenzoate analogously to Example 56, stage a. The compound was obtained in 74% yield after chromatographic purification, FAB-MS: 321 (M⁺).

b) N-(4-tert-Butoxycarbonylbenzyl)-D-valine

The hydrolysis was carried out analogously to Example 64, stage a. White crystals, m.p. 224-226° C. (decomposition), FAB-MS: 307 (M⁺).

c) t-BuOOC-p-C₆H₄CH₂-(D)Val-Pyr-NH—CH₂-5-(3-am)-thioph Acetate

N-(4-t-Butoxycarbonylbenzyl)-D-valine and 3,4-dehydroprolyl-[2-(4-amidino)thienylmethyl]amide dihydrochloride (Example 64, stage c) were coupled analogously to Example 56, stage e. After purification by column chromatography (eluent: CH₂Cl₂/MeOH/50% strength CH₃COOH, 20/5/1), 3.1 g of white amorphous powder were isolated, FAB-MS: 539 (M⁺).

d) HOOC-p-C₆H₄CH₂-(D)Val-Pyr-NH—CH₂-5-(3-am)-thioph HCl

The hydrolysis of the tert-butyl ester was carried out analogously to Example 56, stage f. After freeze-drying, 1.6 g of lyophilized product were isolated, FAB-MS: 483 (M⁺).

The following compounds were obtained analogously to Examples 56 and 64:

EXAMPLE 66 HOOC-m-C₆H₄CH₂-(D)Val-Pyr-NH—CH₂-5-(3-am)-thioph HCl

White amorphous powder, FAB-MS: 483 (M⁺).

EXAMPLE 67 HOOC-p-C₆H₄CH₂-(D)tBu-Ala-Pyr-NH—CH₂-5-(3-am)-thioph Acetate

White amorphous powder, FAB-MS: 511 (M⁺).

EXAMPLE 68 HOOC-p-C₆H₄CH₂-(D)tBu-Gly-Pyr-NH—CH₂-5-(3-am)-thioph HCl

White amorphous powder, FAB-MS: 497 (M⁺).

EXAMPLE 69 HOOC-p-C₆H₄CH₂-Pyr-NH—CH₂-5-(3-am)-thioph HCl

White amorphous powder, FAB-MS: 441 (M⁺).

EXAMPLE 70 HOOC-m-C₆H₄CH₂-Gly-Pyr-NH—CH₂-5-(3-am)-thioph HCl

White amorphous powder, FAB-MS: 441 (M⁺).

EXAMPLE 71 H₂N-p-C₆H₄CH₂—SO₂-(D)CHa-Pyr-NH—CH₂-(3-am)-thioph HCl

N-(4-tert-Butoxycarbonylaminobenzylsulfonyl)-D-cyclohexylalanine (preparation: Example 20, stage d) and 3,4-dehydroprolyl-[2-(4-amidino)thienylmethyl]amide dihydrochloride (Example 64, stage c) were coupled analogously to Example 56, stage c, and the tert-butoxycarbonyl protective group was then eliminated analogously to Example 21. White, amorphous powder, FAB-MS: 572 (M⁺).

EXAMPLE 72 H₂N-p-C₆H₄CH₂-SO₂-(D)Chg-Pyr-NH—CH₂-(3-am)-thioph HCl

Preparation analogous to Examples 20 and 21. The intermediates methyl N-(4-nitrobenzylsulfonyl)- and N-(4-aminobenzylsulfonyl)-(D)-cyclohexylglycine were obtained as slightly yellowish crystals, m.p. 137° C. and 181° C., respectively.

White, amorphous powder, FAB-MS: 558 (M⁺).

EXAMPLE 73 H₂N-p-C₆H₄CH₂-(D)Val-Pyr-NH—CH₂-5-(3-am)-thioph 2HCl

The preparation was carried out analogously to Examples 20 and 21.

Intermediates: methyl N-(4-nitrobenzylsulfonyl)-(D)-valine, slightly yellowish crystals, m.p. 98-100° C., FAB-MS: 330 (M⁺); methyl N-(4-aminobenzylsulfonyl)-(D)-valine, slightly yellowish crystals, m.p. 96-98° C., FAB-MS: 300 (M⁺); methyl N-(4-tert-butoxycarbonylaminobenzylsulfonyl)-D-valine white crystals, m.p. 150-152° C., (i-propanol); N-(4-tert-butoxycarbonylaminobenzylsulfonyl)-D-valine, colorless crystals, m.p. 177-180° C. (decomposition), FAB-MS: 386 M⁺).

The end product was isolated as lyophilized product, FAB-MS: 558 (M⁺).

EXAMPLE 74 H₂N-SO₂-p-C₆H₄CH₂-(D)Chg-Pyr-NH—CH₂-5-(3-am)-thioph HCl

a) Methyl N-(4-Sulfonamidobenzyl)-D-cyclohexylglycine

7.3 g of diisopropylethylamine were added dropwise at room temperature to a solution of 5.2 g (25 mmol) of methyl D-cyclohexylglycine hydrochloride and 5.5 g (22 mmol) of 4-bromomethylbenzenesulfonamide (F. Amer. Chem. Soc. 79 (1957), 4232) in 30 ml of DMF, the temperature increasing to 26° C. The colorless solution remained standing overnight at room temperature. Thereafter, no starting material was detectable. (TLC, CH₂Cl₂/ether, 5/2).

After dilution with 100 ml of ice water, the white precipitate which separated out was filtered off with suction, washed with water and dissolved in ethyl acetate. The ethyl acetate phase was washed several times with sodium chloride solution and dried over Na₂SO₄, and the solvent was distilled off. The residue was recrystallized from 50 ml of isopropanol. 4.8 g (64% of theory) of white crystals were obtained, m.p. 113-114° C., FAB-MS: 340 (M⁺).

b) N-(4-Sulfonamidobenzyl)-D-cyclohexylglycine

4.0 g (11.8 mmol) of the above ester were suspended in 50 ml of water, brought into solution by adding 35 ml of 1 N NaOH and allowed to stand overnight at room temperature. A pH of 5 was established by dropwise addition of 10% strength hydrochloric acid, a fine precipitate separating out. A structure which could be readily filtered off with suction was obtained by brief heating to 80°, slow cooling to room temperature and stirring for 30 minutes while cooling in an ice bath. After being filtered off with suction, the precipitate was washed chloride-free with cold water, then digested with 50 ml of acetone, filtered off with suction again and then washed several times with an acetone/ether mixture and dried. 3.6 g (93.5% of theory) of white powder remained, said powder being extremely sparingly soluble.

c) H₂N-SO₂-p-C₆H₄CH₂-(D)Chg-Pyr-NH—CH₂-5-(3-am)-thioph HCl

Coupling to give the end product was carried out analogously to Example 56, stage e. 1 g of a lyophilized product was obtained, FAB MS: 558 (M⁺).

EXAMPLE 75 HO₃S-p-C₆H₄CH₂-(D)Chg-Pyr-NH—CH₂-5-(3-am)-thioph

4-Bromomethylbenzenesulfonic acid (F. Med. Chem. 33 (1990), 2437) was reacted with methyl D-cyclohexylglycine hydrochloride analogously to Example 74 and the reaction product was hydrolyzed and was then coupled with 3,4-dehydroprolyl-[2-(4-amidino)thienylmethyl]amide dihydrochloride.

White amorphous powder, FAB-MS: 559 (M⁺).

EXAMPLE 76 HO-p-C₆H₄CH₂-(D)Chg-Pyr-NH—CH₂-5-(3-am)-thioph 2HCl

a) Methyl N-(4-tert-Butoxybenzyl)-D-cyclohexylglycine

5.2 g (25 mmol) of methyl D-cyclohexylglycine hydrochloride were dissolved in 200 ml of toluene with gentle heating, 2.6 g (25.7 mmol) of triethylamine were added and stirring was carried out for 1 hour. The triethylamine hydrochloride was filtered off with suction and washed with toluene, after which the filtrate was evaporated down to 70 ml, 4.5 g (25 mmol) of p-tert-butoxybenzaldehyde and 0.1 ml of glacial acetic acid were added and refluxing was carried out for 2.5 hours under a water separator. The toluene was distilled off under reduced pressure, the residue was dissolved in 50 ml of methanol, 1.5 g (25 mmol) of glacial acetic acid were added and 0.9 g of sodium cyanoborohydride was introduced a little at a time at 5° C. (TLC check: CH₂Cl₂/E₂O, 25/1). The methanol was distilled off, excess 5% strength NaHCO₃ was added to the residue and extraction was carried out with ether. After washing the ether phase with sodium chloride solution, drying over Na₂SO₄ and distilling off the ether, the oily residue was purified by column chromatography (eluent: CH₂Cl₂/E₂O, 25/1).

Yield: 4.3 g (51% of theory), colorless oil; FAB-MS: 333 (M⁺).

Analogously to Example 74, the above ester was hydrolyzed and was coupled with 3,4-dehydroprolyl-[2-(4-amidino)thienylmethyl]amide dihydrochloride, and the tert-butyl group was eliminated by means of hydrochloric acid. Amorphous, white powder, FAB-MS: 495 (M⁺).

EXAMPLE 77 HO-p-C₆H₄CH₂-(D)Val-Pyr-NH—CH₂-5-(3-am)-thioph 2HCl

The preparation was carried out analogously to Example 76. White, amorphous powder, FAB-MS: 455 (M⁺).

EXAMPLE 78 HOCH₂-p-C₆H₄CH₂-(D)Val-Pyr-NH—CH₂-5-(3-am)-thioph HCl

The preparation was carried out starting from 4-(hydroxymethyl)benzyl chloride (J. Org. Chem. 61 (1996), 449), analogously to Example 76.

White, amorphous powder, FAB-MS: 469 (M⁺).

EXAMPLE 79 O₂N-p-C₆H₄CH₂-(D)Val-Pyr-NH—CH₂-5-(3-am)-thioph HCl

The preparation was carried out analogously to Example 76. Slightly yellowish, amorphous powder, FAB-MS: 484 (M⁺).

EXAMPLE 80 HOOC-p-C₆H₄CH₂-(D)Val-Pyr-NH—CH₂-5-(3-am)-thioph HCl

4-(tert-Butoxycarbonyl)benzylsulfonyl Chloride

A suspension of 15 g (55 mol) of tert-butyl 4-bromomethylbenzoate and 6.95 g (55 mol) of sodium sulfite in 28.5 ml of water and 13.5 ml of DMF was heated at 80-90° C. for 4 hours while stirring, after addition of 0.4 g of Adogen®. After cooling to room temperature, 100 ml of water were added, extraction was effected ith twice 100 ml of MTBE, 250 ml of MeOH were added to the aqueous phase, the precipitated salts were filtered off with suction and the filtrate was evaporated down, under reduced pressure from an oil pump toward the end. The residue was digested with 200 ml of MeOH, insoluble solid components were filtered off with suction and the methanol was distilled off, after repeated addition of ethanol/toluene toward the end. The residue (16.1 g) was suspended in 200 ml of CH₂Cl₂, 0.8 g of etraethylbenzylammonium chloride was added, 15 g of oxalyl ichloride were added dropwise at 0° C. and refluxing was carried out for 30 minutes. Undissolved matter was filtered off with suction and the CH₂Cl₂ phase was washed with 5% strength NaHCO₃ solution, dried over Na₂SO₄ and distilled off. By treatment with n-hexane, 6.6 g of virtually white crystals were isolated, m.p. 82-83° C. (decomposition).

Analogously to Example 76, reaction was carried out with methyl D-valine hydrochloride, hydrolysis was effected to give the acid, coupling was carried out with 3,4-dehydroprolyl-[2-(4-amidino)thienylmethyl]amide dihydrochloride and the tert-butyl ester group was eliminated.

White, amorphous powder, FAB-MS: 547 (M⁺).

EXAMPLE 81 HOOC-p-C₆H₄CH₂—SO₂-(D)Chg-Pyr-NH—CH₂-5-(3-am)-thioph HCl

The preparation was carried out analogously to Examples 80 and 76.

White, amorphous powder, FAB-MS: 587 (M⁺).

EXAMPLE 82 trans-HOOC-4-Cyclohexylmethyl-Gly-Pyr-NH—CH₂-5-(3-am)-thioph 2HCl

a) trans-4-[N-(o-Nitrophenylsulfonyl)]aminomethylcyclohexane-carboxylic Acid

A solution of 29.9 g (0.135 mol) of o-nitrobenzenesulfonyl chloride in 150 ml of dioxane and 150 ml of 1 N NaOH was added simultaneously and dropwise at 4° C. (ice bath) to a solution of 14.13 g (0.09 mol) of trans-4-(aminomethyl)cyclohexanecarboxylic acid in a two-phase system comprising 90 ml of 1 N NaOH and 90 ml of dioxane. After the slightly exothermic reaction had died down, stirring was carried out for 30 minutes at room temperature, the precipitate which separated out was filtered off with suction and washed with a little ice water and the filtrate was evaporated down under reduced pressure, further precipitation of salt occurring. The combined amounts of salt were digested with ether, suspended in water, acidified with 1 M KHSO₄ solution and extracted with ethyl acetate. The ethyl acetate phase was washed with sodium chloride solution, dried over Na₂SO₄ and evaporated down under reduced pressure.

The residue was recrystallized from acetonitrile. Yield: 27.4 g (89% of theory), m.p. 179° C.

b) tert-Butyl trans-4-[N-(o-Nitrophenylsulfonyl)]aminomethylcyclohexane Carboxylate

11.3 g (90 mmol) of oxalyl dichloride were added dropwise at 0° to a solution of 20.4 g (60 mmol) of the above compound and 0.1 ml of DMF in 350 ml of CH₂Cl₂, and the mixture was then heated until the gas evolution had ended. After the methylene chloride had been distilled off—with the addition of toluene toward the end—the residue was dissolved in ml of methylene chloride and was added dropwise to a solution of 6.1 g (83 mmol) of tert-butanol and 9.4 g (119 mmol) of pyridine in 60 ml of CH₂Cl₂ while cooling with ice. The reaction mixture remained standing at room temperature for 24 hours and was then washed with 1 N KHSO₄ solution, water and NaHCO₃ solution and dried over Na₂SO₄, and the solvent was distilled off. The residue was recrystallized from cyclohexane/ethyl acetate (95/5) and gave 9.3 g of slightly yellowish crystals, m.p. 114° C.

c) tert-Butyl trans-4-[N-(o-Nitrophenylsulfonyl)-N-(methoxycarbonylmethyl)]aminomethylcyclohexanecarboxylate

A solution of 2.68 g (6.7 mmol) of the above compound and 1.23 g (7.6 mmol) of methyl bromoacetate in 50 ml of DMF was stirred overnight at room temperature with the addition of 1.85 g (13.4 mmol) of K₂CO₃ powder (TLC: ethyl acetate/n-hexane, 1/1). 100 ml of water were added to the reaction mixture, extraction was effected several times with ethyl acetate, the combined ethyl acetate extracts were washed with sodium chloride solution and dried over Na₂SO₄ and the solvent was distilled off. After purification by column chromatography (eluent: ethyl acetate/n-hexane, 1/1) and crystallization from ether/n-hexane, 2.6 g (82.3% of theory) of yellowish crystals were obtained, m.p. 123-124° C.

d) tert-Butyl trans-4-[N-(o-Nitrophenylsulfonyl)-N-(hydroxycarbonylmethyl)]aminomethylcyclohexanecarboxylate

The methyl ester group of the above compound was hydrolyzed analogously to Example 20, stage d. Viscous yellow oil, FAB-MS: 456 (M⁺), TLC: ethyl acetate/n-hexane/glacial acetic acid, 34/15/1.5.

e) trans-t-BuOOC-4-Cyclohexylmethyl-(o-NO₂-C₆H₄SO₂)Gly-Pyr-NH—CH₂-5-(3-CN)-thioph

The above acid was coupled with 3,4-dehydroprolyl-[2-(4-cyano)thienylmethyl]amide hydrochloride analogously to Example 20, stage e. Amorphous, yellowish residue, FAB-MS: 671 (M⁺), TLC: CH₂Cl₂/acetone/methanol, 45/5/1.

f) trans-t-BuOOC-4-Cyclohexylmethyl-Gly-Pyr-NH—CH₂-5-(3-N)-thioph

A solution of 3.5 g (5.5 mmol) of the above compound and 0.7 g (6.35 mmol) of thiophenol in 10 ml of DMF was stirred overnight at room temperature with the addition of 2.5 g (18.1 mmol) of K₂CO₃ powder. 100 ml of ice water were added to the yellow reaction mixture, extraction was effected with 4×35 ml of ethyl acetate, the ethyl acetate extracts were washed with sodium chloride solution and dried over Na₂SO₄ and the viscous yellow oil obtained after distilling off the solvent was purified by column chromatography (eluent: CH₂Cl₂/methanol, 50/4). 2.3 g of yellowish amorphous residue were obtained, FAB-MS: 486 (M⁺).

g) trans-HOOC-4-Cyclohexylmethyl-Gly-Pyr-NH-5-(3-am)-thioph 2HCl

The amidine formation was carried out analogously to Example 64, stages b and c. The hydrolysis of the tert-butyl ester was carried out with 4 N hydrochloric acid in dioxane. 1.1 g of lyophilized product were obtained, FAB-MS: 447 (M⁺), TLC: CH₂Cl₂/MeOH/50% strength glacial acetic acid, 35/15/6.

EXAMPLE 83 trans-HOOC-4-Cyclohexylmethyl-(D)Chg-Pyr-NH—CH₂-5-(3-am)-thioph 2HCl

1.9 ml (11 mmol) of trifluoromethanesulfonic anhydride and then 1.2 g (11 mmol) of 2,6-lutidine were added dropwise at −8° C. to a solution of 1.72 g (10 mmol) of methyl S-hexahydromandelate while stirring. After stirring for 20 minutes at 0° C. (TLC: Et₂O/n-hexane, 3/2), a solution of 5.3 g (24.9 mmol) of tert-butyl trans-4-(aminomethyl)cyclohexanecarboxylate and 2.6 g (20 mmol) of diisopropylethylamine in 20 ml of CH₂Cl₂ was added dropwise and stirring was carried out for a further 2 hours at 0° C. and overnight at room temperature (TLC: CH₂Cl₂/ether, 25/3).

The reaction solution was washed with water, with twice 10 ml 1 N hydrochloric acid and with 5% strength NaHCO₃ solution and dried over Na₂SO₄, the solvent was distilled off and the residue was purified by column chromatography (eluent: CH₂Cl₂/ether, 10/1). 2.7 g of a slightly yellowish oil were isolated, which oil was hydrolyzed analogously to Example 56, stage c, to give the acid and then coupled analogously to stage e with 3,4-dehydroprolyl[2-(4-amidino)thienylmethyl]amide dihydrochloride. After hydrolysis of the tert-butyl ester group with 4 N hydrochloric acid in dioxane, the residue was freeze-dried to give a slightly yellowish amorphous powder, FAB-MS: 529 (M⁺), TLC: CH₂Cl₂/MeOH/50% strength acetic acid, 35/15/3.

EXAMPLE 84 4-Benzoylbenzoyl-Ala-Pro-5-(3-am)-thioph

a) 3 g (1.62 mmol) p-nitrophenyl carbonate Wang resin (Novabiochem, substitution 0.54 mmol/g) were suspended in 20 ml of DMF and shaken with 1.15 g (3.24 mmol) of 4-amidino-2-[N-1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl]aminomethylthiophene hydrochloride and 4.48 ml (32.4 mmol) of triethylamine for 4 days at room temperature. The solid was filtered off with suction and was washed with DMF, CH₂Cl₂, methanol and CH₂Cl₂. The resin was then treated with 0.5 M NH₄OAc solution in methanol (3×10 min), washed with methanol, DMF and CH₂Cl₂ and dried under reduced pressure at room temperature. To eliminate the Dde protective group, the resin was treated with 20 ml of a 2% strength solution of hydrazine hydrate in DMF at room temperature for 5 minutes. The solid was filtered off with suction and was washed with DMF. The elimination was repeated twice. Thereafter, the residue was washed with DMF, CH₂Cl₂, methanol and CH₂Cl₂ and was dried under reduced pressure at room temperature (weight obtained: 2.84 g).

b) A solution of 0.088 mmol of 2(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate in 0.5 ml of dimethylformamide was added at room temperature to 0.044 mmol of a resin from a), 0.088 mmol of Fmoc-Pro-OH and 0.088 mmol of N,N,-diisopropylethylamine in 1.5 ml of dimethylformamide and stirring was carried out for 2 hours at room temperature. The solid was then filtered off with suction and was washed with dimethylformamide, CH₂Cl₂, methanol and CH₂Cl₂. The elimination of the Fmoc-protective group was carried out with 2 ml of a solution of 10% of (1,8-diazabicyclo-[5.4.0.]undec-7-ene), 2% of piperidine and 88% of dimethylformamide (3 min). Thereafter, the resin was filtered off with suction and was washed with dimethylformamide, CH₂Cl₂, methanol and CH₂Cl₂.

c) The resin from b) was suspended in a solution of 0.088 mmol of Fmoc-Ala-OH and 0.088 mmol of N,N,-diisopropylethylamine in 1.5 ml of dimethylformamide, a solution of 0.088 mmol of 2-(1H-benzotriazol-1-yl-)-1,1,3,3-tetramethyluronium tetrafluoroborate in 0.5 ml of dimethylformamide was added and stirring was carried out for 2 hours at room temperature. Thereafter, the solid was filtered off with suction and was washed with dimethylformamide, CH₂Cl₂, methanol and CH₂Cl₂. The elimination of the Fmoc protective group was carried out with 2 ml of a solution of 10% of (1,8-diazabicyclo[5.4.0.]undec-7-ene), 2% of piperidine and 88% of dimethylformamide (3 min). Thereafter, the resin was filtered off with suction and was washed with dimethylformamide, CH₂Cl₂, methanol and CH₂Cl₂.

d) The resin from c) was suspended in a solution of 0.088 mmol of 4-benzoylbenzoic acid in 1 ml of CH₂Cl₂, and 0.088 mmol of diisopropylcarbodiimide in 0.5 ml of CH₂Cl₂ was added. Stirring was carried out for 2 hours at room temperature, after which the solid was filtered off with suction and was washed with dimethylformamide, CH₂Cl₂, methanol and CH₂Cl₂. The elimination of the product from the carrier was carried out by treatment with 95:5 trifluoroacetic acid/water (1 h/room temperature).

Yield: 13 mg. HPLC-MS: M+H⁺ 532 (calculated: 532).

The following examples were prepared analogously to Example 84, where, for example, reductive aminations of the resin can be carried out with, for example, 4-carboxybenzaldehyde or other aldehydes under standard conditions with sodium cyanoborohydride in 1% AcOH/DMF instead of the final coupling.

EXAMPLE 85 3-Benzoylbenzoyl-Gly-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 518.

EXAMPLE 86 4-Benzoylbenzoyl-Gly-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 518.

EXAMPLE 87 4-Phenylbenzoyl-Gly-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 490.

EXAMPLE 88 4-Phenylphenylacetyl-Gly-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 504.

EXAMPLE 89 2-(Benzylthio)-benzoyl-Gly-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 536.

EXAMPLE 90 3-Phenylpropionyl-Gly-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 442.

EXAMPLE 91 4-Phenylbutyryl-Gly-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 456.

EXAMPLE 92 5-Phenylvaleryl-Gly-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 470.

EXAMPLE 93 Cinnamoyl-Gly-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 440.

EXAMPLE 94 C₆H₅—C≡C—CO-Gly-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 438.

EXAMPLE 95 9-Fluorenone-4-carbonyl-Gly-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 516.

EXAMPLE 96 3-Benzyloxycarbonylpropionyl-Gly-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 500.

EXAMPLE 97 4-Methoxycarbonylcinnamoyl-Gly-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 498.

EXAMPLE 98

4-Methoxycarbonylbenzoyl-Gly-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 472.

EXAMPLE 99 2-(4′-Chloro-3′-nitrobenzoyl)-benzoyl-Gly-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 597.

EXAMPLE 100 6-(Acetylamino)-pyridyl-3-carbonyl-Gly-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 472.

EXAMPLE 101 3-(3′-Pyridyl)-acryloyl-Gly-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 441.

EXAMPLE 102 4-Acetylaminobenzoyl-Gly-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 471.

EXAMPLE 103

4-(4′-Aminophenoxy)-benzoyl-Gly-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 521.

EXAMPLE 104 4-(2′-Chloro-4′-aminophenoxy)-benzoyl-Gly-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 555.

EXAMPLE 105 4-Aminobenzoyl-Gly-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 486.

EXAMPLE 106 (4-Aminophenyl)acetyl-Gly-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 443.

EXAMPLE 107 (4-Aminophenylthio)-acetyl-Gly-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 475.

EXAMPLE 108 2-(Pyrid-3-yl)-acetyl-Gly-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 429.

EXAMPLE 109 3-(4′-Aminobenzoyl)-butyryl-Gly-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 499.

EXAMPLE 110 4-Benzoylbenzoyl-(D)-Val-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 560.

EXAMPLE 111 4-Phenylphenylacetyl-(D)-Val-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 546.

EXAMPLE 112 4-Phenylphenylacetyl-(D)-Ala-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 518.

EXAMPLE 113 4-Benzoylbenzoyl-β-Ala-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 532.

EXAMPLE 114 4-Benzoylbenzoyl-(D)-Ala-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 532.

EXAMPLE 115 2-(Benzylthio)-benzoyl-(D)-Ala-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 550.

EXAMPLE 116 5-Phenylvaleryl-(D)-Val-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 512.

EXAMPLE 117 5-Phenylvaleryl-(D)-Ala-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 484.

EXAMPLE 118 5-Phenylvaleryl-Ala-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 484.

EXAMPLE 119 3-Phenylpropionyl-(D)-Val-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 484.

EXAMPLE 120 4-Phenylbutyryl-(D)-Val-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 498.

EXAMPLE 121 4-Phenylbutyryl-(D)-Ala-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 470.

EXAMPLE 122

4-Phenylbenzoyl-(D)-Val-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 532.

EXAMPLE 123 4-Phenylbenzoyl-Ala-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 504.

EXAMPLE 124 4-Phenylbenzoyl-Val-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 532.

EXAMPLE 125 3-Phenylpropionyl-(D)-Ala-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 456.

EXAMPLE 126 2-(Benzylthio)-benzoyl-(D)-Val-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 578.

EXAMPLE 127 5-Phenylvaleryl-Val-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 512.

EXAMPLE 128 4-Phenylphenylacetyl-β-Ala-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 518.

EXAMPLE 129 4-Phenylbenzoyl-(D)-Ala-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 504.

EXAMPLE 130 4-Phenylphenylacetyl-Val-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 546.

EXAMPLE 131 4-Phenylphenylacetyl-Ala-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 518.

EXAMPLE 132 3-Phenylpropionyl-Ala-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 456.

EXAMPLE 133 3-Phenylpropionyl-β-Ala-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 456.

EXAMPLE 134 4-Phenylbutyryl-β-Ala-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 470.

EXAMPLE 135 5-Phenylvaleryl-β-Ala-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 484.

EXAMPLE 136 4-Benzoylbenzoyl-Val-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 560.

EXAMPLE 137 4-Phenylbenzoyl-β-Ala-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 504.

EXAMPLE 138 3-Phenylpropionyl-Val-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 484.

EXAMPLE 139 4-Phenylbutyryl-Val-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 498.

EXAMPLE 140 2-(Benzylthio)-benzoyl-Val-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 578.

EXAMPLE 141 2-(Benzylthio)-benzoyl-Ala-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 550.

EXAMPLE 142 4-Benzoylbenzoyl-(D)-Ala-Pyr-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 530.

EXAMPLE 143 4-Benzoylbenzoyl-(D)-Val-Pyr-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 558.

EXAMPLE 144 4-Benzoylbenzoyl-Sar-Pyr-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 530.

EXAMPLE 145 C₆H₅—C≡C—CO-Gly-Pyr-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 436.

EXAMPLE 146 C₆H₅—C≡C—CO-Sar-Pyr-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 450.

EXAMPLE 147 C₆H₅—C≡C—CO-(D)-Val-Pyr-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 478.

EXAMPLE 148 C₆H₅—C≡C—CO-(D)-Ala-Pyr-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 450.

EXAMPLE 149 4-Phenylbutyryl-Ala-Pro-NH—CH₂-5-(3-am)-thioph

ESI-MS [M+H]⁺ 470.

EXAMPLE 150 MeOC(O)—(CH₂)₅—NHC(O)-Gly-Pro-NH—CH₂-5-(3-am)-thioph

a) 0.044 mmol of resin from Example 64/section b), was suspended in a solution of 0.088 mmol of Fmoc-Gly-OH and 0.088 mmol of N,N,-diisopropylethylamine in 1.5 ml of dimethylformamide, 0.088 mmol of 2(1H-benzotriazol-1-yl-)1,1,3,3-tetramethyluronium tetrafluoroborate in 0.5 ml of dimethylformamide was added and stirring was carried out for 2 hours at room temperature. The resin was then filtered off with suction and was washed with dimethylformamide, CH₂Cl₂, methanol and CH₂Cl₂. The elimination of the Fmoc protective group was carried out with 2 ml of a solution of 10% of (1,8-diazabicyclo[5.4.0]undec-7-ene), 2% of piperidine and 88% of dimethylformamide (3 min). Thereafter, the resin was filtered off with suction and was washed with dimethylformamide, CH₂Cl₂, methanol and CH₂Cl₂.

b) The resin was suspended in 1 ml of CH₂Cl₂, and 0.088 mmol of methyl 6-isocyanatocaproate in 0.5 ml of CH₂Cl₂ was added. Stirring was carried out for 2 hours at room temperature, after which the solid was filtered off with suction and was washed with dimethylformamide, CH₂Cl₂, methanol and CH₂Cl₂. The elimination of the product from the carrier was carried out by treatment with 95:5 trifluoroacetic acid/water (1 h/room temperature).

Yield: 18 mg. HPLC-MS: M+H⁺ 481 (calculated: 481).

EXAMPLE 151 Phenylsulfonyl-Gly-Pro-NH—CH₂-5-(3-am)-thioph

0.01 mmol of resin from Example 150/section a) was suspended in 0.2 ml of 1:1 CH₂Cl₂/DMF, and 10.4 μl (0.06 mmol) of N,N,-diisopropylethylamine and then a solution of 2.5 μl (0.02 mmol) of benzenesulfonyl chloride in 200 μl of 1:1 CH₂Cl₂/DMF were added. Stirring was carried out for 2 hours at room temperature after which the solid was filtered off with suction and was washed with dimethylformamide, CH₂Cl₂, methanol and CH₂Cl₂. The elimination of the product from the carrier was carried out by treatment with 95:5 trifluoroacetic acid/water (1 h/room temperature).

Yield: 4.6 mg. HPLC-MS: M+H⁺ 450 (calculated: 450).

EXAMPLE 152 3-[4-(2,5-Dichlorobenzyloxy)phenyl]propionyl(-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph

a) 0.2 mmol of 2-chlorotrityl 3-(4-hydroxyphenyl)propionic acid resin was suspended in a solution of 262 mg (1 mmol) of triphenylphosphine in 2 ml of THF. After the addition of a solution of 2 mmol of 2,5-dichlorobenzyl alcohol in 2 ml of THF, a solution of 408 μl (2 mmol) of diisopropyl azodicarboxylate in 200 μl of THF was added a little at a time in the course of 30 minutes while stirring. After incubation for 20 hours, the resin was filtered off with suction and washed with THF. Step a) was then repeated.

b) For working up, the resin was filtered off with suction and washed with THF and then with methanol and dichloromethane. The product was cleaved from the substrate with trifluoroethanol, acetic acid and dichloromethane (1:1:3) over 45 minutes. After evaporating down under reduced pressure, the residue was dissolved in acetic acid and freeze-dried. Yield: 31 mg.

Reference:

Krchnak, V., Flegelova, Z., Weichsel, A. S., and Lebl, M. (1995). Tetrahedron Lett., 36, 6193.

c) The acid component was coupled with TBTU on polymer-bound H-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph, as described for Example 84. After elimination with TFA-water (95:5) (1 h at room temperature), the product was obtained (ESI-MS [M+H]⁺656).

The following compounds were prepared analogously to the above examples:

153. 4-(2,5-Dichloro-benzyloxy)-benzoyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 628 154. 4-(2-Chloro-benzyloxy)-benzoyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 594 155. 3-[4-(2-Chloro-benzyloxy)-phenyl]-propionyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 622 156. 3-[4-(4-Nitro-benzyloxy)-phenyl]-propionyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 633 157. 3-[4-(4-Methoxycarbonyl-benzyloxy)-phenyl]-propionyl-D-Val- Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 646 158. 3-[4-(4-Fluoro-3-trifluoromethyl-benzyloxy)-phenyl]- propionyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 674 159. 3-[4-(2-Chloro-3-isopropyl-benzyloxy)-phenyl]-propionyl- D-Val-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 664 160. 4-(2,5-Dichloro-benzyloxy)-phenylacetyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 642 161. 4-(4-Chloro-3-nitro-benzyloxy)-phenylacetyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 653 162. 4-(4-Nitro-benzyloxy)-phenylacetyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 619 163. 4-(4-Methoxycarbonyl-benzyloxy)-phenylacetyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 632 164. 4-(4-Fluoro-3-trifluoromethyl-benzyloxy)-phenylacetyl- D-Val-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 660 165. 4-(2-Chloro-3-isopropyl-benzyloxy)-phenylacetyl-D-Val-Pyr- NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 650 166. 4-(4-Chloro-benzyloxy)-phenylacetyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 608 167. 5-[4-(2, 5-Dichloro-benzyloxy)-phenyl]-5-oxo-pentanoyl- D-Val-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 698 168. 5-[4-(4-Chloro-3-nitro-benzyloxy)-phenyl]-5-oxo-pentanoyl- D-Val-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 709 169. 5-[4-(4-Nitro-benzyloxy)-phenyl]-5-oxo-pentanoyl-D-Val-Pyr- NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 675 170. 5-[4-(4-Methoxycarbonyl-benzyloxy)-phenyl]-5-oxo-pentanoyl- D-Val-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 688 171. 5-[4-(4-Fluoro-3-trifluoromethyl-benzyloxy)-phenyl]-5-oxo- pentanoyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 715 172. 5-[4-(2-Chloro-3-isopropyl-benzyloxy)-phenyl]-5-oxo-penta- noyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 706 173. 5-(4-Benzyloxy-phenyl )-5-oxo-pentanoyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 630 174. 5-[4-(4-Chloro-benzyloxy)-phenyl]-5-oxo-pentanoyl-D-Val- Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 664 175. 2-[4-(2, 5-Dichloro-benzyloxy)-phenoxy]-propionyl-D-val-Pyr- NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 672 176. 2-[4-(4-Chloro-3-nitro-benzyloxy)-phenoxy]-propionyl-D-Val- Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 683 177. 2-[4-(2-Chloro-benzyloxy)-phenoxy]-propionyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 638 178. 2-[4-(4-Nitro-benzyloxy)-phenoxy]-propionyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 649 179. 2-[4-(4-Methoxycarbonyl-benzyloxy)-phenoxy]-propionyl- D-Val-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 662 180. 2-[4-(4-Fluoro-3-trifluoromethyl-benzyloxy)-phenoxy]-pro- pionyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 690 181. 2-[4-(2-Chloro-3-isopropyl-benzyloxy)-phenoxy]-propionyl- D-Val-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 680 182. 2-(4-Benzyloxy-phenoxy)-propionyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 604 183. 2-[4-(4-Chloro-benzyloxy)-phenoxy]-propionyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 638 184. 2-[4-(2,5-Dichloro-benzyloxy)-phenyl]-3-methyl-butyryl-Pyr- NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 585 185. 2-[4-(2,5-Dichloro-benzyloxy)-phenyl]-3-methyl-butyryl- D-Val-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 684 186. 2-[4-(4-Chloro-3-nitro-benzyloxy)-phenyl]-3-methyl-butyryl- D-Val-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 695 187. 2-[4-(4-Nitro-benzyloxy)-phenyl]-3-methyl-butyryl-D-Val- Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 661 188. 2-[4-(4-Methoxycarbonyl-benzyloxy)-phenyl]-3-methyl- butyryl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 674 189. 2-[4-(4-Fluoro-3-trifluoromethyl-benzyloxy)-phenyl]-3- methyl-butyryl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 702 190. 2-(4-Benzyloxy-phenyl)-3-methyl-butyryl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 616 191. 2-[4-(4-Chloro-benzyloxy)-phenyl]-3-methyl-butyryl-D-Val- Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 650 192. 2-[4-(2, 5-Dichloro-benzyloxy)-phenoxy]-propionyl-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 573 193. 2-[4-(4-Nitro-benzyloxy)-phenoxy]-propionyl-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 550 194. 2-[4-(4-Methoxycarbonyl-benzyloxy)-phenoxy]-propionyl-Pyr- NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 563 195. 2-[4-(2-Chloro-3-isopropyl-benzyloxy)-phenoxy]-propionyl- Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 581 196. 2-(4-Benzyloxy-phenoxy)-propionyl-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 505 197. 2-[4-(4-Chloro-benzyloxy)-phenoxy]-propionyl-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 539 198. 2-[4-(4-Chloro-3-nitro-benzyloxy)-phenoxy]-propionyl-Pyr- NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 596 199. 3-(2,5-Dichloro-benzyloxy)-benzoyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 628 200. 3-(4-Chloro-3-nitro-benzyloxy)-benzoyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 639 201. 3-(2-Naphthylmethoxy)-benzoyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 610 202. 3-(4-Methyl-3-nitro-benzyloxy)-benzoyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 619 203. 3-(4-Nitro-benzyloxy)-benzoyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 605 204. 3-(4-Fluoro-3-trifluoromethyl)-benzyloxy)-benzoyl-D-Val- Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 646 205. 3-(2-Chloro-3-isopropyl-benzyloxy)-benzoyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 636 206. 3-Benzyloxybenzoyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 560 207. 3-(4-Chlorobenzyloxy)-benzoyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 594 208. 3-(2,5-Dichloro-benzyloxy)-phenylacetyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 642 209. 3-(4-Ch1oro-3-nitro-benzyloxy)-phenylacetyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 653 210. 3-(4-Methyl-3-nitro-benzyloxy)-phenylacetyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 633 211. 3-(4-Nitro-benzyloxy)-phenylacetyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 619 212. 3-(4-Fluoro-3-trifluoromethyl-benzyloxy)-phenylacetyl- D-Val-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 660 213. 3-(2-Chloro-3-isopropyl-benzyloxy)-phenylacetyl-D-Val-Pyr- NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 650 214. 3-Benzyloxy-phenylacetyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 574 215. 3-(4-Chloro-benzyloxy)-phenylacetyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 608 216. 3-[3-(2,5-Dichloro-benzyloxy)-phenyl]-acryloyl-D-Val-Pyr- NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 654 217. 3-[3-(4-Chloro-3-nitro-benzyloxy)-phenyl]-acryloyl-D-Val- Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 665 218. 3-[3-(4-Methyl-3-nitro-benzyloxy)-phenyl]-acryloyl-D-Val- Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 645 219. 3-(3-(4-Nitro-benzyloxy)-phenyl]-acryloyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 631 220. 3-(3-(4-Fluoro-3-trifluoromethyl-benzyloxy)-phenyl]- acryloyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 672 221. 3-[3-(2-Chloro-3-isopropyl-benzyloxy)-phenyl]-acryloyl- D-Val-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 662 222. 3-(3-Benzyloxy-phenyl)-acryloyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 586 223. 4-Phenylbenzenesulfonyl-β-Ala-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 538 224. 4-Phenylbenzenesulfonyl-D-Ala-Pyr-NH—CH₂-5-3-am)-thioph ESI-MS [M + H]⁺ 538 225. 4-Phenylbenzenesulfonyl-Sar-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 538 226. 4-Phenylbenzenesulfonyl-Gly-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 524 227. C₆H₅—C≡C—CO-β-Ala-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 450 228. C₆H₅—C≡-C—CO-D-Asp-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 494 229. C₆H₅—C≡C—CO-D-Arg-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 535 230. 4-Benzoylbenzoyl-β-Ala-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 530 231. 4-Benzoylbenzoyl-D-Ala-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 574 232. 4-Benzoylbenzoyl-D-Arg-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 615 233. C₆H₅—C≡C—CO-Gly-Pyr-NH—CH₂-5-(2-am)-thioph ESI-MS [M + H]⁺ 436 234. C₆H₅—C≡-C—CO-β-Ala-Pyr-NH—CH₂-5-(2-am)-thioph ESI-MS [M + H]⁺ 450 235. C₆H₅—C≡C—CO-D-Ala-Pyr-NH—CH₂- 5-(2-am)-thioph ESI-MS [M + H]⁺ 450 236. C₆H₅—C≡C—CO-D-Val-Pyr-NH—CH₂- 5-(2-am)-thioph ESI-MS [M + H]⁺ 478 237. 4-Benzoylbenzoyl-Gly-Pyr-NH—CH₂-5-(2-am)-thioph ESI-MS [M + H]⁺ 516 238. 4-Benzoylbenzoyl-β-Ala-Pyr-NH—CH₂-5-(2-am)-thioph ESI-MS [M + H]⁺ 530 239. 4-Benzoylbenzoyl-D-Ala-Pyr-NH—CH₂-5-(2-am)-thioph ESI-MS [M + H]⁺ 530 240. 4-Benzoylbenzoyl-D-Val-Pyr-NH—CH₂-5-(2-am)-thioph ESI-MS [M + H]⁺ 558 241. 4-Benzoylbenzoyl-D-Lys-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 587 242. 4-Benzoylbenzoyl-D-Orn-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 573 243. 4-Benzoylbenzoyl-D-His-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H ⁺ 596 244. 4-Benzoylbenzoyl-D-Dab-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H ⁺ 559 245. 4-Benzoylbenzoyl-D-Dap-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 545 246. 4-Benzoylbenzoyl-D-Arg-Pyr-NH—CH₂-5-(2-am)-thioph ESI-MS [M + H]⁺ 615 247. 4-Benzoylbenzoyl-D-Lys-Pyr-NH—CH₂-5-(2-am)-thioph ESI-MS [M + H]⁺ 587 248. 4-Benzoylbenzoyl-D-Orn-Pyr-NH—CH₂-5-(2-am)-thioph ESI-MS [M + H]⁺ 573 249. 4-Benzoylbenzoyl-D-His-Pyr-NH—CH₂-5-(2-am)-thioph ESI-MS [M + H]⁺ 596 250. 4-Benzoylbenzoyl-D-Dab-Pyr-NH—CH₂-5-(2-am)-thioph ESI-MS [M + H]⁺ 559 251. 4-Benzoylbenzoyl-D-Dap-Pyr-NH—CH₂-5-(2-am)-thioph ESI-MS [M + H]⁺ 545 252. 9,10,10-Trioxo-9,10-dihydro-101⁶-thioxanthene-3-carbonyl- D-Ala-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 592 253. 9,10,10-Trioxo-9,10-dihydro-101⁶-thioxanthene-3-carbonyl- Gly-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 578 254. 9,10,10-Trioxo-9,10-dihydro-101⁶-thioxanthene-3-carbonyl- D-Val-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 620 255. 9,10-Dioxo-9,10-dihydro-anthracene-2-carbonyl-D-Ala-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 556 256. 9,10-Dioxo-9,10-dihydro-anthracene-2-carbonyl-Gly-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 542 257. 9,10-Dioxo-9,10-dihydro-anthracene-2-carbonyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 584 258. 4-Benzoylbenzoyl-D-Ser-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 546 259. 4-Aminobenzoyl-D-Ala-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 441 260. 4-Methylaminobenzoyl-D-Ala-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 455 261. 4-Aminobenzoyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 469 262. 4-Methylaminobenzoyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 483 263. 3-Aminobenzoyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 469 264. 4-(4-HOOC-Benzoyl)-benzoyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 602 265. 4-(3-Phenyl-ureido)-benzoyl-D-Ala-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 560 266. 3-(3-Benzyl-ureido)-benzoyl-D-Ala-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 574 267. 3-(3-Phenyl-ureido)-benzoyl-D-Ala-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 560 268. 4-(3-Phenyl-ureido)-benzoyl-Gly-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 546 269. 3-(3-Benzyl-ureido)-benzoyl-Gly-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 560 270. 3-(3-Phenyl-ureido)-benzoyl-Gly-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 546 271. 3-(3-Benzoyl-ureido)-benzoyl-Gly-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 574 272. 4-(3-Phenyl-ureido)-benzoyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 588 273. 3-(3-Phenyl-ureido)-benzoyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 588 274. 3-[3-(3-Acetyl-phenyl)-ureido)-benzoyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 630 275. 4-Benzyloxy-benzoyl-D-Ala-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 532 276. 4-(4-Chloro-benzyloxy)-benzoyl-D-Ala-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 566 277. 3-(4-Benzyloxy-phenyl)-propionyl-D-Ala-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 560 278. 3-[4-(4-Chloro-benzyloxy)-phenyl]-propionyl-D-Ala-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 594 279. 4-Benzyloxy-benzoyl-Gly-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 518 280. 4-(4-Chloro-benzyloxy)-benzoyl-G1y-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 552 281. 3-(4-Benzyloxy-phenyl)-propionyl-Gly-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 546 282. 3-[4-(4-Chloro-benzyloxy)-phenyl]-propionyl-Gly-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 580 283. 4-Benzyloxy-benzoyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 560 284. 4-(4-Chloro-benzyloxy)-benzoyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 594 285. 3-(4-Benzyloxy-phenyl)-propionyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 588 286. 3-[4-(4-Chloro-benzyloxy)-phenyl]-propionyl-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph ESI-MS [M + H]⁺ 622 287. Phenyl-C≡C—CO-D-Chg-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 518 288. Phenyl-C≡C—CO-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 466 289. 4-Benzoylbenzoyl-D-Abu-Pro-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 546 290. 4-Benzoylbenzoyl-D-Chg-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 598 291. HOOC-p-C₆H₄—CH₂-D-Pro-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 482 292. HOOC-p-C₆H₄—CH₂-D,L-Thienyl(3 )glycine-Pyr-NH— CH₂-5-(3-am)-thioph MS [M + H]⁺ 524 293. p-COOH-Benzyl-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 470 294. 4-Benzoyl-benzoyl-Acpc-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 570 295. 4-Benzoyl-benzoyl-N-Me-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 572 296. p-Carboxy-benzyl-D-Ile-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 498 297. HOOC-p-C₆H₄—CH₂-D-Nva-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 484 298. HOOC-p-C₆H₄—CH₂-D-Leu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 498 299. 4-Benzoylbenzoyl-D-Nva-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 558 300. p-Carboxy-benzyl-D-Ala-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 456 301. p-Carboxy-benzyl-Acpc-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 496 302. HOOC-p-C₆H₄—CH₂-N-Me-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 498 303. p-Benzoyl-benzyl-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 530 304. 2-Carboxy-benzyl-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 470 305. (4-COOH—CH═CH)-Benzyl-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 496 306. 4-Carboxy-benzyl-D-Abu-3-Me-Pro-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 486 307. HOOC-p-C₆H₄—CH₂-D-Abu-5-Me-Pro-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 486 308. 2-(CarboxyMethoxy)-benzyl-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 500 309. Benzyl-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 426 310. 4-(CarboxyMethoxy)-benzyl-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 500 311. Benzenesulfonyl-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 490 312. HOOC-p-C₆H₄—CH₂-D-Abu-Pyr-NH—CH₂-5-(2-am)-thioph MS [M + H]⁺ 470 313. 4-Benzoyl-benzoyl-D-Pro-Pyr-NH—CH₂-5-(2-am)-thioph MS [M + H]⁺ 556 314. HOOC-p-C₆H₄—CH₂-D-Pro-Pyr-NH—CH₂-5-(2-am)-thioph MS [M + H]⁺ 482 315. HOOC-p-C₆H₄—CH₂-D-Pip-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 473 316. HOOC-p-C₆H₄—CH₂-D-Abu-Pro-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 472 317. 4-Carboxy-benzyl-D-allo-Ile-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 498 318. 2-HOOC-thienyl(5)-CH₂-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 476 319. 2-COOH-furanyl(5)-CO-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 460 320. HOOC-p-C₆H₄—CH₂-D-Nle-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 498 321. Benzoyl-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 440 322. 4-MeSO₂—C₆H₄—CH₂-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 504 323. Phenylsulfonyl-D-Chg-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 530 324. Phenylacetyl-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 454 325. Phenylsulfonyl-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 476 326. 1-Naphthyl-CH₂CO-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 504 327. 2-Naphthyl-CH₂CO-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 504 328. 1-Indanyl-CO-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 480 329. Benzhydryl-Co-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 530 330. 2-Cl-Phenyl-CH₂CO-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 488 331. 2,6-Dichlorophenyl-CH₂CO-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 524 332. 2-Methyl-phenyl-CH₂CO-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 468 333. Biphenyl-CH₂CO-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 530 334. p-Methyl-phenyl-CH₂CO-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 468 335. 3-Methyl-phenyl-CH₂CO-D-Abu-Pyr-NH—CH₂-5-(3-aIn)-thioph MS [M + H]⁺ 468 336. 2-Nitro-phenyl-CH₂CO-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 499 337. 1-Fluorenyl-CH₂CO-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 542 338. 2-Br-Phenyl-CH₂CO-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 534 339. 2-Fluoro-phenyl-CH₂CO-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 472 340. 2-Phenyl-isobutyryl-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 482 341. p-Benzyloxy-benzoyl-D-val-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 560 342. 2,6-Dichlorophenyl-CH₂CO-D-Abu-Pyr-NH—CH₂-5-(2-am)-thioph MS [M + H]⁺ 524 343. 2,6-Dichlorophenyl-CH₂CO-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 538 344. 2,6-Dichloro-phenyl-CH₂CO-D-Chg-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 578 345. 1-Naphthyl-CO-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 490 346. Cyclopentyl-CH₂CO-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 446 347. 1-Adamantyl-CO-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 498 348. Cyclohexyl-CH₂CO-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 460 349. 2-Thienyl-CH₂CO-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 460 350. 2-Naphthyl-Co-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 490 351. 1-Naphthyl-CH₂-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 476 352. 2-Naphthyl-CH₂-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 476 353. Benzyloxycarbonyl-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 470 354. 4-MeOOC-Benzyl-D-Val-Pyr-NH—CH₂-5-(3-ham)-thioph MS [M + H]⁺ 514 355. 2-Phenyl-2-hydroxy-acetyl-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 470 356. 2-Phenyl-2-methoxy-acetyl-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 484 357. 2-(p-Isobutyl-phenyl)propionyl-D-Abu-Pyr-NH— CH₂-5-(3-am)-thioph MS [M + H]⁺ 524 358. (S)-2-Phenyl-propionyl-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 468 359. (R)-2-Phenyl-propionyl-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 468 360. 3-Pyridyl-CH₂CO-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 455 361. Phenyl-O—CH₂CO-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 470 362. 1-Adamantyl-CH₂CO-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 512 363. 2,4,6-Trimethylphenyl-CH₂CO-D-Abu-Pyr-NH— CH₂-5-(3-am)-thioph MS [M + H]⁺ 496 364. p-Pentoxy-benzoyl-D-val-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 540 365. p-Benzyloxy-phenyl-CH₂CO-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 574 366. 1-Indanyl-CO-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 494 367. 2,6-Dichlorophenyl-CH₂CO-D-Val-Pyr-NH—CH₂-5-(2-am)-thioph MS [M + H]⁺ 538 368. 2-Benzothienyl-CO-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 496 369. HOOC-p-C₆H₄—CH₂-D-Nva-Pyr-NH-3-(6-am)-pico MS [M + H]⁺ 465 370. 2-Tetrahydronaphthyl-CO-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 494 371. 1-Indanyl-CO-D-Ile-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 508 372. 1-Benzocyc1obutane-Co-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 466 373. 1-Benzocyclobutane-CO-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 480 374. 2,4,6-Trimethylphenyl-CH₂CO-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph MS [M + H]⁺ 510 375. 1-Indanyl-CO-D-Chg-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 534 376. 1-Indanyl-CO-D-Leu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 508 377. 1-Indanyl-CO-D-Phe-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 542 378. 1-Anthracenyl-CO-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 540 379. Benzenesulfonyl-D-Cha-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 558 380. p-Hexyloxy-benzoyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 554 381. 2-(p-(Phenoxy)phenyl)-acetyl-D-val-Pyr-NH— CH₂-5-(3-am)-thioph MS [M + H]⁺ 560 382. (R)-1-Indanyl-CO-D-Abu-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 480 383. 1-Indanyl-CO-D-Val-Pyr-NH—CH₂-5-(2-am)-thioph MS [M + H]⁺ 494 384. (S)-1-Indanyl-CO-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 494 385. Butylsulfonyl-D-Phe-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 518 386. (3,5-Bistrifluoromethyl)phenyl(1)-CH₂CO-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph MS [M + H]⁺ 604 387. (3-Trifluoromethyl)phenyl(1)-CH₂CO-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph MS [M + H]⁺ 536 388. 1-Phenyl-cyclopropyl(1)-CO-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 494 389. (S)-1-Indanyl-CO-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 494 390. p-Isopropyl-phenyl-CH₂CO-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 510 391. p-Butoxyphenyl-CH₂CO-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 540 392. Phenyl-CH(iPr)-Co-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 510 393. 1-(4-Cl-Phenyl)-cyclobut-1-ylCO-D-Val-Pyr-NH— CH₂-5-(3-am)-thioph MS [M + H]⁺ 542 394. 2-Carboxy-thien-5-yl-CH₂-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 490 395. 1-Phenyl-cyclopent-1-yl-CO-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 522 396. 1-Adamantyl-CH₂CO-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 526 397 1-Fluorenyl-CO-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 542 398. Benzhydryl-CO-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 544 399. (R)-1-Indanyl-CO-D-Val-Pyr-NH—CH₂-5-(2-am)-thioph MS [M + H]⁺ 494 400. (S)-1-Indanyl-CO-D-Val-Pyr-NH—CH₂-5-(2-am)-thioph MS [M + H]⁺ 494 401. p-COOH-Benzoyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 498 402. 2-Carboxy-5-furyl-CH₂-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 474 403. p-COOMe-Benzoyl-D-Val-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 512 404. m-COOH-Phenyl-SO₂-D-Chg-Pyr-NH—CH_(2-5-(3-am)-thioph) MS [M + H]⁺ 574 405. p-COOH-Phenyl-SO₂-D-Chg-Pyr-NH—CH₂-5-(3-am)-thioph MS [M + H]⁺ 574

The C_(1S) and C_(1R) inhibition values for some novel compounds are shown in the table below.

TABLE C_(1S) IC₅₀ [μmol/l] C_(1R) IC₅₀ [μmol/l] according to Example according to Example Example No. B A 29 0.6 0.9 22 0.6 0.9 23 0.8 0.5 24 0.8 >100 42 1 0.7 49 1 1 21 1 4 20 2 0.6 35 2 2 41 2 2 15 2 3 26 2 >100 50 3 20 4 3 30 44 3 40 51 3 40 52 4 10 17 4 40 7 4 >100 38 5 10 30 5 >100 6 6 25 6 50 1 6 >100 8 6 >100 18 7 10 54 8 5 10 39 10 2 31 10 3 43 10 6 13 10 30 45 20 6 53 20 8 27 20 10 46 20 40 2 20 50 34 20 70 9 20 >100 28 20 >100 16 20 >100 10 20 >100 14 20 >100 32 30 10 19 30 30 48 30 50 3 30 >100 11 30 >100 12 30 >100 35 40 20 33 40 40 47 50 10

The compound of Example 367 is a very particularly preferred and active complement inhibitor. 

We claim:
 1. A compound of the formula I A—B—D—E—G—K—L  (I), or a tautomer, a pharmacologically tolerable salt or a prodrug thereof, where: A is H, C₁₋₆-alkyl, C₁₋₆-alkyl-SO₂, R^(A1)OCO, R^(A2)R^(A3)NCO; R^(A4)OCONR^(A2), R^(A4)CONR^(A2), R^(A1)O, R^(A2)R^(A3)N, HO—SO₂—, phenoxy, R^(A2)R^(A3)N—SO₂, Cl, Br, F, tetrazolyl, H₂O₃P—, NO₂, R^(A1)—N(OH)—CO— or R^(A1)R^(A2)NCONR^(A3), where R^(A1) is H, C₁₋₁₂-alkyl, C₃₋₈-cycloalkyl, C₃₋₈-cycloalkyl-C₁₋₃-alkyl or C₁₋₃-alkylaryl; R^(A2) is H—, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl; R^(A3) is H, C₁₋₆-alkyl or C₀₋₃-alkylaryl; R^(A4) is C₁₋₆-alkyl or C₁₋₃-alkylaryl; where each aryl is optionally substituted with up to 2 identical or different radicals selected from the group consisting of F, Cl, Br, CF₃, CH₃, OCH₃ and NO₂, B is —(CH₂)_(l) _(^(B)) —L^(B)—(CH₂)_(m) _(^(B)) — l^(B) is 0, 1, 2 or 3; m^(B) is 0, 1 or 2; L^(B) is

where a phenyl ring is optionally fused to the abovementioned ring systems, which phenyl ring is optionally substituted with up to 2 identical or different radicals selected from the group consisting of CH₃, CF₃, Br, Cl and F, or is optionally substituted by R⁸OOC—;  where R⁸ is H or C₁₋₃-alkyl; n^(B is) 0, 1 or 2; p^(B) is 0, 1 or 2; q^(B) is 1, 2 or 3; R^(B1) is C₀₋₃-alkylaryl, C₀₋₃-alkylheteroaryl, C₀₋₃-alkyl-C₃₋₈-cycloalkyl or OCH₃; R^(B2) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl; R^(B3) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl R^(B5)OCO, R^(B6)—O, F, Cl, Br, NO₂ or CF₃; R^(B4) is H, C₁₋₆-alkyl, R^(B6)—O, Cl, Br, F or CF₃; R^(B5) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl; R^(B6) is H or C₁₋₆-alkyl; T^(B) is CH₂, O, S, NH or N—C₁₋₆-alkyl; R^(B1′) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl, C₀₋₃-alkylheteroaryl or C₀₋₃-alkyl-C₃₋₈-cycloalkyl; R^(B1) and R^(B2) are optionally bonded together; X^(B) is O, S, NH or N—C₁₋₆-alkyl; Y^(B) is

Z^(B) is CH—,

U^(B) is ═CH— or ═N—; V^(B) is ═CH— or ═N—; or B is —(CH₂)_(l) _(^(B)) —L^(B)—M^(B)—L^(B)—(CH₂)_(m) _(^(B)) , where l^(B) and m^(B) have the abovementioned meanings and the two groups L^(B), independently of one another, are the radicals stated under L^(B); M^(B) is a single bond, O, S, CH₂, CH₂—CH₂, CH₂—O, O—CH₂, CH₂—S, S—CH₂, CO, SO₂, CH═CH or C≡C; or B is -1-adamantyl-CH₂—, -2-adamantyl-CH₂—, -1-adamantyl-, -2-adamantyl-,

or B is

 where h^(B) is 1, 2, 3 or 4; and R^(B7) is C₁₋₆-alkyl or C₃₋₈-cycloalkyl; or B is

 where X^(B1) is a bond, O, S, or

r^(B) is 0, 1, 2 or 3; R^(B9) is H or C₁₋₃-alkyl; or A—B together are

D is a single bond, CO, OCO, NR^(D1)—CO, SO₂ or NR^(D1)SO₂, where R^(D1) is H, C₁₋₄-alkyl or C₀₋₃-alkylaryl; E is a single bond or

 where k^(E) is 0, 1 or 2; l^(E) is 0, 1 or 2; m^(E) is 0, 1, 2 or 3; n^(E) is 0, 1 or 2; p^(E) is 0, 1 or 2; R^(E1) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, aryl, pyridyl, thienyl or C₃₋₈-cycloalkyl having a fused-on phenyl ring, the abovementioned radicals being optionally substituted with up to three identical or different substituents selected from the group consisting of C₁₋₆-alkyl, O—C₁₋₆-alkyl, F, Cl and Br; or R^(E1) is R^(E4)OCO—CH₂; R^(E2) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, phenyl, pyridyl, furyl, thienyl, imidazolyl, tetrahydropyranyl or tetrahydrothiopyranyl, the abovementioned radicals being optionally substituted with up to three identical or different substituents selected from the group consisting of C₁₋₆-alkyl, O—C₁₋₆-alkyl, F, Cl and Br, or is CH(CH₃)OH or CH(CF₃)₂; R^(E3) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl or phenyl, the abovementioned radicals being optionally substituted with up to three identical or different substituents selected from the group consisting of C₁₋₆-alkyl, O—C₁₋₆-alkyl, F, Cl and Br; R^(E4) is H, C₁₋₁₂-alkyl or C₁₋₃-alkylaryl; R^(E2) and R^(B1) together optionally form a bridge having (CH₂)₀₋₄, CH═CH, CH₂-CH═CH or CH═CH—CH₂ groups the groups stated under R^(E1) and R^(E3) are optionally linked to one another via a bond; the groups stated under R^(E2) and R^(E3) are also optionally linked to one another via a bond; or R^(E2) is COR^(E5); R^(E5) is OH, O—C₁₋₆-alkyl or O—C₁₋₃-alkylaryl; or E is D-Asp, D-Glu, D-Lys, D-Orn, D-His, D-Dab, D-Dap or D-Arg; G is

where l^(G) is 2, 3, 4 or 5, and where a CH₂ group of the ring is optionally replaced by O, S, NH, CH(C₁₋₃-alkyl), CHF or CF₂;

 where m^(G) is 0, 1 or 2; n^(G) is 0, 1 or 2; p^(G) is 1 or 3; R^(G1) and R^(G2) are each H; or R^(G1) and R^(G2) together form a CH═CH—CH═CH chain; or G is

 where q^(G) is 0, 1 or 2; r^(G) is 0, 1 or 2; R^(G3) is H, C₁-C₆-alkyl or C₃₋₈-cycloalkyl; R^(G4) is H, C₁-C₆-alkyl, C₃₋₈-cycloalkyl or phenyl; K is NH—(CH₂)_(n) _(^(K)) —Q^(K) where n^(K) is 1 or 2; Q^(K) is

X^(K) is O, S, NH or N—C₁₋₆-alkyl; Y^(K) is ═CH—,

Z^(K) is

 where  R^(L1) is H, OH, O—C₁₋₆-alkyl, O—(CH₂)₀₋₃-phenyl, CO—C₁₋₆-alkyl, CO₂—C₁₋₆-alkyl or CO₂—C₁₋₃-alkylaryl.
 2. The compound claimed in claim 1, or a tautomer, a pharmacologically tolearable salt, or a prodrug thereof, where: A is H, C₁₋₆-alkyl, C₁₋₆-alkyl-SO₂, R^(A1)OCO, R^(A2)R^(A3)NCO, R^(A4)OCONR^(A2), R^(A4)CONR^(A2), R^(A1)O, phenoxy, R^(A2)R^(A3)N, HO—SO₂, R^(A2)R^(A3)N—SO₂, Cl, Br, F, tetrazolyl, H₂O₃P, NO₂, R^(A1)—N(OH)—CO or R^(A1)R^(A2)NCONR^(A3), where R^(A1) is H, C₁₋₁₂-alkyl, C₃₋₈-cycloalkyl, C₁₋₃-alkyl-C₃₋₈-cycloalkyl or C₁₋₃-alkylaryl; R^(A2) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl; R^(A3) is H, C₁₋₆-alkyl or C₀₋₃-alkylaryl; R^(A4) is C₁₋₆-alkyl or C₁₋₃-alkylaryl; where each aryl is optionally substituted with up to 2 identical or different radicals selected from the group consisting of F, Cl, Br, OCH₃, CH₃, CF₃ and NO₂; B is —(CH₂)_(l) _(^(B)) —L^(B)—(CH₂)_(m) _(^(B)) — where l^(B) is 0, 1, 2 or 3; m^(B) is 0, 1, 2 or 3; L^(B) is

where a phenyl ring is optionally fused to the abovementioned ring systems, which phenyl ring is optionally substituted with up to 2 identical or different radicals selected from the group consisting of CH₃, CF₃, Br, Cl and F, or is optionally substituted by R⁸OOC—;  where R⁸ is H or C₁₋₃-alkyl n^(B) is 0, 1 or 2; p^(B) is 0, 1 or 2; q^(B) is 1, 2 or 3; R^(B1) is C₀₋₃-alkylaryl, C₀₋₃-alkylheteroaryl, C₀₋₃-alkyl-C₃₋₈-cycloalkyl, OH or OCH₃; R^(B2) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl; R^(B1) and R^(B2) are optionally bonded together; R^(B2′) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl, C₀₋₃-alkylheteroaryl or C₀₋₃-alkyl-C₃₋₈-cycloalkyl; or B is -1-adamantyl-, -1-adamantyl-CH₂—, -2-adamantyl- or -2-adamantyl-CH₂—,

B is —(CH₂)_(l) _(^(B)) —L^(B1)—M^(B)—L^(B2)—(CH₂)_(m) _(^(B)) —, where l^(B) and m^(B) have the abovementioned meanings and the two groups L^(B1) and L^(B2), independently of one another, are selected from among the following radicals:

where a phenyl ring is optionally fused to the abovementioned ring systems; where n^(B) is 0, 1 or 2; p^(B) is 0, 1 or 2; q^(B) is 1, 2 or 3; R^(B1) is C₀₋₃-alkylaryl, C₀₋₃-alkylheteroaryl, C₀₋₃-alkyl-C₃₋₈-cycloalkyl, OH or OCH₃, or in the case of L^(B2), R^(B1) is additionally H or C₁₋₆-alkyl; R^(B2) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl; R^(B2′) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl, C₀₋₃-alkylheteroaryl or C₀₋₃-alkyl-C₃₋₈-cycloalkyl; R^(B3) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl, C₀₋₃-alkylheteroaryl, R^(B5)OCO, R^(B6)—O, F, Cl, Br, NO₂ or CF₃; R^(B4) is H, C₁₋₆-alkyl, R^(B6)—O, Cl, Br, F or CF₃; R^(B5) is H, C₁₋₆-alkyl or C₁₋₃-alkylaryl; R^(B6) is H or C₁₋₆-alkyl; T^(B) is CH₂, O, S, NH or N—C₁₋₆-alkyl; X^(B) is O, S, NH or N—C₁₋₆-alkyl; X^(B) is O, S, NH or N—C₁₋₆-alkyl;

R^(B1) and R^(B2) are optionally bonded together; M^(B) is a single bond, O, S, CH₂, CH₂—CH₂, CH₂—O, O—CH₂, CH₂—S, S—CH₂, CO, SO₂, CH═CH or C≡C; or B is

 where X^(B1) is a bond, O, S or

r^(B) is 0, 1, 2 or 3; R^(B9) is H or C₁₋₃-alkyl; or A—B together are

D is a single bond, CO, OCO, NR^(D1)—CO, SO₂ or NR^(D1)SO₂, where R^(D1) is H, C₁₋₄-alkyl or C₀₋₃-alkylaryl; or B—D together are

E is a single bond or

 where k^(E) is 0, 1 or 2; l^(E) is 0, 1 or 2; m^(E) is 0, 1, 2 or 3; n^(E) is 0, 1 or 2; p^(E) is 0, 1 or 2; R^(E1) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, phenyl, naphthyl, pyridyl, thienyl or C₃₋₈-cycloalkyl having a fused-on phenyl ring, the abovementioned radicals being optionally substituted with up to three identical or different substituents selected from the group consisting of C₁₋₆-alkyl, O—C₁₋₆-alkyl, F, Cl and Br; or R^(E1) is R^(E4)OCO—CH₂; R^(E2) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, phenyl, pyridyl, thienyl, furyl, imidazolyl, tetrahydropyranyl or tetrahydrothiopyranyl, the abovementioned radicals being optionally substituted with up to three identical or different substituents selected from the group consisting of C₁₋₆-alkyl, OH, O—C₁₋₆-Alkyl, F, Cl and Br, or is CH(CH₃)OH or CH(CF₃)₂; R^(E3) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl or phenyl, the abovementioned radicals being optionally substituted with up to three identical or different substituents selected from the group consisting of C₁₋₆-alkyl, O—C₁₋₆-alkyl, F, Cl and Br; R^(E4) is H, C₁₋₁₂-alkyl or C₁₋₃-alkylaryl; R^(E2) and R^(B1) together optionally form a bridge having (CH₂)₀₋₄, CH═CH, CH₂—CH═CH or CH═CH—CH₂ groups; the groups stated under R^(E1) and R^(E3) are optionally linked to one another via a bond; the groups stated under R^(E2) and R^(E3) are also optionally linked to one another via a bond; or R^(E2) is COR^(E5); R^(E5) is OH, O—C₁₋₆-alkyl or O—C₁₋₃-alkylaryl; or E is D-Asp, D-Glu, D-Lys, D-Orn, D-His, D-Dab, D-Dap or D-Arg; G is

where l^(G)=2, 3, 4 or 5, and where a CH₂ group of the ring is optionally replaced by O, S, NH, CHF, CF₂ or CH(C₁₋₃-alkyl);

 where m^(G) is 0, 1 or 2; n^(G) is 0, 1 or 2; p^(G) is 1 or 3; R^(G1) is H; R^(G2) is H; or R^(G1) and R^(G2) together form a CH═CH—CH═CH chain; or G is

 where q^(G) is 0, 1 or 2; r^(G) is 0, 1 or 2; R^(G3) is H, C₁-C₆-alkyl or C₃₋₈-cycloalkyl; R^(G4) is H, C₁-C₆-alkyl, C₃₋₈-cycloalkyl or phenyl; K is NH—(CH₂)_(n) _(^(K)) —Q^(K) where n^(K) is 1 or 2; Q^(K) is

X^(K) is O, S, NH or N—C₁₋₆-alkyl;

 where R^(L1) is H, OH, O—C₁₋₆-alkyl, O—(CH₂)₀₋₃-phenyl, CO—C₁₋₆-alkyl, CO₂—C₁₋₆-alkyl or CO₂-C₁₋₅-alkylaryl.
 3. The compound claimed in claim 1, or a tautomer, a pharmacologically tolearable salt, or a prodrug thereof, where: A is H, C₁₋₆-alkyl, C₁₋₆-alkyl-SO₂, R^(A1)OCO, R^(A2)R^(A3)NCO, R^(A4)OCONR^(A2), R^(A4)CONR^(A2), R^(A1)O, phenoxy, R^(A2)R^(A3)N, HO—SO₂, R^(A2)R^(A3)N—SO₂, Cl, Br, F, tetrazolyl, H₂O₃P, NO₂, R^(A1)—N(OH)—CO— or R^(A1)R^(A2)NCONR^(A3), where R^(A1) is H, C₁₋₁₂-alkyl, C₃₋₈-cycloalkyl, C₁₋₃-alkyl-C₃₋₈-cycloalkyl or C₁₋₃-alkylaryl; R^(A2) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl; R^(A3) is H, C₁₋₆-alkyl or C₀₋₃-alkylaryl; R^(A4) is C₁₋₆-alkyl or C₁₋₃-alkylaryl; where each aryl is optionally substituted by up to 2 identical or different substituents selected from the group consisting of F, Cl, Br, CH₃, CF₃, OCH₃ and NO₂; B is —(CH₂)_(l) _(^(B)) —L^(B)—(CH₂)_(m) _(^(B)) — where l^(B) is 0, 1, 2 or 3; m^(B) is 0, 1, 2, 3, 4 or 5; L^(B) is

where a phenyl ring is optionally fused to the abovementioned ring systems, which phenyl ring is optionally substituted with up to 2 identical or different radicals selected from the group consisting of CH₃, CF₃, F, Cl and Br, or is optionally substituted by R⁸OOC—; where R^(B3) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl, C₀₋₃-alkylheteroaryl R^(B5)OCO, R^(B6)—O, F, Cl, Br, NO₂ or CF₃; R^(B4) is H, C₁₋₆-alkyl, R^(B6)—O, Cl, Br, F or CF₃; R^(B5) is H, C₁₋₆-alkyl or C₁₋₃-alkylaryl; R^(B5) is H or C₁₋₆-alkyl; R⁸ is H or C₁₋₃-alkyl T^(B) is CH₂, O, S, NH or N—C₁₋₆-alkyl; X^(B) is O, S, NH or N—C₁₋₆-alkyl;

U^(B) is ═CH— or ═N—; V_(B) is ═CH— or ═N—; or B is

 where h^(B) is 1, 2, 3, or 4; R^(B7) is C₁₋₆-alkyl or C₃₋₈-cycloalkyl; or A—B together are

or B is -1-adamantyl-, -2-adamantyl-, -1-adamantyl-CH₂—, -2-adamantyl-CH₂—,

or B is

 where X^(B1) is a bond, O, S, or

r^(B) is 0, 1, 2 or 3; R^(B9) is H or C₁₋₃-alkyl; D is a single bond, —NR^(D1)—CO or —NR^(D1)SO₂,  where R^(D1) is H, C₁₋₄-alkyl or CO₃-alkylaryl; E is a single bond or

 where k^(E) is 0, 1 or 2; l^(E) is 0, 1 or 2; m^(E) is 0, 1, 2 or 3; n^(E) is 0, 1 or 2; p^(E) is 0, 1 or 2; R^(E1) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, aryl, pyridyl, thienyl, C₃₋₈-cycloalkyl having a fused-on phenyl ring, the abovementioned radicals being optionally substituted with up to three identical or different substituents selected from the group consisting of C₁₋₆-alkyl, O—Cl₆-alkyl, F, Cl and Br; or R^(E1) is R^(E4)OCO—CH₂; R^(E2) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, phenyl, pyridyl, furyl, thienyl, imidazolyl, tetrahydropyranyl or tetrahydrothiopyranyl, the abovementioned radicals being optionally substituted with up to three identical or different substituents selected from the group consisting of C₁₋₆-alkyl, O—C₁₋₆-alkyl, F, Cl and Br, or is CH(CH₃)OH or CH(CF₃)₂; R^(E3) is H, C₁₋₆-alkyl or C₃₋₈-cycloalkyl, the abovementioned radicals being optionally substituted with up to three identical or different substituents selected from the group consisting of C₁₋₆-alkyl, O—C₁₋₆-alkyl, F, Cl and Br; R^(E2) and R^(B1) together optionally form a bridge having (CH₂)₀₋₄, CH═CH, CH₂—CH═CH or CH═CH—CH₂ groups; the groups stated under R^(E1) and R^(E3) are optionally linked to one another via a bond; the groups stated under R^(E2) and R^(E3) are also optionally linked to one another via a bond; or R^(E2) is COR^(E5); R^(E4) is H, C₁₋₁₂-alkyl or C₁₋₃-alkylaryl; R^(E5) is OH, O—C₁₋₆-alkyl or OC₁₋₃-alkylaryl; or E is D-Asp, D-Glu, D-Lys, D-Orn, D-His, D-Dab, D-Dap or D-Arg;

where l^(G)=2, 3, 4 or 5, and where a CH₂ group of the ring is optionally replaced by O, S, NH, CHF, CF₂ or CH(C₁₋₃-alkyl);

 where m^(G) is 0, 1 or 2; n^(G) is 0, 1 or 2; p^(G) is 1 or 3; R^(G1) is H; R^(G2) is H; or R^(G1) and R^(G2) together form a CH═CH—CH═CH chain; or G is

 where q^(G) is 0, 1 or 2; r^(G) is 0, 1 or 2; R^(G3) is H, C₁-C₆-alkyl or C₃₋₈-cycloalkyl; R^(G4) is H, C₁-C₆-alkyl, C₃₋₈-cycloalkyl or phenyl; K is NH—(CH₂)_(n) _(^(K)) —Q^(K) where n^(K)=1 or 2; Q^(K) is

X^(K) is O, S, NH or N—C₁₋₆-alkyl;

 where R^(L1) is —H, —OH, —O—C₁₋₆-alkyl, —O—(CH₂)₀₋₃-phenyl, —CO—C₁₋₆-alkyl, —CO₂—C₁₋₆-alkyl or CO₂—C₁₋₃-alkylaryl.
 4. The compound claimed in claim 1, or a tautomer, a pharmacologically tolearable salt, or a prodrug thereof, where A is H, C₁₋₆-alkyl, C₁₋₆-alkyl-SO₂, R^(A1)OCO, R^(A2)R^(A3)NCO; R^(A4)OCONR^(A2), R^(A4)CONR^(A2), R^(A1)O, R^(A2)R^(A3)N, HO—SO₂—, phenoxy, R^(A2)R^(A3)N—SO₂, Cl, Br, F, tetrazolyl, H₂O₃P—, NO₂, R^(A1)—N(OH)—CO— or R^(A1)R^(A2)NCONR^(A3), where R^(A1) is H, C₁₋₁₂-alkyl, C₃₋₈-cycloalkyl, C₃₋₈-cycloalkyl-C₁₋₃-alkyl or C₁₋₃-alkylaryl; R^(A2) is H—, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl; R^(A3) is H, C₁₋₆-alkyl or C₀₋₃-alkylaryl; R^(A4) is C₁₋₆-alkyl or C₁₋₃-alkylaryl; where each aryl is optionally substituted with up to 2 identical or different radicals selected from the group consisting of F, Cl, Br, CF₃, CH₃, OCH₃ and NO₂; B is —(CH₂)_(l) _(^(B)) —L^(B)—(CH₂))_(m) _(^(B)) — where l^(B) is 0, 1, 2 or 3; m^(B) is 0, 1 or 2; L^(B) is

where a phenyl ring is optionally fused to the abovementioned ring systems, which phenyl ring is optionally substituted with up to 2 identical or different radicals selected from the group consisting of CH₃, CF₃, Br, Cl and F, or is optionally substituted by R⁸OOC—; where R⁸ is H or C₁₋₃-alkyl n^(B) is 0,1 or 2; p^(B) is 0, 1 or 2; R^(B1) is C₀₋₃-alkylaryl, C₀₋₃-alkylheteroaryl, C₀₋₃-alkyl-C₃₋₈-cycloalkyl, OH or OCH₃; R^(B2) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl; R^(B3) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl; R^(B5)OCO, R^(B6)—O, F, Cl, Br, NO₂ or CF₃; R^(B4) is H, C₁₋₆-alkyl, R^(B6)—O, Cl, Br, F or CF₃; R^(B5) is H, C₁₋₆-alkyl or C₁₋₃-alkylaryl; R^(B6) is H or C₁₋₆-alkyl; R^(B1′) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl, C₀₋₃-alkylheteroaryl or C₀₋₃-alkyl-C₃₋₈-cycloalkyl; R^(B1) and R^(B2) are optionally bonded together; X^(B) is O, S, NH or N—C₁₋₆-alkyl; Y^(B) is Z^(B) is U^(B) is ═CH— or ═N—; V^(B) is ═CH— or ═N—; or B is —(CH₂)_(l) _(^(B)) —L^(B)—M^(B)—L^(B)—(CH₂)_(m) _(^(B)) , where l^(B) and m^(B) have the abovementioned meanings and the two groups L^(B), independently of one another, are the radicals stated under L^(B); M^(B) is a single bond, O, S, CH₂, CH₂—CH₂, CH₂—O, O—CH₂, CH₂—S, S—CH₂, CO, SO₂, CH═CH or C≡C; or B is -1-adamantyl-CH₂—, -2-adamantyl-CH₂—, -1-adamantyl-, -2-adamantyl-,

or B is

 where h^(B) is 1, 2, 3 or 4; R^(B7) is C₁₋₆-alkyl or C₃₋₈-cycloalkyl; or B is

 where X^(B1) is a bond, O, S or

r^(B) is 0, 1, 2 or 3; R^(B9) is H or C₁₋₃-alkyl; or A—B together are

D is a single bond, CO, OCO or NR^(D1)—CO, SO₂ or NR^(D1)SO₂, where R^(D1) is H, C₁₋₄-alkyl or C₀₋₃-alkylaryl; E is

 where k^(E) is 0 or 1; I^(E) is 0 or 1; m^(E) is 0 or 1; n^(E) is 0 or 1; p^(E) is 0 or 1; R^(E1) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, aryl, pyridyl, thienyl or C₃₋₈-cycloalkyl having a fused-on phenyl ring; or R^(E1) is R^(E4)OCO—CH₂; R^(E2) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, phenyl, pyridyl, furyl, thienyl, imidazolyl, tetrahydropyranyl or tetrahydrothiopyranyl, where the abovementioned radicals optionally carry up to three identical or different substituents selected from the group consisting of C₁₋₆-alkyl, O—C₁₋₆-alkyl, F, Cl and Br, or is CH(CH₃)OH or CH(CF₃)₂; R^(E3) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl or phenyl; R^(E4) is H, C₁₋₁₂-alkyl or C₁₋₃-alkylaryl; R^(E2) and R^(B1) together optionally form a bridge with (CH₂)₀₋₄, CH═CH, CH₂—CH═CH or CH═CH—CH₂ groups; the groups stated under R^(E1) and R^(E2) may be linked to one another via a bond; the groups stated under R^(E2) and R^(E3) may also be linked to one another via a bond; or E is D-Asp, D-Glu, D-Lys, D-Orn, D-His, D-Dab, D-Dap or D-Arg; G is

 where l^(G) is 2, 3, or 4, and where a CH₂ group of the ring is optionally replaced by O, S, CF₂, CHF or CH(C₁₋₃-alkyl);

 where m^(G) is 0, 1 or 2; n^(G) is 0, 1 or 2; R^(G1) and R^(G2) are each H; or G is

 where r^(G) is 0 or 1; R^(G3) is H, C₁-C₆-alkyl or C₃₋₈-cycloalkyl; R^(G4) is H, C₁-C₆-alkyl, C₃₋₈-cycloalkyl or phenyl; K is NH—(CH₂)_(n) _(^(K)) —Q^(K), where n^(K) is 1 or 2; Q^(K) is

X^(K) is O or S;

 where R^(L1) is H, OH, O—C₁₋₆-alkyl, O—(CH₂)₀₋₃-phenyl, CO—C₁₋₆-alkyl, CO₂—C₁₋₆-alkyl or CO₂—C₁₋₃-alkylaryl.
 5. The compound claimed in claim 1, or a tautomer, a pharmacologically tolerable salt, or a prodrug thereof, where A is H, C₁₋₆-alkyl, C₁₋₆-alkyl-SO₂ or R^(A1)OCO, R^(A2)R^(A3)NCO; R^(A4)OCONR^(A2), R^(A4)CONR^(A2), R^(A1)O, R^(A2)R^(A3)N, HO—SO₂—, phenoxy, R^(A2)R^(A3)N—SO₂, Cl, Br, F, tetrazolyl, H₂O₃P—, NO₂, R^(A1)—N(OH)—CO— or R^(A1) R^(A2)NCONR^(A3), where R^(A1) is H, C₁₋₁₂-alkyl, C₃₋₈-cycloalkyl, C₃₋₈-cycloalkyl-C₁₋₃-alkyl or C₁₋₃-alkylaryl; R^(A2) is H—, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl; R^(A3) is H, C₁₋₆-alkyl or C₀₋₃-alkylaryl; R^(A4) is C₁₋₆-alkyl or C₁₋₃-alkylaryl; where each aryl is optionally substituted with up to 2 identical or different radicals selected from the group consisting of F, Cl, Br, CF₃, CH₃, OCH₃ and NO₂, B is —(CH₂)_(l) _(^(B)) —L^(B)—(CH₂)_(m) _(^(B)) — where l^(B) is 0, 1 or 2; m^(B) is 0, 1 or 2; L^(B) is

where a phenyl ring is optionally fused to the abovementioned ring systems, which phenyl ring is optionally substituted with up to 2 identical or different radicals selected from the group consisting of CH₃, CF₃, Br, Cl and F, or is optionally substituted by R⁸OOC—;  where R⁸ is H or C₁₋₃-alkyl n^(B) is 0 or 1; p^(B) is 0 or 1; R^(B1) is C₀₋₃-alkylaryl, C₀₋₃-alkylheteroaryl, C₀₋₃-alkyl-C₃₋₈-cycloalkyl, OH or OCH₃; R^(B2) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl; R^(B3) is H, C₁₋₆-alkyl, R^(B5)OCO, R^(B6)—O, F, Cl, Br, NO₂ or CF₃; R^(B4) is H, C₁₋₆-alkyl, R^(B6)—O, Cl, Br, F or CF₃; R^(B5) is H or C₁₋₆-alkyl; R^(B6) is H or C₁₋₆-alkyl; R^(B1) and R^(B2) are optionally bonded together; or B is —(CH₂)_(l) _(^(B)) —L^(B)—m^(B)—L^(B)—(CH₂)_(m) _(^(B)) , where l^(B) and m^(B) have the abovementioned meanings and the two groups L^(B), independently of one another, are the radicals stated under L^(B); M^(B) is a single bond, O, S, CH₂, CH₂—CH₂, CH₂—O, O—CH₂, CH₂—S, S—CH₂, CH═CH or C≡C; or B is -1-adamantyl-CH₂—, -2-adamantyl-CH₂—,

or B is

 where h^(B) is 1, 2, 3, or 4; R^(B7) is C₁₋₆-alkyl or C₃₋₈-cycloalkyl; or B is

 where X^(B1) is a bond, O, S or

r^(B) is 0 , 1, 2 or 3; R^(B9) is H or C₁₋₃-alkyl; or A—B together are

D is a single bond, CO, OCO, NR^(D1)—CO, SO₂ or NR^(D1)SO₂,  where R^(D1) is H, C₁₋₄-alkyl or C₀₋₃-alkylaryl; E is

 where m^(E is) 0, 1, 2 or 3; R^(E1) is H or C₁₋₆-alkyl; R^(E2) is H, C₁₋₆-alkyl or C₃₋₈-cycloalkyl, where the abovementioned radicals optionally carry up to three substituents selected from the group consisting of C₁₋₆-alkyl and F; or is CH(CH₃)OH or CH(CF₃)₂; R^(E3) is H; the groups stated under R^(E1) and R^(E2) are optionally linked to one another via a bond; or E is D-Asp, D-Glu, D-Lys, D-Orn, D-His, D-Dab, D-Dap or D-Arg; G is

 where l^(G) is 2 or 3, and where a CH₂ group of the ring is optionally replaced by S or CHCH3; or

 where m^(G) is 1; n^(G) is 0; R^(G1) and R^(G2) are each H; K is NH—(CH₂)_(n) _(^(K)) —Q^(K), where n^(K) is 1; Q^(K) is

X^(K) is S; Y^(K) is ═CH— or ═N—; Z^(K) is ═CH— or ═N—; L is

 where R^(L1) is H, OH, CO—C₁₋₆-alkyl, CO₂—C₁₋₆-alkyl or CO₂—C₁₋₃-alkylaryl.
 6. A compound of the formula I A—B—D—E—G—K—L  (I), or a tautomer, a pharmacologically tolerable salt, or a prodrug thereof, where A is H, C₁₋₆-alkyl, C₁₋₆-alkyl-SO₂ or R^(A1)OCO, R^(A2)R^(A3)NCO; R^(A4)OCONR^(A2), R^(A4)CONR^(A2), R^(A1)O, R^(A2)R^(A3)N, HO—SO₂—, phenoxy, R^(A2)R^(A3)N—SO₂, Cl, Br, F, tetrazolyl, H₂O₃P—, NO₂, R^(A1)—N(OH)—CO— or R^(A1)R^(A2)NCONR^(A3), where R^(A1) is H, C₁₋₁₂-alkyl, C₃₋₈-cycloalkyl, C₁₋₃-cycloalkyl-C₁₋₃-alkyl or C₁₋₃-alkylaryl; R^(A2) is H—, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl; R^(A3) is H, C₁₋₆-alkyl or C₀₋₃-alkylaryl; R^(A4) is C₁₋₆-alkyl or C₁₋₃-alkylaryl; where each aryl is optionally substituted with up to 2 identical or different radicals selected from the group consisting of F, Cl, Br, CF₃, CH₃, OCH₃ and NO₂; B is —(CH₂)_(l) _(^(B)) —L^(B)—(CH₂)_(m) _(^(B)) — where l^(B) is 0 or 1; m^(B) is 0, 1 or 2; L^(B) is

where a phenyl ring is optionally fused to the abovementioned ring systems, which phenyl ring is optionally substituted with up to 2 identical or different radicals selected from the group consisting of CH₃, CF₃, Br, Cl and F, or is optionally substituted by R⁸OOC—; where R⁸ is H or C₁₋₃-alkyl n^(B) is 0 or 1; p^(B) is 0 or 1; R^(B1) is C₀₋₃-alkylaryl, C₀₋₃-alkylheteroaryl, C₀₋₃-alkyl-C₃₋₈-cycloalkyl, OH or OCH₃; R^(B2) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl; R^(B3) is H, C₁₋₆-alkyl, R^(B5)OCO, R^(B6)—O, F, Cl, Br, NO₂ or CF₃; R^(B4) is H, C₁₋₆-alkyl, R^(B6)—O, Cl, Br, F or CF₃; R^(B5) is H or C₁₋₆-alkyl; R^(B6) is H or C₁₋₆-alkyl; R^(B1) and R^(B2) are optionally bonded together; X^(B) is O or S; Y^(B) is ═CH— or ═N—; Z^(B) is ═CH— or ═N—; or B is —(CH₂)_(l) _(^(B)) —L^(B)—M^(B)—L^(B)—(CH₂)_(m) _(^(B)) , where l^(B) and m^(B) have the abovementioned meanings and the two groups L^(B), independently of one another, are the radicals —C≡C—,

M^(B) is a single bond, O, CH₂—S, S—CH₂, CO, SO₂ or CH₂—O; or B is

 where h^(B) is 1, 2, 3, or 4; R^(B7) is C₁₋₆-alkyl or C₃₋₈-cycloalkyl; or B is 1-fluorenyl-, 1-adamantyl- or 1-adamantyl-CH₂—; or A—B together are 2-pyridyl-CH₂—, 2-benzothienyl-, 3-benzothienyl-,

D is a single bond, CO or SO₂; E is

 where R^(E1) is H or CH₃; R^(E2) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, thienyl, CH(CH₃)OH or CH(CF₃)₂; R^(E3) is H; the groups stated under R^(E1) and R^(E2) are optionally linked to one another via a bond; the groups stated under R^(E2) and R^(E3) are also optionally linked to one another via a bond; or E is D-Lys, D-Orn, D-Dab, D-Dap or D-Arg where Orn is ornithine, Dab is 2,4-diamino butyric acid and Dap is 2,3-diamino propionic acid; G is

 where l^(G) is 2 or 3, and where a CH₂ group of the ring is optionally replaced by CHCH₃; or

 where m^(G) is 1; n^(G) is 0; R^(G1) and R^(G2) are each H; K is NH—(CH₂)_(n) _(^(K)) —Q^(K), where n^(K) is 1; Q^(K) is

X^(K) is S; Y^(K) is ═CH— or ═N— Z^(K) is ═CH— or ═N— L is

 where R^(L1) is H or OH.
 7. The compound claimed in claim 1, or a tautomer, a pharmacologically tolerable salt, or a prodrug thereof, where A is H, C₁₋₆-alkyl, C₁₋₆-alkyl-SO₂ or R^(A1)OCO, R^(A2)R^(A3)NCO, R^(A4)OCONR^(A2), R^(A4)CONR^(A2), R^(A1)O, phenoxy, R^(A2)R^(A3)N, HO—SO₂, R^(A2)R^(A3)N—SO₂, Cl, Br, F, tetrazolyl, H₂O₃P, NO₂, R^(A1)—N(OH)—CO or R^(A1)R^(A2)NCONR^(A3), where R^(A1) is H, C₁₋₁₂-alkyl, C₃₋₈-cycloalkyl, C₁₋₃-alkyl-C₃₋₈-cycloalkyl or C₁₋₃-alkylaryl; R^(A2) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl; R^(A3) is H, C₁₋₆-alkyl or C₀₋₃-alkylaryl; R^(A4) is C₁₋₆-alkyl or C₁₋₃-alkylaryl; where each aryl is optionally substituted with up to 2 identical or different radicals selected from the group consisting of F, Cl, Br, OCH₃, CH₃, CF₃ and NO₂; B is —(CH₂)_(l) _(^(B)) —L^(B)—(CH₂)_(m) _(^(B)) —, where l^(B) is 0, 1 or 2; m^(B) is 0, 1 or 2; L^(B) is

where a phenyl ring is optionally fused to the abovementioned ring systems, which phenyl ring is optionally substituted with up to 2 identical or different radicals selected from the group consisting of CH₃, CF₃, Br, Cl and F, or is optionally substituted by R⁸OOC—; where R⁸ is H or C₁₋₃-alkyl; n^(B) is 0, 1 or 2; p^(B) is 0, 1 or 2; R^(B1) is C₀₋₃-alkylaryl, C₀ ₃-alkylheteroaryl, C₀₋₃-alkyl-C₃₋₈-cycloalkyl, OH or OCH₃; R^(B2) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl; R^(B1) and R^(B2) are optionally bonded together; or B is -1-adamantyl-CH₂—, -2-adamantyl-CH₂—,

or B is —(CH₂)_(l) _(^(B)) —L^(B1)—M^(B)—L^(B2)—(CH₂)_(m) _(^(B)) —, where l^(B) and m^(B) have the abovementioned meanings and the two groups L^(B1) and L^(B2), independently of one another, are the following radicals:

where a phenyl group is optionally fused to the abovementioned ring systems, and where n^(B) is 0, 1 or 2; p^(B) is 0, 1 or 2; R^(B1) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl, C₀₋₃-alkylheteroaryl, C₀₋₃-alkyl-C₃₋₈-cycloalkyl, OH or OCH₃, and in the case of L^(B2), R^(B1) may also be H or C₁₋₆-alkyl; R^(B2) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl; R^(B3) is H, C₁₋₆-alkyl, aryl, heteroaryl, R^(B5)OCO, R^(B6)—O, F, Cl, Br, NO₂ or CF₃; R^(B4) is H, C₁₋₆-alkyl, R^(B6)—O, Cl, Br, F or CF₃; R^(B5) is H or C₁₋₆-alkyl; R^(B6) is H or C₁₋₆-alkyl; X^(B) is O or S; Y^(B) is ═CH— or ═N—; Z^(B) is ═CH— or ═N—; R^(B1) and R^(B2) may also be bonded together; M^(B) is a single bond, O, S, CH₂, CH₂—CH₂, CH₂—O, O—CH₂, CH₂—S, S—CH₂, CO, SO₂, CH═CH or C≡C; or B is

 where X^(B1) is a bond, O, S or

r^(B) is 0, 1, 2 or 3; R^(B9) is H or C₁₋₃-alkyl; or A—B together are

D is a single bond, CO, OCO, NR^(D1)—CO, SO₂ or NR^(D1)SO₂, where R^(D1) is H, C₁₋₄-alkyl or C₀₋₃-alkylaryl; or B—D together are

E is

 where k^(E) is 0 or 1; m^(E) is 0 or 1; n^(E) is 0 or 1; p^(E) is 0 or 1; R^(E1) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, phenyl, naphthyl, pyridyl, thienyl or C₃₋₈-cycloalkyl having a fused-on phenyl ring; R^(E2) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, phenyl, pyridyl, thienyl, furyl, imidazolyl, tetrahydropyranyl, tetrahydrothiopyranyl, CH(CH₃)OH or CH(CF₃)₂; R^(E3) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl or phenyl; the groups stated under R^(E1) and R^(E2) are optionally linked to one another via a bond; the groups stated under R^(E2) and R^(E3) are also optionally linked to one another via a bond; or E is D-Asp, D-Glu, D-Lys, D-Orn, D-His, D-Dab, D-Dap or D-Arg; G is

 where l^(G) is 2, 3 or 4, and where a CH₂ group of the ring is optionally replaced with CHCH₃; or

 where m^(G) is 1; n^(G) is 0 or 1; R^(G1) is H; R^(G2) is H; or G is

 where q^(G) is 0 or 1; r^(G) is 0 or 1; R^(G3) is H, C₁-C₆-alkyl or C₃₋₈-cycloalkyl; R^(G4) is H, C₁-C₆-alkyl, C₃₋₈-cycloalkyl or phenyl; K is NH—(CH₂)_(n) _(^(K)) —Q^(K), where n^(K) is 1; Q^(K) is

X^(K) is O or S; Y^(K) is ═CH— or ═N—; Z^(K) is ═CH— or ═N—; L is

 where R^(L1) is H, OH, CO—C₁₋₆-alkyl, CO₂—C₁₋₆-alkyl or CO₂—C₁₋₅-alkylaryl.
 8. The compound claimed in claim 1, or a tautomer, a pharmacologic ally tolearable salt, or a prodrug thereof, where A is H, C₁₋₆-alkyl, C₁₋₆-alkyl-SO₂, R^(A1)OCO, R^(A2)R^(A3)NCO, R^(A4)OCONR^(A2), R^(A4)CONR^(A2), R^(A1)O, phenoxy, R^(A2)R^(A3)N, HO—SO₂, R^(A2)R^(A3)N—SO₂, Cl, Br, F, tetrazolyl, H₂O₃P, NO₂, R^(A1)—N(OH)—CO or R^(A1)R^(A2)NCONR^(A3), where R^(A1) is H, C₁₋₁₂-alkyl, C₃₋₈-cycloalkyl, C₁₋₃-alkyl-C₃₋₈-cycloalkyl or C₁₋₃-alkylaryl; R^(A2) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl; R^(A3) is H, C₁₋₆-alkyl or C₀₋₃-alkylaryl R^(A4) is C₁₋₆-alkyl or C₁₋₃-alkylaryl; where each aryl is optionally substituted with up to 2 identical or different radicals from the group consisting of F, Cl, Br, OCH₃, CH₃, CF₃ and NO₂, B is —(CH₂)_(l) _(^(B)) —L^(B)—(CH₂)_(m) _(^(B)) —, where l^(B is) 0 or 1; m^(B) is 0, 1 or 2; L^(B) is

where a phenyl ring is optionally fused to the abovementioned ring systems, which phenyl ring is optionally substituted with up to 2 identical or different radicals selected from the group consisting of CH₃, CF₃, Br, Cl and F, or is optionally substituted by R⁸OOC—;  where R⁸ is H or C₁₋₃-alkyl; n^(B) is 0 or 1; p^(B) is 0 or 1; or B is -1-adamantyl-CH₂—, -2-adamantyl-CH₂—, or

or B is —(CH₂)_(l) _(^(B)) —L^(B1)—M^(B)—L^(B2)—(CH₂)_(m) _(^(B)) —, where l^(B) and m^(B) have the abovementioned meanings and the two groups L^(B1) and L^(B2), independently of one another, are the following radicals:

where a phenyl ring is optionally fused to the abovementioned ring systems; where n^(B) is 1; p^(B) is 0 or 1; R^(B1) is H, C₀₋₃-alkylaryl, C₀₋₃-alkylheteroaryl, C₀₋₃-alkyl-C₃₋₈-cycloalkyl, OH or OCH₃, or in the case of L^(B2), R^(B1) is additionally H or C₁₋₆-alkyl; R^(B2) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl; R^(B3) is H, C₁₋₆-alkyl, R^(B6)—O, F, Cl, Br, NO₂ or CF₃; R^(B4) is H, C₁₋₆-alkyl, R^(B6)—O, Cl, Br, F or CF₃; R^(B6) is H, C₁₋₆-alkyl; R^(B1) and R^(B2) are optionally bonded together; M^(B) is a single bond, O, S, CH₂, CH₂—CH₂, CH₂—O, O—CH₂, CH₂—S, S—CH₂, CO or SO₂; or A—B together are 2-pyridyl-CH_(2—, 2)-benzothienyl-,

D is a single bond, CO or SO₂; or B—D together are

E is

 where R^(E1) is H; R^(E2) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, phenyl, pyridyl, thienyl, furyl, imidazolyl, tetrahydropyranyl, tetrahydrothiopyranyl, CH(CH₃)OH or CH(CF₃)₂; R^(E3) is H; the groups stated under R^(E1) and R^(E2) are optionally linked to one another via a bond; or E is D-Lys, D-Orn, D-Dab, D-Dap or D-Arg; G is

 where l^(G) is 2 or 3, and where a CH₂ group of the ring is optionally replaced with CHCH₃; or

 where m^(G) is 1; n^(G) is 0; R^(G1) is H; R^(G2) is H; K is NH—(CH₂)_(n) _(^(K)) —Q^(K), where n^(K) is 1; Q^(K) is

X^(K) is S; Y^(K) is ═CH— or ═N—; Z^(K) is ═CH— or ═N—;

 where  R^(L1) is H or OH.
 9. The compound claimed in claim 1, or a tautomer, a pharmacologically tolerable salt, or a prodrug thereof, where A is H, C₁₋₆-alkyl, C₁₋₆-alkyl-SO₂, R^(A1)OCO, R^(A2)R^(A3)NCO, R^(A4)OCONR^(A2), R^(A4) CONR^(A2), R^(A1)O, phenoxy, R^(A2)R^(A3)N, HO—SO₂, R^(A2)R^(A3)N—SO₂, Cl, Br, F, tetrazolyl, H₂O₃P, NO₂, R^(A1)—N(OH)—CO— or R^(A1)R^(A2)NCONR^(A3), where R^(A1) is H, C₁₋₁₂-alkyl, C₃₋₈-cycloalkyl, C₁₋₃-alkyl-C₃₋₈-cycloalkyl or C₁₋₃-alkylaryl; R^(A2) is H, C₁₋₆-alkyl, C₀₋₃-alkylaryl or C₀₋₃-alkylheteroaryl; R^(A3) is H, C₁₋₆-alkyl or C₀₋₃-alkylaryl; R^(A4) is C₁₋₆-alkyl or C₁₋₃-alkylaryl; where each aryl is optionally substituted with up to 2 identical or different substituents selected from the group consisting of F, Cl, Br, CH₃, CF₃, OCH₃ and NO₂, B is —(CH₂)_(l) _(^(B)) —L^(B)—(CH₂)_(m) _(^(B)) —, where l^(B) is 0 or 1; m^(B) is 0, 1 or 2; L^(B) is

where a phenyl ring is optionally fused to the abovementioned ring systems; R^(B3) is H, C₁₋₆-alkyl, aryl, R^(B5)OCO, R^(B6)—O, F, Cl, Br, NO₂ or CF₃; R^(B4) is H, C₁₋₆-alkyl, R^(B6)—O, Cl, Br, F or CF₃; R^(B5) is H, C₁₋₆-alkyl or C₁₋₃-alkylaryl; R^(B6) is H or C₁₋₆-alkyl; X^(B) is O or S; Y^(B) is ═CH— or ═N—; Z^(B) is ═CH— or ═N—; U^(B) is ═CH— or ═N—; V^(B) is ═CH— or ═N—; or B is

q^(B) is 0, 1, or 2; R^(B7) is C₁₋₆-alkyl or C₃₋₈-cycloalkyl; or A—B together are

D is a single bond; E is

 where R^(E1) is H; R^(E2) is H, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, phenyl, pyridyl, furyl, thienyl, imidazolyl, tetrahydropyranyl or tetrahydrothiopyranyl, where the abovementioned radicals are optionally substituted with up to three identical or different substituents selected from the group consisting of O—C₁₋₆-alkyl and F; or is CH(CH₃)OH or CH(CF₃)₂; R^(E3) is H; the groups stated under R^(E1) and R^(E2) are optionally linked to one another via a bond; or E is D-Lys, D-Orn, D-Dab, D-Dap or D-Arg; G is

 where l^(G) is 2 or 3, and where a CH₂ group of the ring is optionally replaced with CHCH₃; or

 where m^(G) is 1; n^(G) is 0; R^(G1) is H; R^(G2) is H; K is NH—(CH₂)_(n) _(^(K)) —Q^(N), where n^(K) is 1; Q^(K) is

X^(K) is O or S; Y^(K) is ═CH— or ═N—; Z^(K) is ═CH— or ═N—; L is

 where R^(L1) is —H or —OH.
 10. A composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.
 11. A method of inhibiting C1s comprising contacting C1s with an effective amount of a compound according to claim
 1. 12. A method of inhibiting C1s comprising administering an effective amount of a compound according to claim 1 to a patient in need thereof.
 13. A method of inhibiting C1r comprising contacting C1r with an effective amount of a compound according to claim
 1. 14. A method of inhibiting C1r comprising administering an effective amount of a compound according to claim 1 to a patient in need thereof.
 15. A method of inhibiting complement activation comprising administering an effective amount of a compound according to claim 1 to a patient in need thereof.
 16. A method of inhibiting formation of complement factor C5a comprising administering an effective amount of a compound according to claim 1 to a patient in need thereof. 